var title_f37_26_38304="Betaxolol: Patient drug information";
var content_f37_26_38304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Betaxolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/14/21732?source=see_link\">",
"       Betaxolol (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/33/18965?source=see_link\">",
"       Betaxolol (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11288 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38304=[""].join("\n");
var outline_f37_26_38304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/14/21732?source=related_link\">",
"      Betaxolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/33/18965?source=related_link\">",
"      Betaxolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_26_38305="Patient information: Typhoid fever (The Basics)";
var content_f37_26_38305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/44/21187\">",
"         Patient information: Vaccines for travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Typhoid fever (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/typhoid-fever-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2371502395\">",
"      <span class=\"h1\">",
"       What is typhoid fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Typhoid fever is a fever caused by an infection with a type of bacteria called Salmonella typhi. The fever usually happens along with belly pain and chills.",
"     </p>",
"     <p>",
"      Typhoid fever is not very common in the United States or Europe, but it does occur in other parts of the world, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        India",
"       </li>",
"       <li>",
"        Africa",
"       </li>",
"       <li>",
"        The Philippines",
"       </li>",
"       <li>",
"        Pakistan",
"       </li>",
"       <li>",
"        El Salvador",
"       </li>",
"       <li>",
"        Mexico",
"       </li>",
"       <li>",
"        Haiti",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In these places, the infection that causes typhoid fever spreads when people eat or drink things that have the typhoid-causing bacteria in them. The bacteria can get into foods and drinks in different ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        People who are infected can spread their germs to the food they cook if they do not wash their hands before they touch the food.",
"       </li>",
"       <li>",
"        Bacteria can get into the water supply through the bowel movements of infected people. Then, if the water is not treated properly and is used in cooking or cleaning, it can spread the infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2371502410\">",
"      <span class=\"h1\">",
"       What are the symptoms of typhoid fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Chills",
"       </li>",
"       <li>",
"        &ldquo;Rose spots&rdquo; &ndash; Faint, salmon-colored spots on the belly and trunk",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2371502425\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of typhoid fever, see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2371502440\">",
"      <span class=\"h1\">",
"       Is there a test for typhoid fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To find out if you are infected by the bacteria that cause typhoid fever, your doctor or nurse can order a &ldquo;culture&rdquo; test on your blood. He or she might also order a culture test on a sample of 1 of these things:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bowel movement",
"       </li>",
"       <li>",
"        Urine",
"       </li>",
"       <li>",
"        Skin from 1 of the rose spots",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2371502455\">",
"      <span class=\"h1\">",
"       How is typhoid fever treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment involves taking antibiotic pills for up to 2 weeks. If you are put on antibiotics to treat typhoid fever, it is very important that stay on the medicines for as long as your doctor recommends. Otherwise the infection could come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2371502470\">",
"      <span class=\"h1\">",
"       Can typhoid fever be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are 2 main ways to keep from getting typhoid fever:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Get the vaccine before you travel",
"        </strong>",
"        &ndash; If you are planning a trip outside of the US and Europe, ask your doctor or nurse if you need the",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/59/10161?source=see_link\">",
"         typhoid vaccine",
"        </a>",
"        or any other vaccines. There are 2 forms of the vaccine. One comes in 4 pills that you take on different days. The other comes in a single shot.",
"       </li>",
"       <li>",
"        <strong>",
"         Be careful what you eat and drink",
"        </strong>",
"        &ndash; While traveling, you should:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Wash your hands with soap and water before eating or handling food.",
"       </li>",
"       <li>",
"        Drink only bottled water or water that has been boiled for at least 1 minute.",
"       </li>",
"       <li>",
"        Do not get ice in drinks and do not eat popsicles or flavored ice.",
"       </li>",
"       <li>",
"        Eat food that has been completely cooked and is still hot.",
"       </li>",
"       <li>",
"        Eat only fruits that have a peel and that you wash and peel yourself. Do not eat the peels.",
"       </li>",
"       <li>",
"        Do not eat vegetables or salads.",
"       </li>",
"       <li>",
"        Do not buy food or drinks from street vendors.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2371502485\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"       Patient information: Vaccines for travel (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/26/38305?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83903 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38305=[""].join("\n");
var outline_f37_26_38305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502395\">",
"      What is typhoid fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502410\">",
"      What are the symptoms of typhoid fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502425\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502440\">",
"      Is there a test for typhoid fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502455\">",
"      How is typhoid fever treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502470\">",
"      Can typhoid fever be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2371502485\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_26_38306="Drug eruption lymphomatoid";
var content_f37_26_38306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38306=[""].join("\n");
var outline_f37_26_38306=null;
var title_f37_26_38307="Circumvallate placenta";
var content_f37_26_38307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumvallate placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A double layer of amnion and chorion, as well as necrotic villi and fibrin, form a raised white ring around the surface of the placental disk at a variable distance from the umbilical cord insertion site; the fetal vessels do not extend beyond this ring",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38307=[""].join("\n");
var outline_f37_26_38307=null;
var title_f37_26_38308="Close-grip pull-down";
var content_f37_26_38308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Close-grip pull-down exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While seated, grasp the handle of a pulley bar directly in front of you and, while maintaining an erect posture, gradually pull the bar straight to your belly, hold for one second, and then return the bar to the starting position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38308=[""].join("\n");
var outline_f37_26_38308=null;
var title_f37_26_38309="Skin biopsy adult Stills";
var content_f37_26_38309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56878%7ERHEUM%2F72353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56878%7ERHEUM%2F72353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin biospy from adult onset Still's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This skin biopsy demonstrates some mild perivascular inflammation and dermal edema in an area of skin involved with the rash of adult Still's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa Mandl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin biopsy of adult Still's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this micrograph of a biopsy specimen from the involved skin from a patient with adult Still's disease, perivascular infiltration of inflammatory cells and edema separating collagen bundles in the dermis is apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa Mandl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38309=[""].join("\n");
var outline_f37_26_38309=null;
var title_f37_26_38310="Nortriptyline: Pediatric drug information";
var content_f37_26_38310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nortriptyline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"    see \"Nortriptyline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/22/25957?source=see_link\">",
"    see \"Nortriptyline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pamelor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nortriptyline&reg;;",
"     </li>",
"     <li>",
"      Ava-Nortriptyline;",
"     </li>",
"     <li>",
"      Aventyl&reg;;",
"     </li>",
"     <li>",
"      Dom-Nortriptyline;",
"     </li>",
"     <li>",
"      Norventyl;",
"     </li>",
"     <li>",
"      Nu-Nortriptyline;",
"     </li>",
"     <li>",
"      PMS-Nortriptyline;",
"     </li>",
"     <li>",
"      Teva-Nortriptyline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic (Secondary Amine)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"      see \"Nortriptyline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nocturnal enuresis: Children: Administer dose 30 minutes before bedtime; usual treatment duration: &le;3 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-7 years (20-25 kg): 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-11 years (25-35 kg): 10-20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;11 years (35-54 kg): 25-35 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Depression:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved for use in pediatric patients; controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents (Dopheide, 2006; Wagner, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 1-3 mg/kg/day or 10-20 mg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 1-3 mg/kg/day or 30-50 mg/day in 3-4 divided doses; usual maximum dose: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 25 mg 3-4 times/day up to 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use lower doses and slower titration; individualization of dosage is recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamelor&trade;: 10 mg, 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 10 mg/5 mL (473 mL, 480 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamelor&trade;: 10 mg/5 mL (480 mL [DSC]) [contains benzoic acid, ethanol 4%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food to decrease GI upset; dilute oral solution in water, milk, or fruit juice immediately before use; do not dilute in grape juice or carbonated beverages",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of various forms of depression, often in conjunction with psychotherapy; nocturnal enuresis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aventyl&reg; HCl may be confused with Bentyl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nortriptyline may be confused with amitriptyline, desipramine, Norpramin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pamelor&trade; may be confused with Demerol&reg;, Tambocor&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F202757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, flushing, heart block, hypertension, MI, orthostatic hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, delusions, disorientation, dizziness, drowsiness, EEG changes, exacerbation of psychosis, extrapyramidal symptoms, fatigue, hallucinations, headache, hypomania, incoordination, insomnia, nightmares, panic, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Blood sugar increased/decreased, breast enlargement, galactorrhea, gynecomastia, libido increased/decreased, sexual dysfunction, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, black tongue, constipation, diarrhea, epigastric distress, nausea, paralytic ileus, stomatitis, taste disturbance, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Delayed micturition, impotence, nocturia, polyuria, testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), eosinophilia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, peripheral neuropathy, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, disturbances in accommodation, eye pain, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (eg, general edema or of the face/tongue), diaphoresis (excessive),  withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nortriptyline or amitriptyline (cross-sensitivity with other tricyclics may occur) or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); use during acute recovery period after MI",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac conduction disturbances, cardiovascular disease, seizure disorder, history of urinary retention, hyperthyroidism, or those receiving thyroid hormone replacement",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nortriptyline is not approved for use in pediatric patients. Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not discontinue abruptly in patients receiving high doses chronically (withdrawal symptoms may occur). To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). May worsen psychosis in some patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with extreme caution with renal or hepatic impairment. Capsule may contain sodium bisulfite and/or benzyl alcohol, both of which may cause allergic reactions in susceptible individuals; solution contains benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of nortriptyline products containing benzoic acid or benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F202746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Riboflavin dietary requirements may be increased",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9465719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies are inconclusive. Nortriptyline and its metabolites cross the human placenta and can be detected in cord blood. According to the manufacturer, the decision to use nortriptyline during pregnancy or in women of childbearing potential should take into account the potential benefits and possible risks. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, mental status, weight, plasma concentrations. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1054500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 50-150 ng/mL (SI: 190-570 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Therapeutic antidepressant effects begin in 7-21 days; maximum effects may not occur for &ge;2-3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid; well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 14-22 L/kg; crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes significant first-pass metabolism; primarily detoxified in the liver via hydroxylation followed by glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (mean &plusmn; SD): 18 &plusmn; 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults (mean &plusmn; SD): 46 &plusmn; 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 7-8.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites and small amounts of unchanged drug excreted in urine; small amounts of biliary elimination occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not Dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/22/25957?source=see_link\">",
"      see \"Nortriptyline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of nortriptyline. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol and the herbal medicine St John's wort; limit caffeine; do not discontinue medication abruptly; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/26/38310/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/26/38310/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/26/38310/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12653 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38310=[""].join("\n");
var outline_f37_26_38310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709176\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054497\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054489\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202690\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202674\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874747\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054502\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054492\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054501\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202760\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202757\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054506\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054488\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054487\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202746\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202683\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054508\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9465719\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054496\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054500\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054486\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054504\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054505\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054494\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=related_link\">",
"      Nortriptyline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/22/25957?source=related_link\">",
"      Nortriptyline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_26_38311="Management of intrapartum category I, II, and III fetal heart rate tracings";
var content_f37_26_38311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of intrapartum category I, II, and III fetal heart rate tracings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38311/contributors\">",
"     George Macones, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38311/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38311/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38311/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/26/38311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11183965\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of high interobserver and intraobserver variability in the interpretation of fetal heart rate (FHR) tracings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the National Institute of Child Health and Human Development (NICHD) convened a workshop to standardize definitions and interpretation for electronic fetal monitoring (EFM), propose management guidelines, and develop research questions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Major outputs from this workshop were a clear standard for FHR interpretation (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"mobipreview.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    ) and a three-tier system for the categorization of intrapartum EFM (",
"    <a class=\"graphic graphic_table graphicRef57583 \" href=\"mobipreview.htm?11/43/11964\">",
"     table 2",
"    </a>",
"    ). This system has been widely adopted in the United States and elsewhere, and is the basis for this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197194995\">",
"    <span class=\"h1\">",
"     FREQUENCY OF CATEGORY I, II, AND III TRACINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of the intrapartum FHR characteristics of over 48,000 patients with a singleton, nonanomalous fetus in term labor at 10 hospitals, category I patterns were observed at some point in over 99 percent of tracings, category II patterns were observed in 84 percent of tracings, and category III patterns were observed in 0.1 percent of tracings; 84 percent of patients had a mix of categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/6\">",
"     6",
"    </a>",
"    ]. Over the course of labor, FHR pattern was category I for 78 percent of the time, category II for 22 percent of the time, and category III for 0.004 percent of the time. In the two hours before delivery, category I tracings became less common, and category II and category III tracings became more common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11183972\">",
"    <span class=\"h1\">",
"     CATEGORY I FHR TRACINGS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Baseline rate: 110 to 160 beats per minute (bpm)",
"     </li>",
"     <li>",
"      Moderate baseline FHR variability",
"     </li>",
"     <li>",
"      No late or variable decelerations",
"     </li>",
"     <li>",
"      Early decelerations may be present or absent",
"     </li>",
"     <li>",
"      Accelerations may be present or absent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Category I EFM tracings are considered &ldquo;normal&rdquo; because studies have demonstrated that these findings are associated with the absence of fetal metabolic acidemia at the time of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. No intervention is indicated.",
"   </p>",
"   <p>",
"    EFM is generally continuous since the fetal status can change, but if the maternal and fetal conditions appear stable, it is reasonable to interrupt a category I EFM tracing for up to 30 minutes to facilitate ambulation, bathing, or position changes. In pregnancies at low risk of development of intrapartum fetal acidosis, ACOG recommends that the EFM tracing be reviewed at least every 30 minutes in the first stage of labor and every 15 minutes in the second stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/11\">",
"     11",
"    </a>",
"    ]. In patients with pregnancy complications (eg, fetal growth restriction, preeclampsia) where the risk of developing fetal acidosis is higher, the EFM should be reviewed at least every 15 minutes in the first stage of labor and every 5 minutes during the second stage. Similar guidelines are used in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/12\">",
"     12",
"    </a>",
"    ], and based on expert opinion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11183979\">",
"    <span class=\"h1\">",
"     CATEGORY III FHR TRACINGS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absent baseline FHR variability and any of the following:",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recurrent late decelerations",
"     </li>",
"     <li>",
"      Recurrent variable decelerations",
"     </li>",
"     <li>",
"      Bradycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     or",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinusoidal pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A category III tracing is &ldquo;abnormal&rdquo; because studies have demonstrated that these findings are associated with an increased risk of fetal hypoxic acidemia, which can lead to cerebral palsy and neonatal hypoxic ischemic encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is hypothesized that detection of potential fetal decompensation and timely and effective intervention before acidosis becomes severe can prevent",
"    <span class=\"nowrap\">",
"     perinatal/neonatal",
"    </span>",
"    morbidity or mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, when the FHR has a category III pattern, preparations for delivery should be made while initiating resuscitative measures: repositioning the mother to left or right lateral, providing oxygen supplementation, and administering an intravenous fluid bolus (",
"    <a class=\"graphic graphic_table graphicRef57979 \" href=\"mobipreview.htm?26/49/27420\">",
"     table 3",
"    </a>",
"    ). The goal of these interventions is to improve fetal oxygenation by improving uteroplacental perfusion. Scalp stimulation to provoke FHR acceleration should be attempted, as acceleration is a sign that the fetus is not acidotic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H22#H22\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'FHR response to stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If scalp stimulation does not result in acceleration and there is no improvement in the FHR tracing after conservative measures, delivery should be accomplished. The time from decision to delivery should consider the health of both mother and fetus; there may be circumstances (eg, maternal obesity with poor airway, maternal coagulopathy) where delivery cannot be safely performed expeditiously (within 20 to 30 minutes of the beginning of the category III tracing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11183986\">",
"    <span class=\"h1\">",
"     CATEGORY II FHR TRACINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Category II FHR tracings include all FHR patterns that are not classified as category I (normal) or category III (abnormal) (",
"    <a class=\"graphic graphic_table graphicRef57583 \" href=\"mobipreview.htm?11/43/11964\">",
"     table 2",
"    </a>",
"    ). The Society of Obstetricians and Gynaecologists of Canada classify these tracings as &ldquo;atypical&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential for development of fetal acidosis varies widely across the different types of category II tracings. Patients with these tracings should be evaluated for factors that may reduce fetal oxygenation, taking into account associated clinical circumstances. Conservative intervention is usually indicated, with frequent reassessment to determine whether delivery should be performed.",
"   </p>",
"   <p>",
"    There is no standard for evaluation of these fetuses. In general, the presence of either moderate variability (ie, amplitude 6 to 25 bpm) or fetal heart rate accelerations is highly predictive of normal fetal acid-base status and provides reassurance that expeditious delivery is unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Continued surveillance and frequent reassessment are indicated until the pattern resolves or progresses to category III.",
"   </p>",
"   <p>",
"    The management of specific types of category II fetal heart rate tracings is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11183993\">",
"    <span class=\"h2\">",
"     Recurrent late decelerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent late decelerations are caused by a reflex central nervous system response to fetal hypoxia and acidemia, as well as direct myocardial depression and humoral factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H1059913#H1059913\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Recurrent late decelerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal hypoxia may occur in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterine tachysystole",
"     </li>",
"     <li>",
"      Maternal hypotension (eg, from hemorrhage, sepsis, anesthesia)",
"     </li>",
"     <li>",
"      Maternal hypoxia (eg, from respiratory disorders, severe anemia)",
"     </li>",
"     <li>",
"      Maternal vasculopathy (eg, antiphospholipid syndrome, diabetes, lupus)",
"     </li>",
"     <li>",
"      Placental disorders (eg, abruption, infarction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of the pregnancy with recurrent late decelerations should therefore include assessment of uterine contraction frequency and intensity, assessment of FHR variability and accelerations, vaginal bleeding, uterine tenderness, maternal oxygenation, and blood pressure.",
"   </p>",
"   <p>",
"    General measures in the management of recurrent late decelerations are aimed at improving the uteroplacental circulation and maternal oxygenation, and include (",
"    <a class=\"graphic graphic_table graphicRef57979 \" href=\"mobipreview.htm?26/49/27420\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Repositioning the woman on her left or right lateral side",
"     </li>",
"     <li>",
"      Administration of oxygen (eg, 8 to 10",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      of oxygen via nonrebreather mask)",
"     </li>",
"     <li>",
"      Administration of an intravenous (IV) fluid bolus (eg, 500 to 1000 mL of lactated Ringer's or normal saline solution)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changing the maternal position may reduce cord compression and improve maternal blood flow to the placenta. The result is usually improved fetal gas exchange.",
"   </p>",
"   <p>",
"    Although no randomized trials have evaluated the efficacy of oxygen administration for management of fetal distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/21\">",
"     21",
"    </a>",
"    ], administering oxygen can improve fetal oxygenation. Fetal pO2 and oxygen saturation can reach a higher steady state within 8 to 10 minutes, but decrease after supplemental maternal oxygen is withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. There are conflicting data on the effect of maternal oxygen supplementation on fetal pH; some studies show an adverse effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. Although improved delivery of oxygen to the fetal tissues may be beneficial in some cases, the underlying causes of fetal hypoxemia need to be addressed, as fetal acidemia will not be corrected by maternal oxygen administration alone.",
"   </p>",
"   <p>",
"    An intravenous fluid bolus of non-glucose crystalloid can improve placental blood flow if the patient is hypovolemic from prolonged lack of intake, vomiting, or sympathetic blockade, and thus may improve fetal oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/24\">",
"     24",
"    </a>",
"    ]. However, fluid administration should be cautious when there is concern about possible volume overload, such as in women with preeclampsia, cardiac disease, or receiving beta-adrenergic drugs for tocolysis. &nbsp;",
"   </p>",
"   <p>",
"    Uterotonic drugs can be stopped or the dose decreased; these drugs should be discontinued in the presence of tachysystole (defined as more than five contractions in 10 minutes, averaged over a 30-minute window [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/11\">",
"     11",
"    </a>",
"    ]). Since uterine activity causes intermittent interruption of blood flow to the intervillous space, excessive uterine activity that exceeds the critical level for an individual fetus will result in fetal hypoxemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H26#H26\">",
"     \"Principles of labor induction\", section on 'Tachysystole'",
"    </a>",
"    .) If there is no prompt response to these measures, we suggest administering a tocolytic drug, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    250 mcg subcutaneously.",
"   </p>",
"   <p>",
"    If maternal hypotension secondary to recent epidural dosing is identified, administration of an alpha-adrenergic agonist (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or ephedrine) and an intravenous fluid bolus is corrective and will improve uteroplacental blood flow. Reduced placental perfusion from sympathetic blockade can occur without marked changes in maternal blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link&amp;anchor=H6#H6\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Hypotension'",
"    </a>",
"    .) These medications should be administered by someone with expertise in the dosing and side effects of these medications.",
"   </p>",
"   <p>",
"    An assessment of fetal heart rate variability and accelerations should be part of the evaluation of recurrent late decelerations, given that the predictive value of late decelerations for fetal acidosis and poor neonatal outcome is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Absent or minimal variability (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"mobipreview.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    ) is concerning as it can be a result of cerebral hypoxemia and acidosis, and can signify failure of fetal compensatory mechanisms to maintain adequate oxygenation of the brain, while normal FHR variability is strongly associated (98 percent) with an umbilical pH &gt;7.15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a FHR acceleration is present or can be elicited (rise of &ge;15 bpm above baseline lasting for &ge;15 seconds), absence of acidosis (ie, fetal pH greater than 7.20) is likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. In general, when accelerations are induced by scalp stimulation, acidosis is present in less than 10 percent of fetuses, and when no accelerations occur, acidosis is present in about 50 percent of fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/18,19,33,34\">",
"     18,19,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H22#H22\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'FHR response to stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore, if recurrent late decelerations are accompanied by",
"    <span class=\"nowrap\">",
"     minimal/absent",
"    </span>",
"    variability and absent accelerations and persist despite attempts at intrauterine resuscitation, then fetal acidemia cannot be excluded and expeditious delivery is generally indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11184000\">",
"    <span class=\"h2\">",
"     Fetal tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal tachycardia is defined as a baseline fetal heart rate of greater than 160 bpm for at least 10 minutes. Causes of fetal tachycardia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal-fetal infection",
"     </li>",
"     <li>",
"      Medications (eg, beta-agonists,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      , cocaine)",
"     </li>",
"     <li>",
"      Maternal hyperthyroidism",
"     </li>",
"     <li>",
"      Placental abruption",
"     </li>",
"     <li>",
"      Fetal hypoxia",
"     </li>",
"     <li>",
"      Elevated maternal catecholamine levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, fetal tachycardia can be due to a fetal tachyarrhythmia, such as atrial flutter or supraventricular tachycardia. These tachyarrhythmias are characterized by a very high fetal heart rate, often in excess of 200 bpm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24202?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\", section on 'Tachyarrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal tachycardia less than 200 bpm alone has not been strongly associated with fetal acidemia, unless associated with recurrent decelerations, absent accelerations, or",
"    <span class=\"nowrap\">",
"     minimal/absent",
"    </span>",
"    variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/35-38\">",
"     35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of fetal tachycardia should include assessment for maternal infection or abruption and a review of maternal medications. Appropriate treatment should be initiated if the underlying cause can be identified. In addition, scalp stimulation should be performed to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic. Delivery is indicated if the tracing does not improve and acidemia is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11184007\">",
"    <span class=\"h2\">",
"     Intermittent and recurrent variable decelerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable decelerations occur when the umbilical cord is compressed. Intermittent variable decelerations (associated with &lt;50 percent of contractions) are frequently observed in labor tracings and are not usually associated with adverse consequences, presumably because transient cord compression is well tolerated by the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, they do not require intervention.",
"   </p>",
"   <p>",
"    Metabolic acidosis or mixed metabolic and respiratory acidosis can develop, however, with increasing duration, depth, and frequency of variable decelerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/40\">",
"     40",
"    </a>",
"    ]. Therefore, recurrent variable decelerations (&gt;50 percent of contractions) require a greater degree of surveillance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H1059921#H1059921\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Recurrent variable decelerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation is aimed at assessing the frequency, depth, and duration of the decelerations and associated contraction pattern. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variable decelerations of increasing depth and duration are predictive of impending acidemia.",
"     </li>",
"     <li>",
"      Variable decelerations with a slow return to baseline (&ldquo;late return&rdquo;) are more predictive of impending acidemia than those with a rapid return to baseline.",
"     </li>",
"     <li>",
"      Moderate variability or fetal accelerations suggests the absence of fetal acidemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of variable decelerations is generally aimed at resolving cord compression. Change of maternal position is a reasonable first treatment option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/41\">",
"     41",
"    </a>",
"    ]. Amnioinfusion can be useful in resolving persistent variable decelerations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5252?source=see_link\">",
"     \"Amnioinfusion: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43203?source=see_link\">",
"     \"Amnioinfusion: Technique\"",
"    </a>",
"    .) Adjunctive measures to improve fetal oxygenation (oxygen supplementation, intravenous fluid bolus, reduce uterine contraction frequency) may be useful. In addition, scalp stimulation should be performed to provoke fetal heart rate acceleration, which is a sign that the fetus is not acidotic. Delivery is indicated if the tracing does not improve and acidemia is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11184014\">",
"    <span class=\"h2\">",
"     Minimal variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;FHR variability results from oscillatory input by the parasympathetic nervous system. New onset minimal variability (amplitude 0 to 5 bpm) may occur for several reasons, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal sleep cycle - These cycles generally last approximately 20 minutes, but may persist for as long as one hour. When the fetal sleep cycles are over, moderate variability should return.",
"     </li>",
"     <li>",
"      CNS depressants - The most common medications that decrease variability are opioids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      . The effect of maternal opioids on FHR variability generally lasts no more than two hours.",
"     </li>",
"     <li>",
"      Fetal hypoxemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the FHR pattern had been normal, a reasonable approach to the assessment and management of new onset decreased fetal variability is to consider a fetal sleep cycle or the effect of recently administered maternal medications. Both of these causes warrant expectant management. It is also prudent to attempt to induce accelerations with scalp stimulation, as the presence of accelerations is strong evidence of the absence of fetal acidemia at that time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/19\">",
"     19",
"    </a>",
"    ]. A maternal fluid bolus, repositioning,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maternal oxygen administration are appropriate adjunctive measures (",
"    <a class=\"graphic graphic_table graphicRef57979 \" href=\"mobipreview.htm?26/49/27420\">",
"     table 3",
"    </a>",
"    ), especially in settings in which a benign etiology is less certain, such as coexistent FHR abnormalities or pregnancy complications associated with uteroplacental insufficiency.",
"   </p>",
"   <p>",
"    The new onset of decreased variability is important because absent or decreased variability can also be related to congenital or acquired anomalies of the CNS or heart, or to prematurity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38311/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H12#H12\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Absent or minimal variability with decelerations or bradycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11184021\">",
"    <span class=\"h2\">",
"     Fetal bradycardia/prolonged deceleration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal bradycardia (below 110 bpm) or a prolonged deceleration (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"mobipreview.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    ) are approached in a similar manner clinically, since the distinction between these two entities is based primarily on the number of minutes of the decrease in fetal heart rate. The causes of prolonged deceleration or fetal bradycardia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid fetal descent",
"     </li>",
"     <li>",
"      Cord prolapse",
"     </li>",
"     <li>",
"      Placental abruption",
"     </li>",
"     <li>",
"      Maternal hypotension",
"     </li>",
"     <li>",
"      Uterine rupture",
"     </li>",
"     <li>",
"      Tachysystole",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetal acidemia is more likely when bradycardia is associated with minimal or absent variability and absent accelerations during normal baseline periods, if present.",
"   </p>",
"   <p>",
"    Treatment of fetal bradycardia or prolonged deceleration is aimed at the cause. Evaluation should include assessment of maternal blood pressure and contraction frequency and strength, and physical examination for evidence of rapid fetal descent, cord prolapse, placental abruption, or uterine rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29494?source=see_link\">",
"     \"Umbilical cord prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44102?source=see_link\">",
"     \"Rupture of the unscarred uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"     \"Uterine rupture after previous cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If nonsurgical management of the underlying cause is not possible or does not result in resolution of the bradycardia, delivery is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11184028\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three-tier system for the categorization of intrapartum fetal heart rate tracings is a useful means of approaching management (",
"      <a class=\"graphic graphic_table graphicRef57583 \" href=\"mobipreview.htm?11/43/11964\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11183965\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Category I tracings are not associated with fetal metabolic acidemia at the time of observation. Uncomplicated patients with category I tracings can be followed routinely, with reassessment of the tracing at least every 30 minutes in the first stage of labor and every 15 minutes in the second stage. (See",
"      <a class=\"local\" href=\"#H11183972\">",
"       'Category I FHR tracings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Category III tracings are associated with an increased risk of fetal hypoxic acidemia. Patients with category III tracings should be prepared for delivery while initiating resuscitative measures. If there is no improvement in the tracing after conservative measures (",
"      <a class=\"graphic graphic_table graphicRef57979 \" href=\"mobipreview.htm?26/49/27420\">",
"       table 3",
"      </a>",
"      ) and scalp stimulation does not result in acceleration, delivery should be accomplished expeditiously, but ensuring maternal safety. (See",
"      <a class=\"local\" href=\"#H11183979\">",
"       'Category III FHR tracings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential for development of fetal acidosis varies widely across the different types of category II tracings. Patients with these tracings should be evaluated for factors that may reduce fetal oxygenation, taking into account associated clinical circumstances. Conservative intervention is usually indicated (",
"      <a class=\"graphic graphic_table graphicRef57979 \" href=\"mobipreview.htm?26/49/27420\">",
"       table 3",
"      </a>",
"      ), with frequent reassessment to determine whether delivery should be performed. (See",
"      <a class=\"local\" href=\"#H11183986\">",
"       'Category II FHR tracings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/1\">",
"      Nielsen PV, Stigsby B, Nickelsen C, Nim J. Intra- and inter-observer variability in the assessment of intrapartum cardiotocograms. Acta Obstet Gynecol Scand 1987; 66:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/2\">",
"      Beaulieu MD, Fabia J, Leduc B, et al. The reproducibility of intrapartum cardiotocogram assessments. Can Med Assoc J 1982; 127:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/3\">",
"      Chauhan SP, Klauser CK, Woodring TC, et al. Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes: interobserver variability. Am J Obstet Gynecol 2008; 199:623.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/4\">",
"      Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/5\">",
"      Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/6\">",
"      Jackson M, Holmgren CM, Esplin MS, et al. Frequency of fetal heart rate categories and short-term neonatal outcome. Obstet Gynecol 2011; 118:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/7\">",
"      Berkus MD, Langer O, Samueloff A, et al. Electronic fetal monitoring: what's reassuring? Acta Obstet Gynecol Scand 1999; 78:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/8\">",
"      Krebs HB, Petres RE, Dunn LJ, Smith PJ. Intrapartum fetal heart rate monitoring. VI. Prognostic significance of accelerations. Am J Obstet Gynecol 1982; 142:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/9\">",
"      Tejani N, Mann LI, Bhakthavathsalan A, Weiss RR. Correlation of fetal heart rate-uterine contraction patterns with fetal scalp blood pH. Obstet Gynecol 1975; 46:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/10\">",
"      Dellinger EH, Boehm FH, Crane MM. Electronic fetal heart rate monitoring: early neonatal outcomes associated with normal rate, fetal stress, and fetal distress. Am J Obstet Gynecol 2000; 182:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/11\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/12\">",
"      Liston R, Sawchuck D, Young D, et al. Fetal health surveillance: antepartum and intrapartum consensus guideline. J Obstet Gynaecol Can 2007; 29:S3.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Neonatal encephalopathy and cerebral palsy: defining the pathogenesis and pathophysiology. Elk Grove Village (IL): AAP; ACOG, Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/14\">",
"      Winkler CL, Hauth JC, Tucker JM, et al. Neonatal complications at term as related to the degree of umbilical artery acidemia. Am J Obstet Gynecol 1991; 164:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/15\">",
"      Parer JT, King T, Flanders S, et al. Fetal acidemia and electronic fetal heart rate patterns: is there evidence of an association? J Matern Fetal Neonatal Med 2006; 19:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/16\">",
"      Lin CC, Vassallo B, Mittendorf R. Is intrapartum vibroacoustic stimulation an effective predictor of fetal acidosis? J Perinat Med 2001; 29:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/17\">",
"      Clark SL, Gimovsky ML, Miller FC. Fetal heart rate response to scalp blood sampling. Am J Obstet Gynecol 1982; 144:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/18\">",
"      Clark SL, Gimovsky ML, Miller FC. The scalp stimulation test: a clinical alternative to fetal scalp blood sampling. Am J Obstet Gynecol 1984; 148:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/19\">",
"      Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. Obstet Gynecol 2002; 99:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/20\">",
"      Westgate JA, Wibbens B, Bennet L, et al. The intrapartum deceleration in center stage: a physiologic approach to the interpretation of fetal heart rate changes in labor. Am J Obstet Gynecol 2007; 197:236.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/21\">",
"      Fawole B, Hofmeyr GJ. Maternal oxygen administration for fetal distress. Cochrane Database Syst Rev 2012; 12:CD000136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/22\">",
"      Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstet Gynecol 2005; 105:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/23\">",
"      McNamara H, Johnson N, Lilford R. The effect on fetal arteriolar oxygen saturation resulting from giving oxygen to the mother measured by pulse oximetry. Br J Obstet Gynaecol 1993; 100:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/24\">",
"      Thorp JA, Trobough T, Evans R, et al. The effect of maternal oxygen administration during the second stage of labor on umbilical cord blood gas values: a randomized controlled prospective trial. Am J Obstet Gynecol 1995; 172:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/25\">",
"      Khazin AF, Hon EH, Hehre FW. Effects of maternal hyperoxia on the fetus. I. Oxygen tension. Am J Obstet Gynecol 1971; 109:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/26\">",
"      Morishima HO, Daniel SS, Richards RT, James LS. The effect of increased maternal PaO2 upon the fetus during labor. Am J Obstet Gynecol 1975; 123:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/27\">",
"      Antoine C, Young BK, Silverman F. Simultaneous measurement of fetal tissue pH and transcutaneous pO2 during labor. Eur J Obstet Gynecol Reprod Biol 1984; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/28\">",
"      Suidan JS, Antoine C, Silverman F, et al. Human maternal-fetal lactate relationships. J Perinat Med 1984; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/29\">",
"      Nelson KB, Dambrosia JM, Ting TY, Grether JK. Uncertain value of electronic fetal monitoring in predicting cerebral palsy. N Engl J Med 1996; 334:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/30\">",
"      Larma JD, Silva AM, Holcroft CJ, et al. Intrapartum electronic fetal heart rate monitoring and the identification of metabolic acidosis and hypoxic-ischemic encephalopathy. Am J Obstet Gynecol 2007; 197:301.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/31\">",
"      Paul RH, Suidan AK, Yeh S, et al. Clinical fetal monitoring. VII. The evaluation and significance of intrapartum baseline FHR variability. Am J Obstet Gynecol 1975; 123:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/32\">",
"      Powell OH, Melville A, MacKenna J. Fetal heart rate acceleration in labor: excellent prognostic indicator. Am J Obstet Gynecol 1979; 134:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/33\">",
"      Edersheim TG, Hutson JM, Druzin ML, Kogut EA. Fetal heart rate response to vibratory acoustic stimulation predicts fetal pH in labor. Am J Obstet Gynecol 1987; 157:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/34\">",
"      Smith CV, Nguyen HN, Phelan JP, Paul RH. Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations. Am J Obstet Gynecol 1986; 155:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/35\">",
"      Honjo S, Yamaguchi M. Umbilical artery blood acid-base analysis and fetal heart rate baseline in the second stage of labor. J Obstet Gynaecol Res 2001; 27:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/36\">",
"      Strachan BK, Sahota DS, van Wijngaarden WJ, et al. Computerised analysis of the fetal heart rate and relation to acidaemia at delivery. BJOG 2001; 108:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/37\">",
"      Gilstrap LC 3rd, Hauth JC, Hankins GD, Beck AW. Second-stage fetal heart rate abnormalities and type of neonatal acidemia. Obstet Gynecol 1987; 70:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/38\">",
"      Krebs HB, Petres RE, Dunn LJ. Intrapartum fetal heart rate monitoring. V. Fetal heart rate patterns in the second stage of labor. Am J Obstet Gynecol 1981; 140:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/39\">",
"      Garite TJ, Dildy GA, McNamara H, et al. A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns. Am J Obstet Gynecol 2000; 183:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/40\">",
"      Frasch MG, Grasch MG, Frasch MG, et al. Measures of acidosis with repetitive umbilical cord occlusions leading to fetal asphyxia in the near-term ovine fetus. Am J Obstet Gynecol 2009; 200:200.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/41\">",
"      Simpson KR. Intrauterine resuscitation during labor: review of current methods and supportive evidence. J Midwifery Womens Health 2007; 52:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/42\">",
"      Giannina G, Guzman ER, Lai YL, et al. Comparison of the effects of meperidine and nalbuphine on intrapartum fetal heart rate tracings. Obstet Gynecol 1995; 86:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/43\">",
"      Kopecky EA, Ryan ML, Barrett JF, et al. Fetal response to maternally administered morphine. Am J Obstet Gynecol 2000; 183:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/44\">",
"      Hallak M, Martinez-Poyer J, Kruger ML, et al. The effect of magnesium sulfate on fetal heart rate parameters: A randomized, placebo-controlled trial. Am J Obstet Gynecol 1999; 181:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/45\">",
"      Devoe LD. Antepartum fetal heart rate testing in preterm pregnancy. Obstet Gynecol 1982; 60:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/46\">",
"      Assali NS, Brinkman CR 3rd, Woods JR Jr, et al. Development of neurohumoral control of fetal, neonatal, and adult cardiovascular functions. Am J Obstet Gynecol 1977; 129:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38311/abstract/47\">",
"      van der Moer PE, Gerretsen G, Visser GH. Fixed fetal heart rate pattern after intrauterine accidental decerebration. Obstet Gynecol 1985; 65:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16663 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38311=[""].join("\n");
var outline_f37_26_38311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11184028\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11183965\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197194995\">",
"      FREQUENCY OF CATEGORY I, II, AND III TRACINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11183972\">",
"      CATEGORY I FHR TRACINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11183979\">",
"      CATEGORY III FHR TRACINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11183986\">",
"      CATEGORY II FHR TRACINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11183993\">",
"      Recurrent late decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11184000\">",
"      Fetal tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11184007\">",
"      Intermittent and recurrent variable decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11184014\">",
"      Minimal variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11184021\">",
"      Fetal bradycardia/prolonged deceleration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11184028\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/16663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/5/3165\" title=\"table 1\">",
"      NICHHD FHR interpretation guide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/43/11964\" title=\"table 2\">",
"      Category I II and III FHR tracings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/49/27420\" title=\"table 3\">",
"      Resuscitative measures for category II and III FHR tracings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5252?source=related_link\">",
"      Amnioinfusion: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43203?source=related_link\">",
"      Amnioinfusion: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44102?source=related_link\">",
"      Rupture of the unscarred uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29494?source=related_link\">",
"      Umbilical cord prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_26_38312="Metformin in the treatment of diabetes mellitus";
var content_f37_26_38312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metformin in the treatment of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38312/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38312/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38312/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/26/38312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of oral hypoglycemic drugs directly improve insulin action: biguanides (only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is currently available) and thiazolidinediones. In the absence of contraindications, metformin is considered the first choice for oral treatment of type 2 diabetes (",
"    <a class=\"graphic graphic_table graphicRef56876 \" href=\"mobipreview.htm?3/22/3437\">",
"     table 1",
"    </a>",
"    ). A 2006 consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), updated in 2009, proposed that metformin therapy (in the absence of contraindications) be initiated, concurrent with lifestyle intervention, at the time of diabetes diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology, efficacy, and side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for the treatment of diabetes will be reviewed here. A general discussion of initial pharmacologic treatment of type 2 diabetes and the role of metformin in the prevention of diabetes, in the treatment of polycystic ovary syndrome, and in gestational diabetes are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H20#H20\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37866?source=see_link&amp;anchor=H18999792#H18999792\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is effective only in the presence of insulin, and its major effect is to decrease hepatic glucose output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, metformin increases insulin-mediated glucose utilization in peripheral tissues (such as muscle and liver), particularly after meals, and has an antilipolytic effect that lowers serum free fatty acid concentrations, thereby reducing substrate availability for gluconeogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. As a result of the improvement in glycemic control, serum insulin concentrations decline slightly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    also increases intestinal glucose utilization via nonoxidative metabolism, at least in experimental animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4\">",
"     4",
"    </a>",
"    ]. The lactate produced by this process is largely metabolized in the liver as a substrate for gluconeogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/3\">",
"     3",
"    </a>",
"    ]. The latter effect could protect against hypoglycemia.",
"   </p>",
"   <p>",
"    The molecular mechanisms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    action are not fully known. Activation of the enzyme AMP-activated protein kinase (AMK) appears to be the mechanism by which metformin lowers serum lipid and blood glucose concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Metformin works through the Peutz-Jeghers protein, LKB1, to regulate AMPK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/11\">",
"     11",
"    </a>",
"    ]. LKB1 is a tumor suppressor and activation of AMPK through LKB1 may play a role in inhibiting cell growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1209560\">",
"     'Cancer incidence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    may also inhibit hepatic glucose production via a mechanism independent of AMK and LKB1. In mice deficient in AMK or LKB1, metformin successfully inhibited glucose production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/13\">",
"     13",
"    </a>",
"    ]. The inhibition was associated with a reduction in intracellular ATP concentration. Thus, alternative pathways are likely to be involved in the inhibition of gluconeogenesis by metformin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    typically lowers fasting blood glucose concentrations by approximately 20 percent and A1C by 1.5 percent, a response similar to that achieved with a sulfonylurea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/3,4,6,7,14\">",
"     3,4,6,7,14",
"    </a>",
"    ]. The US Multicenter Metformin Study Group, for example, randomly assigned obese patients with type 2 diabetes who were inadequately controlled on diet alone to either metformin or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/15\">",
"     15",
"    </a>",
"    ]. After 29 weeks, the mean A1C concentration was 7.1 percent in the metformin group as compared with 8.6 percent in the placebo group.",
"   </p>",
"   <p>",
"    In those who are obese,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    promotes modest weight reduction or at least weight stabilization (",
"    <a class=\"graphic graphic_figure graphicRef55968 \" href=\"mobipreview.htm?43/19/44350\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4,6,14\">",
"     4,6,14",
"    </a>",
"    ]. This is in contrast to the weight gain often associated with insulin or sulfonylurea treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. In one large study, for example, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    , or insulin gained an average of 3.5 to 4.8 kg, whereas those receiving metformin had no change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to causing modest weight loss,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has other advantages as compared with other oral agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      may be less likely to cause hypoglycemia. Careful blood glucose monitoring is still needed during the first weeks or months of treatment with metformin to avoid this problem.",
"     </li>",
"     <li>",
"      It has lipid-lowering activity, resulting in a decrease in serum triglyceride and free fatty acid concentrations, a small decrease in serum low-density-lipoprotein (LDL) cholesterol concentrations, and a very modest increase in serum high-density-lipoprotein (HDL) cholesterol concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/3,4,7\">",
"       3,4,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of 29 trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      as monotherapy compared with other oral agents (sulfonylureas, thiazolidinediones, meglitinides, glucosidase inhibitors), insulin, diet, or placebo found that metformin, in overweight and obese diabetics, resulted in decreased all-cause mortality and decreased rate of myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A comparison of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and other oral agents for initial therapy is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H20#H20\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Comparison of initial therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of drugs are often necessary to achieve optimal glycemic control.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    can be given in combination with sulfonylureas, insulin, glinides, alpha-glucosidase inhibitors, thiazolidinediones,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    , and DPP-IV inhibitors. Combination therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Combination with metformin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are gastrointestinal, including a metallic taste in the mouth, mild anorexia, nausea, abdominal discomfort, and soft bowel movements or diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4\">",
"     4",
"    </a>",
"    ]. These symptoms are usually mild, transient, and reversible after dose reduction or discontinuation of the drug. In clinical trials, only 5 percent of study subjects discontinue metformin because of the gastrointestinal side effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    reduces intestinal absorption of vitamin B12 in up to 30 percent of patients, and lowers serum vitamin B12 concentrations in 5 to 10 percent, but only rarely causes megaloblastic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/17\">",
"     17",
"    </a>",
"    ]. In some patients with vitamin B12 deficiency, peripheral neuropathy may precede the development of megaloblastic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link&amp;anchor=H2126391#H2126391\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose and duration of use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    correlates with the risk of vitamin B12 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study, this reduction appeared to be due to poor absorption of B12 in the ileum and was corrected by administration of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    (1.2 g daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study, supplementation with a daily multivitamin was associated with a lower prevalence of B12 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biguanide therapy in type 2 diabetes with phenformin in the past or currently with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    can lead to lactic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Symptoms of lactic acidosis are nonspecific and may include anorexia, nausea, vomiting, abdominal pain, lethargy, hyperventilation, and hypotension. Serum lactate concentrations are usually less than 2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in patients taking metformin, values that are not clinically important. More serious lactic acid accumulation occurs with superimposed shock or in the presence of predisposing conditions to metformin toxicity as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Predisposing factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    -induced lactic acidosis can occur in patients with normal renal and hepatic function. One such setting is a purposeful metformin overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In addition, patients with the genetic diabetes syndrome, maternally inherited diabetes and deafness (MIDD), are at increased risk of developing lactic acidosis with metformin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H18#H18\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Genetic defects in mitochondrial DNA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=see_link\">",
"     \"Causes of lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lactic acidosis in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    users appears to be very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ]. In a review of 11,800 patients treated with metformin for a mean of about two years, only two patients developed lactic acidosis (incidence nine cases per 100,000 person-years of exposure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/23\">",
"     23",
"    </a>",
"    ]. This compares with a rate of 40 to 64 per 100,000 patient-years in those taking phenformin, a previously approved biguanide that was removed from the market because of this side effect.",
"   </p>",
"   <p>",
"    This finding is consistent with a systematic review of 347 randomized trials and prospective cohort studies representing 70,490 patient-years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    use and 55,451 patient-years in the comparator group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/28\">",
"     28",
"    </a>",
"    ]. There were no cases of lactic acidosis. Almost one-half of the studies allowed inclusion of patients with a serum creatinine above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     micromol/L],",
"    </span>",
"    and almost all allowed inclusion of patients with at least one contraindication to metformin therapy. However, the number of patients who actually had these contraindications was not presented and, therefore, the safety of metformin in the presence of standard contraindications could not be assessed. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Contraindications in clinical practice'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its rarity, lactic acidosis related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    remains a concern because of the high case fatality rate. Most cases have occurred in patients with shock or tissue hypoxia or in the presence of several other predisposing conditions; all are relative or absolute contraindications to the institution of metformin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4,22,29\">",
"     4,22,29",
"    </a>",
"    ]. Of these factors, impaired renal function is of greatest concern, heart failure least worrisome.",
"   </p>",
"   <p>",
"    These predisposing",
"    <span class=\"nowrap\">",
"     factors/contraindications",
"    </span>",
"    are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired renal function, which has been variably defined; one definition is serum creatinine concentration above 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (124",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in women and 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in men",
"     </li>",
"     <li>",
"      Concurrent liver disease or alcohol abuse",
"     </li>",
"     <li>",
"      Heart failure; however, despite safety concerns,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      use has been common and well tolerated in diabetic patients with heart failure (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=see_link&amp;anchor=H12#H12\">",
"       \"Heart failure in diabetes mellitus\", section on 'Metformin'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Past history of lactic acidosis",
"     </li>",
"     <li>",
"      Decreased tissue perfusion or hemodynamic instability due to infection or other causes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of all of the contraindications,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    accumulation due to renal insufficiency is of greatest concern. Use of the serum creatinine alone may not be accurate in elderly patients or others with reduced muscle mass. These patients have diminished creatinine production. As a result, a given serum creatinine can represent a substantially lower glomerular filtration rate (GFR) than seen in patients with normal muscle mass. Rather than using serum creatinine alone, the GFR can be estimated in patients with a stable serum creatinine concentration. An estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    would be the approximate equivalent of the above serum creatinine cutoffs (1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [124",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in women and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in men). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United Kingdom where serum creatinine limits are 130 or 150",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    (1.5 or 1.7",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    calculation of estimated GFR in over 30,000 patients with type 2 diabetes and analysis of the proportion of patients in whom creatinine and estimated GFR limits contraindicated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    showed that the serum creatinine limits approximately corresponded to estimated GFR thresholds of 30 to 49",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise serum creatinine limits and eGFR thresholds for the safe use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    remain uncertain. In clinical practice, some UpToDate experts use an eGFR of &gt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    as a threshold for the safe use of metformin. For a patient with an eGFR between 30 and 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    we typically reduce the metformin dose by half. In addition, we advise such patients to stop taking metformin if they have any illness, such as influenza, upper respiratory infection, or urinary tract infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Contraindications in clinical practice'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    should be discontinued in patients who develop one of the predisposing factors listed above. In addition, patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure) or undergo a surgical procedure (with potential compromise of circulation) should have metformin held until stable renal function can be established (normal urine output, normal serum creatinine, and no physical exam evidence of fluid overload or circulatory compromise). Serum creatinine is typically assessed two to three days after contrast administration. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Contraindications in clinical practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used according to current prescribing recommendations, the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    -induced lactic acidosis is close to zero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/32\">",
"     32",
"    </a>",
"    ]. However, inappropriate prescription of metformin remains a common problem. A number of patients treated with metformin have one or more of the above contraindications (most often renal insufficiency or heart failure). The frequency with which this occurs has varied in different series, with a range of 14 to 27 percent in most reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the appreciable disregard of contraindications, the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    -induced lactic acidosis is not increasing. This finding has led some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/37-40\">",
"     37-40",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/41\">",
"     41",
"    </a>",
"    ] to recommend a reevaluation of the contraindications to metformin therapy, particularly in patients with stable, well-compensated heart failure or with estimated GFR above 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Improved clinical outcomes with metformin have been reported in observational studies of patients with diabetes and heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the relationship between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    use, intravenous contrast administration, and the occurrence of lactic acidosis is not well studied. In a systematic review of studies and evidence-based guidelines on the use of intravenous contrast in patients taking metformin, the only available data were from case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/39\">",
"     39",
"    </a>",
"    ]. The majority of cases of metformin-related lactic acidosis occurred in patients with abnormal renal function who received intravenous contrast medium. The risk of metformin-induced lactic acidosis in patients with normal renal function who receive intravenous contrast is unknown but appears to be rare. Until more data are available, however, we prefer to hold metformin in patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure), irrespective of baseline renal function, until stable renal function can be established. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Predisposing factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In summary, the risk of lactic acidosis in the overall population of patients with type 2 diabetes treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is low. Although patients with one or more of the predisposing factors cited above are most at risk, the incidence of lactic acidosis in these patients is not known and may be low in patients with borderline risk factors, such as well-compensated heart failure. This is an important issue because the benefits of metformin in the treatment of type 2 diabetes mellitus may outweigh the risk in such patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of bicarbonate therapy in patients with lactic acidosis and shock or tissue hypoxia is not well established, except in severe metabolic acidosis, because of concern about possible worsening of intracellular acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this may not apply to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    -associated lactic acidosis since, in patients with concurrent renal failure, bicarbonate hemodialysis can both correct the acidosis and remove metformin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Treatment of metformin-induced lactic acidosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21799?source=see_link\">",
"     \"Metformin poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential drug interaction exists between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , as cimetidine may lower the renal clearance of metformin due to competitive inhibition of renal tubular secretion of metformin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/48\">",
"     48",
"    </a>",
"    ]. This interaction could increase the risk of hypoglycemia in patients taking metformin plus a sulfonylurea or insulin. Other H2-blockers are less likely to affect the renal handing of metformin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=see_link\">",
"     \"Drugs that elevate the serum creatinine concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    should be discontinued immediately prior to and for 48 hours after any radiologic procedure involving parenteral administration of iodinated contrast material. The rationale for this recommendation is to avoid the potential for high plasma metformin concentrations (and lactic acidosis) if the patient develops contrast-induced acute renal failure. In a review of the 110 published cases of lactic acidosis associated with metformin, nine occurred in patients with contrast-induced renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/29\">",
"     29",
"    </a>",
"    ]. This risk for contrast-induced acute renal failure is greatest in diabetic patients with renal insufficiency; however, such patients should not be on metformin in the first place. Metformin can be restarted once normal renal function has been demonstrated (normal urine output, normal serum creatinine, and no physical exam evidence of fluid overload or circulatory compromise). Serum creatinine is typically assessed two to three days after contrast administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1209560\">",
"    <span class=\"h2\">",
"     Cancer incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data suggest that use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    decreases cancer incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In meta-analyses of predominantly case-control and cohort studies in patients with type 2 diabetes, use of metformin compared with nonuse or with use of other diabetes treatment was associated with a reduced risk of all cancers (RR 0.61, 95% CI 0.54-0.70) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], colorectal cancer (RR 0.64, 95% CI 0.54-0.76) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], and lower cancer mortality (RR 0.66, 95% CI 0.49-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/52\">",
"     52",
"    </a>",
"    ]. Among the meta-analyses, the summary effect estimates were similar. With the exception of colorectal cancer, there was significant heterogeneity among the individual studies.",
"   </p>",
"   <p>",
"    In contrast to the observational data, a meta-analysis of randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    to a comparator (thiazolidinedione, sulfonylurea, DPP-IV inhibitor, or placebo) did not show a reduction in cancer incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/55\">",
"     55",
"    </a>",
"    ]. The majority of the trials were not designed to explore cancer outcomes, which were not uniformly collected or adjudicated; therefore, malignancies were noted as serious adverse events. In addition, average follow-up for cancer outcomes was only four years. A longer interval may be required to adequately assess cancer outcomes. Thus, prospective clinical trial data are required to confirm or refute this protective effect.",
"   </p>",
"   <p>",
"    A possible mechanism by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    may decrease cancer incidence is regulation of AMPK through LKB1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/11\">",
"     11",
"    </a>",
"    ]. LKB1 is a tumor suppressor and activation of AMPK through LKB1 may play a role in inhibiting cell growth. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DOSING AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is absorbed rapidly from the small intestine, with peak plasma concentrations attained in two hours. It is not bound to plasma proteins, is not metabolized, and is rapidly excreted in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4,56\">",
"     4,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is available as 500, 850, or 1000 mg tablets, and should be taken with meals. We begin with 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast. The dose can be increased slowly (one tablet every one to two weeks) as necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4\">",
"     4",
"    </a>",
"    ]. The usual effective dose is 1500 to 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    per day; the maximum dose of 2550",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (850 mg TID) provides only marginally better glycemic control and is often not tolerated due to GI side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/1\">",
"     1",
"    </a>",
"    ]. Extended release tablets are also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38312/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], although patients who are doing well on immediate release metformin should probably continue with this preparation, as there is little, if any, additional benefit documented with the long-acting preparation. Combination tablets of metformin and sulfonylureas, thiazolidinediones, or DPP-IV inhibitors are also available.",
"   </p>",
"   <p>",
"    For patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , we measure A1C every three to six months, serum creatinine annually, and hemoglobin, hematocrit, and red cell indices at diagnosis and at other times if the patient develops symptoms suggestive of anemia, neuropathy, or deteriorating renal function. If anemia is present, vitamin B12 and folate should be measured and treated accordingly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    typically lowers A1C concentrations by approximately 1.5 percent, is not associated with weight gain, and is less likely to cause hypoglycemia than sulfonylureas and insulin. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the absence of specific contraindications, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    as initial therapy in most patients with type 2 diabetes (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). Insulin can also be considered a first-line therapy for all patients with type 2 diabetes, particularly patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    random glucose consistently &gt;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (16.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or ketonuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    at the time of diabetes diagnosis, along with consultation for lifestyle intervention (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). The dose of metformin should be titrated to its maximally effective dose (usually 1700 to 2550 mg per day in divided doses) over one to two months, as tolerated.",
"   </p>",
"   <p>",
"    Alternative initial treatment for patients with contraindications or intolerance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is reviewed separately. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Predisposing factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Medications for initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are gastrointestinal, including a metallic taste in the mouth, mild anorexia, nausea, abdominal discomfort, and soft bowel movements or diarrhea. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Lactic acidosis is an extremely uncommon side effect. However, it remains a concern because of the high case fatality rate. Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    should not be administered to individuals with predisposing factors for developing lactic acidosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Predisposing factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most important of these factors is impaired renal function. In non-elderly patients with normal muscle mass, one definition of impaired renal function is serum creatinine concentration above 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in women and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in men. Use of the serum creatinine alone may not be accurate in elderly patients or others with reduced muscle mass. Rather than using serum creatinine alone in these patients, the GFR can be estimated (if serum creatinine concentration is stable). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The precise serum creatinine limits and eGFR thresholds for the safe use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    remain uncertain. In the elderly or others with reduced muscle mass, an estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    would be the equivalent of the serum creatinine cutoffs of 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in women and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in men. However, in clinical practice, some experts use an eGFR of &gt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    as a threshold for the safe use of metformin. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Predisposing factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Contraindications in clinical practice'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/1\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/2\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/3\">",
"      Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/4\">",
"      Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/5\">",
"      Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/6\">",
"      United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/7\">",
"      Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/8\">",
"      Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/9\">",
"      Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277:25226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/10\">",
"      Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/11\">",
"      Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/12\">",
"      Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/13\">",
"      Foretz M, H&eacute;brard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/14\">",
"      Hermann LS, Scherst&eacute;n B, Bitz&eacute;n PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/15\">",
"      DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/16\">",
"      Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; :CD002966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/17\">",
"      de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340:c2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/18\">",
"      Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010; 103:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/19\">",
"      Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006; 166:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/20\">",
"      Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/21\">",
"      Pflipsen MC, Oh RC, Saguil A, et al. The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med 2009; 22:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/22\">",
"      Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992; 152:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/23\">",
"      Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/24\">",
"      Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010; 33:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/25\">",
"      Pepper GM, Schwartz M. Lactic acidosis associated with Glucophage use in a man with normal renal and hepatic function. Diabetes Care 1997; 20:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/26\">",
"      Teale KF, Devine A, Stewart H, Harper NJ. The management of metformin overdose. Anaesthesia 1998; 53:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/27\">",
"      Cryer DR, Nicholas SP, Henry DH, et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005; 28:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/28\">",
"      Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; :CD002967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/29\">",
"      Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/30\">",
"      Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/31\">",
"      Warren RE, Strachan MW, Wild S, McKnight JA. Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. Diabet Med 2007; 24:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/32\">",
"      Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004; 27:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/33\">",
"      Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions. JAMA 2002; 287:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/34\">",
"      Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/35\">",
"      Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003; 290:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/36\">",
"      Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010; 12:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/37\">",
"      Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007; 335:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/38\">",
"      McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005; 173:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/39\">",
"      Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/40\">",
"      Khurana R, Malik IS. Metformin: safety in cardiac patients. Heart 2010; 96:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/41\">",
"      Fantus IG. Metformin's contraindications: needed for now. CMAJ 2005; 173:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/42\">",
"      Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/43\">",
"      Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/44\">",
"      Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/45\">",
"      Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010; 53:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/46\">",
"      Lalau JD, Westeel PF, Debussche X, et al. Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin. Intensive Care Med 1987; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/47\">",
"      Heaney D, Majid A, Junor B. Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 1997; 12:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/48\">",
"      Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/49\">",
"      Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/50\">",
"      Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/51\">",
"      Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/52\">",
"      Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7:e33411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/53\">",
"      Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/54\">",
"      Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/55\">",
"      Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/56\">",
"      Sch&auml;fer G. Biguanides. A review of history, pharmacodynamics and therapy. Diabete Metab 1983; 9:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38312/abstract/57\">",
"      Direct-to-consumer advertisements for Glucophage XR. Med Lett Drugs Ther 2001; 43:25.",
"     </a>",
"    </li>",
"    <li>",
"     \"The Pink Sheet\" May 3, 2004; 66:16.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1809 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38312=[""].join("\n");
var outline_f37_26_38312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Contraindications in clinical practice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1209560\">",
"      Cancer incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DOSING AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1809|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/19/44350\" title=\"figure 1\">",
"      Drug therapy in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1809|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/22/3437\" title=\"table 1\">",
"      Options for diabetes Tx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=related_link\">",
"      Drugs that elevate the serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21799?source=related_link\">",
"      Metformin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_26_38313="Evaluation of the peripheral blood smear";
var content_f37_26_38313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the peripheral blood smear",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38313/contributors\">",
"     David S Rosenthal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38313/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/26/38313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/26/38313/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/26/38313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the peripheral blood smear is an inexpensive but powerful diagnostic tool in both children and adults. It provides rapid, reliable access to information about a variety of hematologic disorders. The smear offers a window into the functional status of the bone marrow, the factory producing all blood elements. It is particularly important when assessing cytopenic states (eg, anemia, leukopenia, thrombocytopenia). Review of the smear is an important adjunct to other clinical data; in some cases, the peripheral smear alone is sufficient to establish a diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Automated machines that deliver increasingly sophisticated data about blood counts and morphology tend to generalize and include a wide array of morphologic abnormalities. However, only an experienced reviewer can weigh the relative significance of observed findings and assess their importance within the context of other clinical data. A trained eye will also appreciate other subtleties of morphology that may be undetected by automated review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link\">",
"     \"Automated hematology instrumentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Review of the peripheral smear is not required in all patients with a hematological disorder. Certain straightforward conditions such as iron deficiency anemia can be easily diagnosed on the basis of clinical information and basic laboratory data (eg, mean corpuscular volume, serum iron, ferritin) alone. However, there are a number of settings in which interpretation of the peripheral smear is especially important. Three examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemolytic anemia &mdash; Review of red cell morphology may identify the cause of erythrocyte destruction (eg, the presence of bite cells points to a Heinz body hemolytic anemia) and the ultimate diagnosis (eg, oxidant damage to the red cell secondary to drugs)",
"     </li>",
"     <li>",
"      Thrombocytopenia &mdash; Distinguishing between increased platelet consumption and reduced platelet production can often be made through review of platelet size",
"     </li>",
"     <li>",
"      White cell disorders &mdash; The precise disease classification may rely upon evaluation of abnormal circulating cells (eg, the presence of Auer rods in a blast form in patients with acute myeloid leukemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of the peripheral blood smear will be discussed here. Evaluation of bone marrow aspirate smears is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13689?source=see_link\">",
"     \"Evaluation of bone marrow aspirate smears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reviewer must develop a systematic approach to the assessment of the peripheral smear. Below is one proposed system, which can be tailored to meet individual preferences and efficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Slide preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, peripheral blood smears are prepared using a wedge technique, either manually or via an automated technique. Smears should be made from one small drop of blood which has not been allowed to clot, and which has been completely mixed, if made from an anticoagulated blood sample that may have been allowed to settle for some time.",
"   </p>",
"   <p>",
"    The importance of a",
"    <strong>",
"     clean",
"    </strong>",
"    slide, free from dust, dirt, grease, and fingerprints, cannot be overstated. The presence of such contaminants can often be surmised when a large number of target cells or stomatocytes is present only in localized areas on the smear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/2\">",
"     2",
"    </a>",
"    ]. Repeating the procedure with alcohol-cleaned slides corrects this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Optimal area for review",
"    </span>",
"    &nbsp;&mdash;&nbsp;Review of the peripheral smear starts with choosing the best prepared and stained slide for examination. Scanning the entire slide under low power enables selection of an optimal area. All slides have areas that can interfere with an accurate assessment of morphology (",
"    <a class=\"graphic graphic_figure graphicRef52991 \" href=\"mobipreview.htm?4/50/4909\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One end of smear is too thick; stacks or clusters of red cells in this area cause erythrocytes to appear small and dark (",
"      <a class=\"graphic graphic_picture graphicRef61577 \" href=\"mobipreview.htm?20/13/20698\">",
"       picture 1",
"      </a>",
"      ). This area of the slide may be useful when searching for the presence of malarial parasites.",
"     </li>",
"     <li>",
"      The other end of the slide (the feather edge) will be spread too thin; red cells assume a \"brick-like\" or \"cobblestone\" type of pattern in this area (",
"      <a class=\"graphic graphic_picture graphicRef73335 \" href=\"mobipreview.htm?1/60/1992\">",
"       picture 2",
"      </a>",
"      ). Red cells in this area are not biconcave discs. However, this area may be useful when searching for small cytoplasmic inclusions, cellular fragments, cells containing Auer rods, and large circulating tumor cells (",
"      <a class=\"graphic graphic_picture graphicRef82314 \" href=\"mobipreview.htm?43/46/44771\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the optimal area, red cells will be more or less evenly spaced, and central pallor will be appreciated. In normal patients it should be rare to see two or more cells abutting (",
"      <a class=\"graphic graphic_picture graphicRef59683 \" href=\"mobipreview.htm?17/50/18210\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abnormal cell distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an otherwise optimal area of the peripheral smear shows abnormal distribution of red cells, this may be due to a number of medical conditions or artifacts, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rouleaux formation due to elevated levels of plasma proteins",
"      </strong>",
"      &mdash; In this setting the red cells may take on the appearance of a stack of coins, a phenomenon called rouleaux formation. This is most commonly seen in multiple myeloma (",
"      <a class=\"graphic graphic_picture graphicRef74369 \" href=\"mobipreview.htm?27/33/28183\">",
"       picture 5",
"      </a>",
"      ), but is also present in patients with increased levels of fibrinogen or total proteins from whatever cause (eg, polyclonal or monoclonal gammopathies) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Irregular collections of red cells",
"      </strong>",
"      &mdash; This may signify the presence of cold agglutinins (",
"      <a class=\"graphic graphic_picture graphicRef50522 \" href=\"mobipreview.htm?15/10/15527\">",
"       picture 6",
"      </a>",
"      ), as seen following certain infections and in cold agglutinin disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=see_link\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Collections of amorphous material",
"      </strong>",
"      &mdash; This may signify the presence of precipitates of cryoglobulins, as might occur in patients with hepatitis C infection. This can result in WBC counts as high as",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      and a doubling of the platelet count, both of which are attributed to various sizes of precipitated cryoglobulin particles, which may be counted as white blood cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelets in automated cell counters. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24681?source=see_link&amp;anchor=H11#H11\">",
"       \"Approach to the patient with thrombocytosis\", section on 'Mixed cryoglobulinemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Presence of large, clear areas",
"      </strong>",
"      &mdash; The presence of large, clear areas on an otherwise well-prepared smear, along with circular gaps between red cells, rouleaux formation, and red cell aggregates has been attributed to the presence of a circulating surfactant or oil-based material. One example would be the presence of polyoxyethylated castor oil (Cremophor), a nonionic surfactant used for solubilization of such hydrophobic agents as anesthetic agents, sedatives, immunosuppressives, sensitizers, antifungals, and antineoplastics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/4\">",
"       4",
"      </a>",
"      ]. Another would be presence of chemoembolization material containing a viscous oil together with a suspension of microparticles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RED BLOOD CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytes are the most numerous cells encountered in the peripheral smear. Morphologic examination should include assessment of size, shape, and color (pallor), and the presence of inclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal red cells approximate the size of the lymphocyte nucleus, with a diameter of 7 to 8 microns and a mean corpuscular volume (MCV) of approximately 90 femtoliters (",
"    <a class=\"graphic graphic_picture graphicRef59683 \" href=\"mobipreview.htm?17/50/18210\">",
"     picture 4",
"    </a>",
"    ). Automated Coulter Counters confirm the actual size, providing a numerical value in the form of the MCV. However, the MCV can be misleading in the presence of a dimorphic population of microcytic (small) and macrocytic (large) cells, since the average may be normal. A high red cell distribution width (RDW) is suggestive of such a divergent population of red cells of different sizes (ie, the presence of",
"    <strong>",
"     anisocytosis",
"    </strong>",
"    ), but does not permit direct appreciation of the components explaining the variation in size. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link&amp;anchor=H5#H5\">",
"     \"Mean corpuscular volume\", section on 'Red blood cell distribution width'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link&amp;anchor=H4#H4\">",
"     \"Automated hematology instrumentation\", section on 'The red blood cell volume histogram'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link&amp;anchor=H5#H5\">",
"     \"Automated hematology instrumentation\", section on 'Red cell distribution width'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cells should appear more or less round and have a smooth contour. Permutations in red blood cell shape (ie, the presence of",
"    <strong>",
"     poikilocytosis",
"    </strong>",
"    ) can signify important pathologic processes. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large oval-shaped cells (macroovalocytes, (",
"      <a class=\"graphic graphic_picture graphicRef74901 \" href=\"mobipreview.htm?9/45/9942\">",
"       picture 7",
"      </a>",
"      )) suggest a megaloblastic process (eg, deficiency of vitamin B12 or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      ). A high percentage of oval or elliptical cells (ovalocytes, elliptocytes) is characteristic of a number of inherited red cell abnormalities (",
"      <a class=\"graphic graphic_picture graphicRef63129 \" href=\"mobipreview.htm?9/61/10199\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=see_link&amp;anchor=H3#H3\">",
"       \"Hereditary elliptocytosis: Clinical features and diagnosis\", section on 'Clinical syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fragmented erythrocytes (schistocytes, helmet shaped cells, pieces of red cells) point to destruction within the vascular spaces as might occur in thrombotic thrombocytopenic purpura, disseminated intravascular coagulation (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef50715 \" href=\"mobipreview.htm?22/13/22739\">",
"       picture 10",
"      </a>",
"      ), or a defective prosthetic heart valve (",
"      <a class=\"graphic graphic_picture graphicRef74544 \" href=\"mobipreview.htm?23/11/23734\">",
"       picture 11",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tear drop-shaped red cells are commonly found in patients with extramedullary hematopoiesis (eg, primary myelofibrosis) (",
"      <a class=\"graphic graphic_picture graphicRef55274 \" href=\"mobipreview.htm?42/37/43606\">",
"       picture 12",
"      </a>",
"      ) as well as in the thalassemic disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Color",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of the red cell should be clear, in the form of central pallor (",
"    <a class=\"graphic graphic_picture graphicRef59683 \" href=\"mobipreview.htm?17/50/18210\">",
"     picture 4",
"    </a>",
"    ). A decrease in this proportion indicates hyperchromia (increase in hemoglobin concentration). Complete loss of central pallor is characteristic of spherocytes; these are dense, dark cells which are seen in hereditary spherocytosis and autoimmune hemolytic anemia (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"     picture 13",
"    </a>",
"    ). Hypochromic red cells, which are often also microcytic, are seen in conditions such as thalassemia, iron deficiency, and the sideroblastic anemias, and have just a thin rim of pink hemoglobin (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"     picture 14",
"    </a>",
"    ). A bluish tinge suggests excessive amounts of RNA, as would be seen in the reticulocyte (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 15",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     WHITE BLOOD CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal peripheral smear should contain a spectrum of mature leukocytes including lymphocytes, neutrophils, and monocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small lymphocytes comprise about 30 to 40 percent of the circulating white cells. They are identified by their clumped nucleus and scant rim of deep blue cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef56282 \" href=\"mobipreview.htm?13/7/13430\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The large granular lymphocyte (LGL) is a morphologically distinct lymphoid subset comprising 10 to 15 percent of normal peripheral blood mononuclear cells. These cells are approximately twice the size of red cells, with abundant cytoplasm, a round to oval nucleus, and a small number of azurophilic cytoplasmic granules (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"mobipreview.htm?0/1/28\">",
"     picture 17",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21018?source=see_link&amp;anchor=H458745942#H458745942\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atypical lymphocytes with a more generous and malleable cytoplasm, often indented by surrounding red cells, can be seen following viral infections such as infectious mononucleosis (",
"    <a class=\"graphic graphic_picture graphicRef55986 \" href=\"mobipreview.htm?1/24/1410\">",
"     picture 18",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\", section on 'Reactive lymphocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neutrophil series",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neutrophil series matures in an orderly fashion (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"mobipreview.htm?30/58/31651\">",
"     figure 2",
"    </a>",
"    ), from myeloblast (",
"    <a class=\"graphic graphic_picture graphicRef74014 \" href=\"mobipreview.htm?37/11/38067\">",
"     picture 19",
"    </a>",
"    ) to promyelocyte (",
"    <a class=\"graphic graphic_picture graphicRef73480 \" href=\"mobipreview.htm?21/25/21908\">",
"     picture 20",
"    </a>",
"    ) to myelocyte (",
"    <a class=\"graphic graphic_picture graphicRef54089 \" href=\"mobipreview.htm?1/7/1138\">",
"     picture 21",
"    </a>",
"    ) to metamyelocyte (",
"    <a class=\"graphic graphic_picture graphicRef59197 \" href=\"mobipreview.htm?25/60/26563\">",
"     picture 22",
"    </a>",
"    ) to band form (",
"    <a class=\"graphic graphic_picture graphicRef82140 \" href=\"mobipreview.htm?16/42/17060\">",
"     picture 23",
"    </a>",
"    ) to mature neutrophil (",
"    <a class=\"graphic graphic_picture graphicRef60666 \" href=\"mobipreview.htm?30/37/31316\">",
"     picture 24",
"    </a>",
"    ). Only the last two of these stages, the band form and the mature neutrophil, are normally present in the peripheral smear.",
"   </p>",
"   <p>",
"    An increased absolute number of neutrophilic band forms is called a &ldquo;left shift&rdquo; or &ldquo;bandemia&rdquo;, and is most often associated with infection. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to the patient with neutrophilia\", section on 'Left shift in the WBC differential'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metamyelocytes, and rarely myelocytes, may be seen during infections, pregnancy, leukemoid reactions, and recovery from myelosuppression. Forms less mature than the myelocyte (eg, promyelocytes, myeloblasts) are almost exclusively present in the peripheral blood in hematologic malignancies. The combined presence of early neutrophil forms, nucleated red blood cells, and tear drop-shaped red blood cells is called a \"leuko-erythroblastic\" blood picture, and suggests the presence of bone marrow invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Leukoerythroblastic smear'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The presence of a greater percent of myelocytes than metamyelocytes on the WBC differential (\"leukemic hiatus\") is strongly suspicious of the diagnosis of chronic myeloid leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lobulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils should have a three- to four-lobed nucleus and a pink-sandy, granular cytoplasm.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than five lobes defines hypersegmentation and suggests either a megaloblastic process (",
"      <a class=\"graphic graphic_picture graphicRef70609 \" href=\"mobipreview.htm?12/47/13046\">",
"       picture 25",
"      </a>",
"      ) or, rarely, iron deficiency anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/6\">",
"       6",
"      </a>",
"      ]. Grape-like (botryoid) multiple lobulations can also be seen in patients suffering from heat stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H40#H40\">",
"       \"Approach to the adult patient with anemia\", section on 'Neutrophil hypersegmentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the Pelger-Huet anomaly, which can occur as an inherited disorder or can be acquired in patients with myelodysplastic syndromes, there is reduced lobulation of mature neutrophils. Such cells typically have a bilobed nucleus connected by a thin strand, giving a \"pince-nez\" appearance, often accompanied by reduced or absent granulation (",
"      <a class=\"graphic graphic_picture graphicRef71990 \" href=\"mobipreview.htm?4/45/4816\">",
"       picture 26",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H4010760#H4010760\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'White blood cells'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Granulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dark blue, coarse granules (\"toxic granulations\") are non-specific findings characteristic of toxic systemic illnesses (",
"    <a class=\"graphic graphic_picture graphicRef70248 \" href=\"mobipreview.htm?7/17/7449\">",
"     picture 27",
"    </a>",
"    ). They represent azurophilic granules with abnormal staining properties. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the patient with neutrophilia\", section on 'Detection of infection or inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dohle bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;D&ouml;hle bodies are light blue in color, peripheral in location, and are most commonly seen in the periphery of neutrophils in patients with infection (",
"    <a class=\"graphic graphic_picture graphicRef70248 \" href=\"mobipreview.htm?7/17/7449\">",
"     picture 27",
"    </a>",
"    ). However, they have also been described in patients with burns, myelodysplasia, and in pregnancy. They represent areas of rough endoplasmic reticulum with bound ribosomes, giving them their blue color.",
"   </p>",
"   <p>",
"    Similar-looking inclusions are seen in patients with the May-Hegglin anomaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Abnormal or giant granules",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Azurophilic cytoplasmic inclusions (Alder-Reilly granules) have been described in neutrophils in the mucopolysaccharidoses (",
"      <a class=\"graphic graphic_picture graphicRef70847 \" href=\"mobipreview.htm?28/33/29201\">",
"       picture 28",
"      </a>",
"      ), but also have been seen in myeloperoxidase mutations, and myelodysplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Giant cytoplasmic granules within neutrophils, especially in a child with recurrent pyogenic infections, may indicate presence of the Chediak-Higashi syndrome (",
"      <a class=\"graphic graphic_picture graphicRef71313 \" href=\"mobipreview.htm?37/52/38722\">",
"       picture 29",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link&amp;anchor=H8#H8\">",
"       \"Primary disorders of phagocytic function: An overview\", section on 'Chediak-Higashi syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Eosinophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophils, normally present in small numbers (less than 5 percent of white cells), are recognized by their vibrant orange granules and a characteristic bilobed nucleus (",
"    <a class=\"graphic graphic_picture graphicRef53980 \" href=\"mobipreview.htm?8/1/8213\">",
"     picture 30",
"    </a>",
"    ). Increased numbers of eosinophils can be a clue to an underlying allergic state, parasitic infection, or other conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Basophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basophils, the least common of the circulating white blood cells, comprise less than 1 percent of the total white blood cell count, and are recognized by their prominent dark blue-black granules (",
"    <a class=\"graphic graphic_picture graphicRef51971 \" href=\"mobipreview.htm?22/41/23185\">",
"     picture 31",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Basophilic leukocytosis is a distinctly unusual condition, and is most often associated with basophilic or mast cell variants of acute or chronic leukemia. The most common causes of basophilia include myeloproliferative disorders, hypersensitivity or inflammatory reactions, hypothyroidism (myxedema), and certain infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Monocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monocytes are the largest normal cells encountered in the peripheral blood. They have a grayish blue cytoplasm, often replete with vacuoles, and a distinctive folded nucleus (",
"    <a class=\"graphic graphic_picture graphicRef56282 \" href=\"mobipreview.htm?13/7/13430\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PLATELETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are small purplish anuclear cells. There is normally at least one platelet visualized per oil-immersion field, and seven platelets per 100-power field; less than this number should alert the observer to possible thrombocytopenia. As an example, in an area of the peripheral blood smear where RBCs barely touch, the number of platelets per 100-power field, when multiplied by",
"    <span class=\"nowrap\">",
"     20,000/microL,",
"    </span>",
"    gives an estimate of the platelet count. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=see_link&amp;anchor=H7#H7\">",
"     \"Automated hematology instrumentation\", section on 'Platelet counting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Review of the smear is particularly important when the platelet count is depressed; pseudothrombocytopenia can be diagnosed by finding large clumps of platelets in smears taken from blood samples anticoagulated with EDTA&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"mobipreview.htm?26/15/26872\">",
"     picture 32",
"    </a>",
"    ), but not in samples anticoagulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or citrate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large platelets suggest a heightened marrow response secondary to a destructive process such as immune thrombocytopenia. When associated with fragmentation of red cells, microangiopathic processes such as DIC, HELLP syndrome, HUS, or TTP should be suspected (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a very high platelet count, extremely large platelets,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    megakaryocyte fragments is abnormal and suggests an underlying myeloproliferative neoplasm, such as essential thrombocythemia (",
"    <a class=\"graphic graphic_picture graphicRef61742 \" href=\"mobipreview.htm?22/0/22536\">",
"     picture 33",
"    </a>",
"    ) or primary myelofibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Platelet and white blood cell abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While platelets the size of red blood cells (&ldquo;giant platelets&rdquo;) may be seen in patients with increased platelet turnover or a myeloproliferative neoplasm, they may also be seen in a variety of congenital bleeding disorders (",
"    <a class=\"graphic graphic_picture graphicRef72433 \" href=\"mobipreview.htm?17/31/17911\">",
"     picture 34",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H27#H27\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Giant platelet disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RED CELL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several red cell abnormalities are common",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    important to recognize:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Permutation in size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microcytosis in the adult has a limited differential diagnosis which includes iron deficiency, thalassemia, the anemia of chronic disease, and the sideroblastic anemias (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    ). In addition, in the child microcytosis can be caused by chronic lead exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It can be difficult to distinguish between iron deficiency and thalassemia trait on the peripheral smear alone. The former is suggested by variation in cell size and shape (reflected by an increased red cell distribution width) and characteristic \"pencil cells\", whereas uniformly sized cells with increased numbers of target cells and teardrop cells are characteristic of thalassemia trait. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link\">",
"     \"Mean corpuscular volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macrocytosis has a broader differential. Reticulocytes are larger than the normal red cells and have a bluish tinge (polychromatophilia) (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 15",
"    </a>",
"    ). Macroovalocytes are large, oval shaped red cells, and are typical of megaloblastic processes such as folate and cobalamin deficiency (",
"    <a class=\"graphic graphic_picture graphicRef74901 \" href=\"mobipreview.htm?9/45/9942\">",
"     picture 7",
"    </a>",
"    ). Macrocytosis can also be seen in liver disease and primary bone marrow failure states such as aplastic anemia and myelodysplastic syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Permutation in shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several red cells disorders are associated with distinctive changes in red cell shape and contour.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fragmentation of the red cell (ie, schistocytes, helmet cells) is probably the most important to recognize since it can indicate a life-threatening condition such as DIC, HUS, or TTP (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef50715 \" href=\"mobipreview.htm?22/13/22739\">",
"       picture 10",
"      </a>",
"      ). Morphologic changes can be subtle and easily overlooked in mild cases or early in the course of these diseases. In normal subjects schistocytes generally comprise less than 0.5 percent of the red cell population. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H4#H4\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Definition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      \"Bite cells\" are caused by phagocytes which have extracted rigid precipitates of denatured hemoglobin (Heinz bodies) (",
"      <a class=\"graphic graphic_picture graphicRef73790 \" href=\"mobipreview.htm?25/28/26054\">",
"       picture 35",
"      </a>",
"      ); these cells may be the earliest clue to the pathogenesis of a hemolytic anemia due to oxidant sensitivity, such as a deficiency of glucose-6-phosphate dehydrogenase (G6PD).",
"     </li>",
"     <li>",
"      Sickle cells are unique in their spiculated shape (",
"      <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"       picture 36",
"      </a>",
"      ). In patients with SC disease, the cells are only partially sickled, tempering the morphologic appearance and rendering them more \"canoe-like\" or \"pita bread-like\" (",
"      <a class=\"graphic graphic_picture graphicRef71393 \" href=\"mobipreview.htm?42/19/43318\">",
"       picture 37",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Target cells have a \"bull's eye\" extra drop of hemoglobin in their center. They are characteristic of liver disease (particularly obstructive liver disease), postsplenectomy states, and hemoglobinopathies such as thalassemia and Hb C, Hb D, and Hb E (",
"      <a class=\"graphic graphic_picture graphicRef80318 \" href=\"mobipreview.htm?4/3/4151\">",
"       picture 38",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Spiculated red cells have an irregular outline. Those with similarly sized, regularly spaced projections are called echinocytes, burr cells, or crenated cells, and are seen most commonly in uremia, or as an artifact of preparation (",
"      <a class=\"graphic graphic_picture graphicRef62090 \" href=\"mobipreview.htm?17/63/18423\">",
"       picture 39",
"      </a>",
"      ). Those with irregularly sized and spaced projections are called acanthocytes or spur cells, and are seen most commonly in liver disease (",
"      <a class=\"graphic graphic_picture graphicRef80080 \" href=\"mobipreview.htm?14/26/14760\">",
"       picture 40",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=see_link&amp;anchor=H2#H2\">",
"       \"Spiculated cells (echinocytes and acanthocytes) and target cells\", section on 'Echinocytes and acanthocytes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tear drop-shaped red cells are commonly found in patients with extramedullary hematopoiesis (eg, primary myelofibrosis, (",
"      <a class=\"graphic graphic_picture graphicRef55274 \" href=\"mobipreview.htm?42/37/43606\">",
"       picture 12",
"      </a>",
"      ) as well as in the thalassemic disorders).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Red cell inclusions and other changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mature circulating red cell contains no inclusions which can be seen on routine (Wright or Giemsa) staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Reticulocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reticulocytes, the youngest of the circulating red cells contain polyribosomes which cannot be seen on routine staining, but which give the cytoplasm a blue tint (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 15",
"    </a>",
"    ). A reticular network can be seen in reticulocytes only in the presence of certain supravital dyes, such as new",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef74294 \" href=\"mobipreview.htm?35/61/36822\">",
"     picture 41",
"    </a>",
"    ). In normal subjects, reticulocytes comprise about 1 percent of the red cell population. An increased percentage of reticulocytes is seen in response to bleeding or hemolysis (",
"    <a class=\"graphic graphic_picture graphicRef53523 \" href=\"mobipreview.htm?32/10/32935\">",
"     picture 42",
"    </a>",
"    ) or following use of hematinics such as iron, vitamin B12, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    for the appropriate deficiency state. Reticulocytes are reduced in the presence of a suppressed or otherwise abnormal bone marrow, such as in aplastic anemia, pure red cell aplasia, or following systemic chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Nucleated red blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleated red blood cells (normoblasts) are not normally seen in the peripheral blood. When present, they usually indicate the presence of severe degrees of hemolysis (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"     picture 36",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50601 \" href=\"mobipreview.htm?9/21/9552\">",
"     picture 43",
"    </a>",
"    ), profound stress or hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/11\">",
"     11",
"    </a>",
"    ], or a myelophthisic condition, such as myelofibrosis (",
"    <a class=\"graphic graphic_picture graphicRef68110 \" href=\"mobipreview.htm?29/43/30390\">",
"     picture 44",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H41#H41\">",
"     \"Approach to the adult patient with anemia\", section on 'Circulating nucleated red blood cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of binucleated normoblasts on the smear in a patient with congenital hemolytic anemia suggests the diagnosis of congenital dyserythropoietic anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link&amp;anchor=H23#H23\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Congenital dyserythropoietic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Howell Jolly bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Howell-Jolly bodies are nuclear remnants within red cells that are ordinarily removed by the spleen. They are usually single, round, dark purple-red in color and peripheral in location. The presence of Howell-Jolly bodies most frequently indicates either absence of the spleen (eg, surgical removal) (",
"    <a class=\"graphic graphic_picture graphicRef60588 \" href=\"mobipreview.htm?38/45/39638\">",
"     picture 45",
"    </a>",
"    ) or splenic hypofunction (eg, sickle cell disease) (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"     picture 36",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Heinz bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heinz bodies, which are aggregates of denatured hemoglobin, are not normally present in red cells. If present, they cannot be seen on routine staining, but become obvious following use of a supravital dye such as crystal violet (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"mobipreview.htm?25/28/26054\">",
"     picture 35",
"    </a>",
"    ). They are most commonly found in glucose-6-phosphate dehydrogenase deficient subjects, following exposure to oxidant compounds, in the thalassemias, and in certain unstable hemoglobin variants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=see_link&amp;anchor=H3#H3\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Drug-induced oxidative hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Basophilic stippling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basophilic stippling refers to the presence of blue granules of various sizes dispersed throughout the cytoplasm of the red cell, which represent ribosomal precipitates. They are most often seen in the thalassemias, alcohol abuse, lead and heavy metal poisoning, and the rare condition hereditary pyrimidine 5'-nucleotidase deficiency (",
"    <a class=\"graphic graphic_picture graphicRef71989 \" href=\"mobipreview.htm?39/22/40294\">",
"     picture 46",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Pappenheimer bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pappenheimer bodies are iron-containing dark blue granules found in red cells in patients with sideroblastic anemia. The red cells are usually hypochromic, with basophilic stippling that stains positive for iron (",
"    <a class=\"graphic graphic_picture graphicRef51160 \" href=\"mobipreview.htm?31/27/32178\">",
"     picture 47",
"    </a>",
"    ). Red cells containing Pappenheimer bodies are called siderocytes in contrast to iron-containing nucleated red cells, which are called sideroblasts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Red blood cell parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell parasites such as babesiosis (",
"    <a class=\"graphic graphic_picture graphicRef56898 \" href=\"mobipreview.htm?24/56/25478\">",
"     picture 48",
"    </a>",
"    ) and malaria (",
"    <a class=\"graphic graphic_picture graphicRef77517 \" href=\"mobipreview.htm?6/11/6327\">",
"     picture 49",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80296 \" href=\"mobipreview.htm?34/9/34966\">",
"     figure 3",
"    </a>",
"    ) are often detected only by well-trained hematology technicians or clinicians who are specifically looking for RBC inclusions in a patient with unexplained hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/34/6697?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Hemoglobin crystals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin crystals are occasionally seen in hemoglobin C disease or hemoglobin SC disease, especially if the blood sample has become slightly dehydrated before the peripheral smear is made. The crystals are often hexagonal or rhomboid in shape (",
"    <a class=\"graphic graphic_picture graphicRef61082 \" href=\"mobipreview.htm?5/48/5892\">",
"     picture 50",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16984?source=see_link&amp;anchor=H11#H11\">",
"     \"Introduction to hemoglobin mutations\", section on 'Hemoglobin C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Red cell ghosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell ghosts, which are red cell membranes devoid of hemoglobin, are never normally seen in the peripheral blood. They are red cells which have undergone intravascular lysis, with leakage of their hemoglobin content into the plasma (",
"    <a class=\"graphic graphic_picture graphicRef53404 \" href=\"mobipreview.htm?33/25/34193\">",
"     picture 51",
"    </a>",
"    ). Red cell ghosts may be seen in certain fulminant bacterial infections; the most common organism associated with this finding is Clostridium perfringens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/34/6697?source=see_link&amp;anchor=H12#H12\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\", section on 'Clostridium perfringens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     WORRISOME FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain abnormalities should never be found on the normal peripheral smear and",
"    <strong>",
"     always",
"    </strong>",
"    signify a pathologic process:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Blasts or tumor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is normal to identify a range of early white cells in pregnancy or during a leukemoid reaction. However, it is",
"    <strong>",
"     never",
"    </strong>",
"    normal to see blast forms (eg, lymphoblasts, myeloblasts) on the peripheral smear. Further evaluation of such patients (eg, review of the peripheral smear, hematologic consultation, bone marrow examination) is warranted.",
"   </p>",
"   <p>",
"    The presence of myeloblasts, which are immature cells with large nuclei, nucleoli, and a scant rim of dark blue cytoplasm, suggests an underlying malignant hematologic disorder (",
"    <a class=\"graphic graphic_picture graphicRef74014 \" href=\"mobipreview.htm?37/11/38067\">",
"     picture 19",
"    </a>",
"    ). Other circulating cells which suggest the presence of lymphoma or leukemia include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cells with Auer rods (a rod-like conglomeration of granules in the cytoplasm) within a blast cell are pathognomonic of acute myeloid leukemia (",
"      <a class=\"graphic graphic_picture graphicRef78291 \" href=\"mobipreview.htm?17/50/18214\">",
"       picture 52",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small lymphoid cells with cleaved nuclei (small cleaved B-cells, centrocytes) may be seen in the circulation in patients with follicular lymphoma (",
"      <a class=\"graphic graphic_picture graphicRef65023 \" href=\"mobipreview.htm?23/54/24416\">",
"       picture 53",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=see_link\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphoid cells with bipolar villous projections (",
"      <a class=\"graphic graphic_picture graphicRef59065 \" href=\"mobipreview.htm?35/23/36209\">",
"       picture 54",
"      </a>",
"      ) may be seen in patients with splenic marginal zone lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33416?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphoid cells with ragged or \"hairy\" cytoplasm (",
"      <a class=\"graphic graphic_picture graphicRef81031 \" href=\"mobipreview.htm?41/56/42884\">",
"       picture 55",
"      </a>",
"      ) may be seen in hairy cell leukemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=see_link\">",
"       \"Clinical features and diagnosis of hairy cell leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphoid cells with hyperlobulated nuclei (clover leaf or flower cells) (",
"      <a class=\"graphic graphic_picture graphicRef72646 \" href=\"mobipreview.htm?4/40/4736\">",
"       picture 56",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef82314 \" href=\"mobipreview.htm?43/46/44771\">",
"       picture 3",
"      </a>",
"      ) may be seen in patients with adult T-cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9945?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atypical lymphoid cells with \"cerebriform\" nuclei (Sezary cells) may be seen in the circulation of patients with cutaneous T-cell lymphoma (",
"      <a class=\"graphic graphic_picture graphicRef75793 \" href=\"mobipreview.htm?10/56/11137\">",
"       picture 57",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Leukoerythroblastic smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined presence of tear drop-shaped red cells (",
"    <a class=\"graphic graphic_picture graphicRef55274 \" href=\"mobipreview.htm?42/37/43606\">",
"     picture 12",
"    </a>",
"    ), circulating nucleated red cells, and early white cells (",
"    <a class=\"graphic graphic_picture graphicRef68110 \" href=\"mobipreview.htm?29/43/30390\">",
"     picture 44",
"    </a>",
"    ) suggest a myelophthisic process in the bone marrow. This outpouring of immature forms (leukoerythroblastic reaction) usually results from marrow fibrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasion, which is either idiopathic (eg, primary myelofibrosis) or reactive to conditions such as cancer metastatic to the bone marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Inclusions within neutrophils and monocytes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, and especially in patients with overwhelming sepsis, circulating neutrophils or monocytes may be found to contain the invading organism, which may be bacterial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], such as ehrlichiosis or anaplasmosis (",
"    <a class=\"graphic graphic_picture graphicRef60471 \" href=\"mobipreview.htm?1/27/1459\">",
"     picture 58",
"    </a>",
"    ), or fungal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link&amp;anchor=H19#H19\">",
"     \"Human ehrlichiosis and anaplasmosis\", section on 'Buffy coat examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the sensitivity of the peripheral smear for detecting such organisms is low. In one study, detection of candidemia by peripheral blood smear examination required a yeast concentration of 1 to 5 x 10(5)",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    or greater; this degree of fungemia is unusual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/16\">",
"     16",
"    </a>",
"    ]. Sensitivity of smear review for yeast detection was greatly increased when the microscopist was specifically directed to look for the presence of yeast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Pigmented inclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmented inclusions, composed of hemoglobin incompletely digested by plasmodial organisms (hemozoin, malarial pigment), may be found in circulating neutrophils and monocytes in patients with severe degrees of malaria (eg, severe anemia, cerebral malaria) (",
"    <a class=\"graphic graphic_picture graphicRef52098 \" href=\"mobipreview.htm?25/53/26448\">",
"     picture 59",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10248?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of malaria\", section on 'Other diagnostic approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21481644\">",
"    <span class=\"h3\">",
"     Ingested nuclear material",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils which have ingested nuclear material can be sometimes be found in the peripheral blood of patients with systemic lupus erythematosus (SLE; the &ldquo;LE cell&rdquo;) (",
"    <a class=\"graphic graphic_picture graphicRef62681 \" href=\"mobipreview.htm?41/12/42191\">",
"     picture 60",
"    </a>",
"    ). These cells can also be seen on occasion in the bone marrow or in body fluids of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Smudge cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon examination of the peripheral blood smear in patients with chronic lymphocytic leukemia (CLL), mature-appearing small lymphocytes may account for 50 to 100 percent of the leukocytes. One may also see lymphocytes which appear flattened or smudged in the process of being spread on the glass slide. Such \"smudge\" cells, reflecting fragility or vulnerability to distortion of B-CLL cells upon mechanical manipulation, are considered characteristic of CLL (",
"    <a class=\"graphic graphic_picture graphicRef54469 \" href=\"mobipreview.htm?22/17/22803\">",
"     picture 61",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Importance of the peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the peripheral blood smear provides a window into the functional status of the bone marrow. It is particularly important when assessing cytopenic states (eg, anemia, leukopenia, thrombocytopenia). In some cases, the peripheral smear alone is sufficient to establish a reliable diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/26/38313/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     How to look at the peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral smear should be made using a clean, oil-free slide and the optimal portion of the slide should be viewed (",
"    <a class=\"graphic graphic_figure graphicRef52991 \" href=\"mobipreview.htm?4/50/4909\">",
"     figure 1",
"    </a>",
"    ). Irregular distribution of red cells should be evaluated, if present. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Initial approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     What to look for",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral smear is indispensable for evaluating the number, size, and shape of red cells, white cells, and platelets. Additional features to evaluate include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;color, irregular borders, presence of nuclei, inclusions, or parasites. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Red blood cells'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Red cell abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     White cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presence of early forms, abnormal lobulation or nuclear contour, abnormal or absent granulation, presence of parasites or other inclusions. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'White blood cells'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H34\">",
"     'Worrisome findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increase or decrease in platelet number and size, absence of granules, presence of platelet aggregation, megakaryocyte fragments. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Platelets'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/1\">",
"      Bain BJ. Diagnosis from the blood smear. N Engl J Med 2005; 353:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/2\">",
"      Exner M, Schwarzinger I. Targeting the dust. Br J Haematol 2001; 114:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/3\">",
"      Amati F, Canellini G, Beris P. Polyclonal hypergammaglobulinaemia with hyperviscosity syndrome. Br J Haematol 2002; 116:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/4\">",
"      Ng V. Chemical-associated artifacts. Blood 2009; 113:4487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/5\">",
"      Todd A, Pardoe L, O'Brian R. Unexpected blood abnormalities following chemoembolisation. Br J Haematol 2010; 150:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/6\">",
"      Westerman DA, Evans D, Metz J. Neutrophil hypersegmentation in iron deficiency anaemia: a case-control study. Br J Haematol 1999; 107:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/7\">",
"      Ward PC, McKenna RW, Kroft SH. White blood cell changes in hyperthermia. Br J Haematol 2007; 138:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/8\">",
"      Peterson L, Parkin J, Nelson A. Mucopolysaccharidosis type VII. A morphologic, cytochemical, and ultrastructural study of the blood and bone marrow. Am J Clin Pathol 1982; 78:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/9\">",
"      Presentey B. Alder anomaly accompanied by a mutation of the myeloperoxidase structural gene. Acta Haematol 1986; 75:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/10\">",
"      Ghandi MK, Howard MR, Hamilton PJ. The Alder-Reilly anomaly in association with the myelodysplastic syndrome. Clin Lab Haematol 1996; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/11\">",
"      Stachon A, Sondermann N, Imohl M, Krieg M. Nucleated red blood cells indicate high risk of in-hospital mortality. J Lab Clin Med 2002; 140:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/12\">",
"      Zanella A, Bianchi P, Fermo E, Valentini G. Hereditary pyrimidine 5'-nucleotidase deficiency: from genetics to clinical manifestations. Br J Haematol 2006; 133:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/13\">",
"      Tay HS, Mills A, Bain BJ. Diagnosis from a blood film following dog-bite. Am J Hematol 2012; 87:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/14\">",
"      Lancashire J, Crowther M. Blood smear: fulminant pneumococcal bacteremia. Blood 2012; 120:4458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/15\">",
"      Bhargava P, Longhi LP. Images in clinical medicine. Peripheral smear with Malassezia furfur. N Engl J Med 2007; 356:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/16\">",
"      Branda JA, Ferraro MJ, Kratz A. Sensitivity of peripheral blood smear review for the diagnosis of Candida fungemia. Arch Pathol Lab Med 2007; 131:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/17\">",
"      Lyke KE, Diallo DA, Dicko A, et al. Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. Am J Trop Med Hyg 2003; 69:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/26/38313/abstract/18\">",
"      Abdulsalam AH, Sabeeh N, Hatim A, Bain BJ. Diagnosis of systemic lupus erythematosus from a bone marrow aspirate. Am J Hematol 2012; 87:620.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4435 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38313=[""].join("\n");
var outline_f37_26_38313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Slide preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Optimal area for review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abnormal cell distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RED BLOOD CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Shape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Color",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      WHITE BLOOD CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neutrophil series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lobulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Granulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dohle bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Abnormal or giant granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Eosinophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Basophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Monocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PLATELETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RED CELL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Permutation in size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Permutation in shape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Red cell inclusions and other changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Reticulocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Nucleated red blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Howell Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Heinz bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Basophilic stippling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Pappenheimer bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Red blood cell parasites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Hemoglobin crystals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Red cell ghosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      WORRISOME FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Blasts or tumor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Leukoerythroblastic smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Inclusions within neutrophils and monocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Pigmented inclusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21481644\">",
"      - Ingested nuclear material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Smudge cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Importance of the peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      How to look at the peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      What to look for",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Red cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - White cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4435|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/50/4909\" title=\"figure 1\">",
"      Examining the peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/58/31651\" title=\"figure 2\">",
"      PMN development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/9/34966\" title=\"figure 3\">",
"      Plasmodium blood smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4435|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/13/20698\" title=\"picture 1\">",
"      Blood smear too thick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/60/1992\" title=\"picture 2\">",
"      Blood smear too thin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/46/44771\" title=\"picture 3\">",
"      ATL peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/50/18210\" title=\"picture 4\">",
"      Normal blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/33/28183\" title=\"picture 5\">",
"      Rouleaux in myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/10/15527\" title=\"picture 6\">",
"      Cold agglutinin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/45/9942\" title=\"picture 7\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/61/10199\" title=\"picture 8\">",
"      Elliptocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 9\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/13/22739\" title=\"picture 10\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/11/23734\" title=\"picture 11\">",
"      Waring blender syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/37/43606\" title=\"picture 12\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/1/27670\" title=\"picture 13\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/45/22232\" title=\"picture 14\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/9/31895\" title=\"picture 15\">",
"      Polychromatophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/7/13430\" title=\"picture 16\">",
"      Lymphocyte and monocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/1/28\" title=\"picture 17\">",
"      Large granular lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/24/1410\" title=\"picture 18\">",
"      Atypical lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/11/38067\" title=\"picture 19\">",
"      Normal human myeloblast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/25/21908\" title=\"picture 20\">",
"      Normal human promyelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/7/1138\" title=\"picture 21\">",
"      Normal human myelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/60/26563\" title=\"picture 22\">",
"      Normal human metamyelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/42/17060\" title=\"picture 23\">",
"      Normal human band form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/37/31316\" title=\"picture 24\">",
"      Normal human PMN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/47/13046\" title=\"picture 25\">",
"      Hypersegmented neutrophil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/45/4816\" title=\"picture 26\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/17/7449\" title=\"picture 27\">",
"      Toxic granulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/33/29201\" title=\"picture 28\">",
"      Alder-Reilly granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/52/38722\" title=\"picture 29\">",
"      Giant granules in Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/1/8213\" title=\"picture 30\">",
"      Eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/41/23185\" title=\"picture 31\">",
"      Basophils in CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/15/26872\" title=\"picture 32\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/0/22536\" title=\"picture 33\">",
"      Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/31/17911\" title=\"picture 34\">",
"      Giant platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/28/26054\" title=\"picture 35\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/42/1703\" title=\"picture 36\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/19/43318\" title=\"picture 37\">",
"      Hemoglobin SC disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/3/4151\" title=\"picture 38\">",
"      Target cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18423\" title=\"picture 39\">",
"      Echinocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/26/14760\" title=\"picture 40\">",
"      Acanthocytes or spur cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/61/36822\" title=\"picture 41\">",
"      Reticulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/10/32935\" title=\"picture 42\">",
"      Warm reactive AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/21/9552\" title=\"picture 43\">",
"      Nucleated RBC in AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/43/30390\" title=\"picture 44\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/45/39638\" title=\"picture 45\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/22/40294\" title=\"picture 46\">",
"      Basophilic stippling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/27/32178\" title=\"picture 47\">",
"      Pappenheimer bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/56/25478\" title=\"picture 48\">",
"      Babesia microti thin smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/11/6327\" title=\"picture 49\">",
"      Malaria trophozoites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/48/5892\" title=\"picture 50\">",
"      Hemoglobin C disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/25/34193\" title=\"picture 51\">",
"      Intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/50/18214\" title=\"picture 52\">",
"      Myeloblasts with Auer rod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/54/24416\" title=\"picture 53\">",
"      FL with leukemic cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/23/36209\" title=\"picture 54\">",
"      Villous lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/56/42884\" title=\"picture 55\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/40/4736\" title=\"picture 56\">",
"      Adult T cell Leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/56/11137\" title=\"picture 57\">",
"      Sezary cells mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/27/1459\" title=\"picture 58\">",
"      Anaplasmosis peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/53/26448\" title=\"picture 59\">",
"      Hemozoin in monocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/12/42191\" title=\"picture 60\">",
"      LE cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/17/22803\" title=\"picture 61\">",
"      CLL smear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=related_link\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_26_38314="Vascular malformation 9AB";
var content_f37_26_38314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76350%7EOBGYN%2F55273%7EOBGYN%2F69077%7EOBGYN%2F76792%7EOBGYN%2F57864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76350%7EOBGYN%2F55273%7EOBGYN%2F69077%7EOBGYN%2F76792%7EOBGYN%2F57864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    A 40-year-old woman (G0) who presented with history of three days of intermittent profuse vaginal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Ultrasound of the pelvis demonstrates hypoechoic regions (arrows). (B) Duplex color Doppler ultrasound shows a hypervascular lesion within the fundus that measures 2.6x2.3x1.3 cms, consistent with arteriovenous fistula or malformation. She was s/p TAB at 14 weeks, 5 months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Coronal view of pelvic MR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 467px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHTAe0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhb2wtobYW1spWPGBznisS18G6aJy9zGzqTkjJrqhG0K75VU59e1U7m+U/KoGR6UAZsug+G7d1MVpIsing7u9WLyO0vYfs0sZMJGMZ7VnXd0sZJOTms9rmWRsxMM+5oA6PT/AWiXIDGMgd/mqzqHgvwxa27FLZpHHo1ZelanLb4Dykn0BzW4dZgjj3vEW45460AYH277ABDbRssa9AaedSe4XY/TpVDVdYW/uClvCqnPYYqKK3mWPdKQv40AKNPtEneQkDdwcnsa1dNuNL02EpECueTz3rnZkdyRvOB05qJbdsZbkjpQBrard2+oSKJEZlU/Lg1U1Qq9qY58LFjGD3GKm0+3AyzL279qz9dh88mMt16igCroFnpUl4rLGzFTwQ5xXot60T2QVVIAHHNc74U0y3t4lbaCw55rV1a7wpREAPTpQBH4g1DVNe0+z06edRZ25BRcdAPerctjZy6eI7o70AwQDjOKx4LiRBkge1MkllnkBJIHoKAJmjtIovJt0Ij6YzmobW3iskY26lS3qasQIqnJBz+lTTSqRtCCgCpaW8NtO1wVIkk6tnrWmt4ijhhk1SWN3ABxtFDKsRwdpNAAxa4ulyeMjtXqnhU2lvpnzsN2Oma8nN40bfJH09BWvpep3DDaysB9KAIfiE5u7wrERgH696oaUphg6jpW3cWX2mTe2OeeajmtoYISHZPzoAx3uHMx5FXSTNb4Y8ZzVYPbCTOQee1TvewxwkAD8RQB2GseMdEvfCVrpOo6Jc3kluPkaNwOR3rh4oYtRgkFzavBDn5UY9B9arpfsZTtKqPrirXnb0IllbHoDQBp6bJbWESRW5CqvTnNThtGfWIbzV7d7gR44RscVgpMisQoLDtkU6ScYztBoA3/ih42tvE2m2Gk6TpM9vb2rgh2IOcVk3ESzW8SJ2UZ9qx7q5kI+X5cdMd6gj1GZBgjmgCHWtGdU37S4Pt1qhod0LK4ULbOSCPbFbqao0i7Jhx2pscVvJJvXIx7UAdzpuvztYgIpj471lvNe3V3kyBh9KxheiAbFZjjit7w7eKZlaRBtz6UALf2szW53KSa4q7s5Uuc7SBn8q90iuLCe3AEQJx6VzuvWULhjFbjP0oA4rS2KxjJGcUmpQidTn86uNYSbsMVQZ4xxT2jCDbwR3zzQBzUVjHcTLHLEzqh4xxiuhu7eGWx+zS/6sgcelILTLblIT6U4wBMAOz560AYn9jxQx+XCh8sCm2SxWIaKCJkVjkknrmumhjRFBOefWs7VYlk+ZAB60ATaHpNo1w06fLK33jmuutorKS3NjdsGtpD8wzjNcFZSsnyhyv0NXTPJEwbJIHPJoA9Yu9A0fU9CtrJIy8EB3RqG6EVz2o2LW7KkSny0GAD6CrXgnU/PCoSfQ12l7pqzKGVRzznFAHCWkTmJk8tmVwVYfWix05NDikGmAoJCWYHnk12EemeQC3H4Vmai8aNgqMDrxQB5x4ska+KC9QtsbcO3NT6B4jnUpCEJC8Kcdq0dbWGYkACsrTdPjjm3ByMn1oAfq3gzTtZumvbpD5snJOetaGheGIdJhZLEHYTkjrk1vWEAZACSwA4zWgpaAZ2AAe1AHD65oaXjL9rjbYhyvtiqU0626CONSpXgHPSur1y+QxNkcgV5frusGG4OVJUHsKALt7pLaoQ1whcA5U471VuNEvgQsUbbAMfhVvw/4oiZlSYBU969G0XVtJuCqMy5OPSgDxDXNKuAircIdoP8AWl0PRrCGQTTShXHQFjX0Jq3hCw1q3H2Ml5G6BccV4546+Hep6BqccM8yq0h3Im/qDQBy3iWO3lkKRTBskdD79as6TpJNqCg4q9o/wx13WrsmAJEy877ghU/Wu5sPhxrtpD5b3+k5Hb7Qv+NAGVq15dfZgzgjjPNY+j3kctwFmxmvRPEGhNc2mIoz0rzKXRL6zvOARzmgDoNU062lhDRkAkZrlrmzkiyVOQK6KDTbp4gZJABj1qJ7CXzdo+ZT1oA5jTppRfBWU4yB+tekhLZ9L+YLu21StdDiWPzCg3Yz071Qv0ukbaMhRQBltClveM8ag570uoSSyptQHkVFcSNCMtjcaWxZ55BkjFAEEdvIiAvnmr9jFE/3yKsTW8jgKAefarun6CWG9pAv40AZ+oFbeAmJhnFc3a77u+/etxnFdnqWmRr8pkBA96zorO3tRuVSWoA1bMxWtsoVQTiqNzceaTjGaYLiWX5FGF6c1NDbxo2WOT1oAzzHKzDIO3PpWpaQoqZYAmkumO0CNTjtUMCz5ycCgC3PBI6/u8AVRMUsbHcc1ZeWZVwDUKK0jZkbFAD0EjgYJGKkWz3HMgJJq7brGqYBBPtRLJt+6v6UALBZxIu7aDgVQ1K/ktyVgQAjpVjz3wQMVj6isrNkKcUAMF3qNwTlyi1Tu/MJ/ezZqaJJm+VyR9Dih9OZzn5jmgCvbMq5C5NJcO5GRnFXreykjYfIa0YdP3YLJzQBhW0If5mJBqaQMnCkmtxrJgcKgpDZSjkRj8qAMON5vQ/lUihv4lNa66fdyEBYwAfar0Hhu5YAyFcdaAOfWMMMGo5bcAZ2E11i6EsR5OTTpNMOMKo/EUAcHKrxtkRkVYtMsMHjPrXV3GjM6Ywuax7vQbhTlCB3oAggs98oJYda37YrbIFAyT3rO0+xa3OZiTjtVm/vTHHshgcnHXFAHa+F2SWRfMIxXW6tBbNaYQqDjrXknhjUJ47nE2VB6dq63V7maW2BikIGKAM7U9HMrsVlwM1jNZSQSYJLAe1WLXVJLaYiUlsnHJq9NfpNHnaM4oAz3tN8eQeaS3hWFssmT71KmXf72Aa1ba3gdcM43UAZN5GJI8qMCsK+fyoyO9d3JbQeXtBB4ri/E1nIoYxK2KAMrSmWW7HmsAMiu5k0q0vbZfKdc4FeNXdzPaz4LlSTgD/61dV4OvLx3VmkJXPqelAHovhyyk0y7GASoPWvVLHUIHgXfjOBXmEetQ28KiTBYVYt/EkeMg/hQB6XNJbOCRjmuL8WMiROYsdKzn8QM4O08fWsHU9Ve4JUsMdOtAHP3V3Ibg+Y2AKWLUkSQY+Y/Wq2qRKQWJPNY8MkcMo3MT+NAHoum61IiDaCBjvT9R19xGS0gxiuYtb+Aw8bsisLW79gxCZ5oA2b3xCkrFAwc/WsLUUS4BZkGKwklkaTcEP+PNW0+0zAIMhaAMu8IjkKxgjHf0q5o8t55qmJ2GDxWjFoisu+UknrT0sZEYLBn6+lAHpGk+OLzT4NOttHtyl8XCyy5zuBI7Gq/wC0nqVzD4g0W5OTM0Skj1OBXG23n6ddW9xIeI3DMfoRWh8SfGOn+LvEOlvBFKsduio+8cZAHfpQB3/jjVrmP4TaJPETE8rBXwMEg44zXMW2k6VNBHI0Ugd1DMfMPJ/OrB8U6TqmlQaT4lWRtNt8NF9mwG4p6a74ARAsVrrrKOOKAOv07VEniAkYfNT73RYLxTImCx5rxPR/FjEIS5Ar0jwz4tik2qzg5x3oAi1TSJ4WO1TgVT0+FIpP9IHIPcV3F7qsFxBwoyRXOXMUb5kZTQBcWWz8kAAZx6ViasqSRtsUZPSq1xLMX226Nx7U1nnRMzjafegDldRsXDFpSQO1R6OoW5VT0zWxfSxyZBIb6Vz9zKYZwYzgUAdpPEFtwygZxmsKXUbiNyu47auadd+ZagSuDx61BI1u03IoAofbRJNmQnr3rQJhkiG1hnFZWowIz/ugetWLG0lSLc2cCgCZQN3B+lOfCcselQecocqAc05isvXNAEjXLFcITgelMjufm2u1S26RLxg5NSvpm7EgBAoAnEYliBSqxtXZ8EHmrlpIkA2tjFNubpVcFRxQBLDamFM8805trEKTgmpLe586PBHNUrn5JwxzxQBPLpzrEZAxxjNYU+pBZ/KYH0r0TRNNfUrMhATxXH+ItHOm3u+aM9SelAFzSLO3mUO6g59ulak9pCsfyKBisrRNXtWAj4BHHWt5ws6Zjbg0AZ0diWbOeKuR2qKvJ/Sp7eEp1yafJkD7h/KgCm9tzlakjjbGCBQ4kb7owKYGMRyzjNAFlYmBGCRT3eRF+Ziajind1IRSfwqtcS3EZyY2I+lAEnmMz8CrC5C5bFULe4kkOGQr+FTzKxXIcUAOfknGMGoZE2jLEGoTHO/yoT9aBYSnmWQAUATQta53SRK31qjr2qQQwkW8IB9hUeoXlvYRkGVSawhq8NyW4DgHtigCvpVxcXd/1YDIxXbakZoNP4BPFcrYXyrdL5UJBzivRBCbnSt0g42jt7UAee2jedcHzQSfT0rUuPlUbRiozshv2AQ9a0Lva0QJGMigCtayJjnrRNcFXG3PFQIiZ4bn60sisGBAJH0oAvW94RjcxxWzAtteQFWwTXOxx+YuSpBqRp5bNSUzigDG8UeDTdTF4VG3PT1qlbWcukREKvIrRuvEU2/DMAO+ar/2pDOwEgOD1oAzX1Ceach1IH1rTt7qJFBd8GobowSriDAJpdP8Nz3bbmmVV+tAGkmpIUwCMfWqlxdopJAGfrUesaSlhDgXClx15rl3vzExDOCegoA0dRvp5CQoIUH1rKZn3biCecn2qKXUXkJEakj6U62eVwQyHP0oAsx3zR8ZPFI0rzuO4qWHS5bhgTnr6d62LPR2hILD9KAINL05piAQR611Flo1vGu5/mA65pbFvsyZVBwKuQR3uoyAQxmC3zhrlx8ifWgCtcQWyghEUjHNc9qWpW9k2YcEjtXefFLw/Z+G/BdlqFpcrdXUzYaWM/Kc+1eSWem3erXEawwySSPyEA5NAFiS7uNSIHO09B6Vah8I3UwDhCFPOa9h+Gnw5s4rK4utXmjaWKIt9m/jQgZrnv8AhIbS8+2R2kLRiBynPfFAHMWHhIwKHlkOPQ0+622TiKErjGTWnPb6y8YmaF1t3OEYjg+wr0DwF8M7bWdJa51+zuEnLYXkjIoA+brixCk+STkcjmtDw9cSWlyvmZxU1nCu3OQTUV0zJICi9+tAHo9nrluYFBAzinTaoJlITp6Vwen3Mp4KH8a2DIywFzIFPpQBtHV47UFmIBrA1TXWvJCsZODWHf3DTuR5gwDVRbtbbuM0Ab8I+QsTzjmsnUmAf5SxNRw3z3DfM2AO1XozuUBIySe9AEVjcMqDc5A96dcalGikJktSTRgAGchRTY3tFGVUMR70AW9KkM8gZ8/iK6C5b/R9seenauUj1Jo5tscRAzXTafKZosuMHFAGO0EnmHPfvUyQyDqx/A1du0IY7cVXiGD8xoAuWEUauGlbOOa07m9iEW1M+lZChSe9TiSKMZAz+NAFi3j87koMGmXNkFOdwx9aassrKTGMA9KjEdxLJ87EA0ACt5JwppJJA7AuTipJIBGBnk1majd+TGRtNAHs/wALLmJpFjKqQRjmu3+IXgyz1HTHmAiVtue1fNvhfxTdWM2Ycgj9K6y98d6rfQeU8rBCMUAcXreif2TfuY5eh7VLp+t3K4ijTcelOvVe+mzI5LGtjRrGG2UMygmgC/plzcuu6VcCr9xd4TAA3VXIeZv3fCio5oXj+ZjkigCF/tEpyrEA04RlBmTDn3p6SuwwoqRYZCdzGgB1vqgtekAwKln1xZ0wIFz06UwpH3ApPJhB+UDmgCoJJZCSEABqJvM3/NWmdq45HNPEEUi5JFAGZJeSIm2NRnFUcXc8mZJGVfrWzJbKrHauaqXhKKcRmgDB1TR0kyWcv3xWLdmHTYiBEMjvjrXZWkyk/NCSfrWN4qszcg+XAQCPSgDF0TUBdXI2J0+tepaXcubIIwJBFeX6HC1hJueMiu60LXomlWNwB2oAqavDJHcmQJwTUkUa3EOGfBHvXXamtpdWQYlQTXJi0UTHZIMZPegDPMCwTEZLAGrglRU5BqK8/cvnYTz1piyNNgKpz6UATCdA2ckCm3sqzQlUAzimS2reXlgRUNgoSYBjnmgDmb+xfzizA4q9p2nLdAAKQRXYXFtFLFnaOlZiyR2YYqw4oAyLzSHtQWGfWsS+1u8sspGxHYc1s6vrhYFfMFcjqDm4zhxz7UAR3Gsz3B/fsx3e/f2ptpB9qcfID+FV7fShPOG25bPWu00PSViClh+lAFa00YhAQgGR6Vcg0pwQAgxXSqsMaAcdKgeaNQcMKAILW2FuAWGTVsTK4+VBj6VVSQO5yc1YkmEUeI15oAHbCHAHuKwNZ1C/axltLW7ljt3PzRrwDVuWa4kfhwgP61BPCFjK5BB5zQB2HxGiMPwb0FCcneO/0rD8Mf6MLeeJzFMFG1h2rP1m61XWtJtdMkux9igOUj21dt4PIt0QE8DmgD0j4a20smp61eT3kszvA2Qx9q8t8NR77vViRkCdvp1rd0bVtQ01Z1sphH5qFDkZ4IxWZotrJpwuRNKJPPfcxA7k0Abs63t5FZxNd3EUMTgouPl4PTNX/iBrXjhbyzTTZmigSEKPs75B+vvWLrWpanf6dDYQTpHBGc8KMn8a2PD+tXek2XkRXCjud/PNAHkMqyWo4BOKhg1AtIBIox3zXWvbQ3MfIHIrFvdGUOTFjNAFaa6Xb+7IB9qhEskq4aRsHjrQ2lyxtuYnFOeD5CVJ4HNABHbhTuJz+Oc1I0dtglwCenIBqhvdHwxOP6VY/dumdwyaAJ4UhZ8KFAq/O0McPyuAcdjXOy7g5EbGlKSOvzE+9ACXO6eQgyNtB4yakiiWMYycmmxLHGeepqZNjOAD1oAv2Fsr4Zs881tI4iXap5qCwjjEIxjOKryybZuQcUAXS0jHNWYTDtywGRUVvIjJggUkjRqcBRz70ATiQTMUjUelQT2kkZ3ZH50wSNGdyJ1qVHlujggigBkNy6tsHXpWjbxSyYJIH41SeHyccc06K5lUcE4oAt3RWAfOc4965vV7kXLFUXg9eK0L+9Xb+8PNYU92gJEYyc9KAI7JhaydTg9a6mwaO4jBB5rE03Tm1BwZBtHvW/8AZ4NKQYYEgUAWLW2/f9D1rokhVYehz9K5ez12ISkEACtOfxFGIcIBkigDctGCHtTL2RGUkt+tcumqTzsSoIB96r3V5MAQXP50AbyzKr5QjI9TUsmoFU+dkx9a5I3Um3liKhe48w4aQ0AdhDqNvuy0g+mamfU4CP3Y5ri0aCMElsnrQuofNwpAFAHUyXfmvyQB9asJfw28fLEketcdJeu33c1DPNM6Hk0AdsurxNyTwRxiqc+rb3wqEr9K5S1uHU4YHrWqLnbHlQM0AdDY38CsPMAB+lbXmWVzHklMEe1eZvNK85yTjNasLO0PyuQKANHXzaQowUrwD0xXGWlwG1FVjL9a0rpULESZY5q5oGnxveI2AFzQB1dtayzaepDvgDPWsQXxtbvYysTnFezaDpNg2kr91n21554u0uK1vS0UYzz2oAjRUvLfcUA/Csi5QW8p2k1PFc3CRhVBA6VII/NH7wfMe9AFNHMpwzHFW4rKLG4Nk1HJbhe9LFIsect0oAxNdvpLTIWQgdK5ybWA/DE5P41peLXRw21ee1cZaRM84DZxn1oAt3O+4bIBweafZ2zs4QoCDWjDBtQBQK3tB01pJlZhxmgCzoWijaJJFAHXpWzO0FuQgA4FWb64WytQq4z0rmTMbubJJ60AaVxLGy/Lis+SPdIOuDUhgIIAJqykQQZYdKAIoIlXoGJpLsuB8oxxVkSyYxGOapzxXMjZfIFADIYcAvIR0qrNKhk2gN6VNcTJbxYdsn0qnDIZpRtXHNAGnZQnAIFaUS4I3Yx3pLQpDENzA0yScM/yigCO/mZfliRQB3Aplixc4kNOnbK8jmq0AfecZHNAGjOu1QFIFU2YKfnlAP1p84cRk7jwDXonwr8J6Pruhy3Gq2yzTCTaGJPTmgDx5ZmU7VIq3aSKW/edaiW125KgkH2qFo238EjFAF69iEq/LjmqMWn5cjI5qQTOvB6VZtplyD3oAxtT0hiPlxVOHSZEXLE10d3cFjgDimxszLggc0AcvdQG2+bB59ajtpfMYLsOc+ldLcWK3AwwBxWZc2L2jbkTge1AFS4smZNwX9KpRqYpANp44q+2oNja+QR9aozXihu+SfSgDpNLdigJHGKnuwD0Q5qHw4wmVcLnjjite/tDjPmFaAMm3yTyQAPWp2VOucmoJQkKnLkn6VVjuwzHigC20jMcKpxmr1q6xLmTOarwlSoYtzUi4Y4xmgB083mthAcVIFRICWIzTggiQs6jB6VUM3m5CrQBg6uwaQ4JAzTbJIEjJkZWbrgYqXUNNur65WOAHlsda9a+GXwZm1CJLjUQQmQTnmgDygahMjhbeNgucZrpNPsxfW26fcWI9a9k8RfDaxsYvLtI1LDjOK4O+0qTR3IIHqKAOBv9NNtMegFNiCLjJB/GtjWIJrlt2Dg1Rt7FVOCOaAK8128a4jA9OlV0aaQ5fp3rVnsJGA2pxTIdOlJwScGgDNYhThmGKlSNGXIzmtI6K2QdpqyumDYQAc/SgDCIRevOPSow4JztOK05NLdHyT3qzDaRMACBnvQBi+cnA2mp0kLLgKa2DpcOcgVOmnKwARRmgDnlhnmchVAx3xVj7OYlxIST7Guog0vYMvjBq5Ho0EpBJGR7UAcpZWfmuCFP41pyWTJH8groDaQWy4BHHeq00gxsjAYnpQBiRWZdh5yr1qLUGSxO6MkY54NXbyG5UBj8q/Wq32AXsZVpCzdKAO4+HPiPzB5bNnjHJzWz4mt/tMgdigBFeb6PBLo9x5gUhfWtrUvEPnRYZjn60AdZp3h+2nttwZScZ4rn9dsxay7Y1NY1t4vntE2xA+lNfVpNRk3zzlfbOaACRWIyzYFQebEGwASamnaNkwjFyfaq0MRQ7iAMGgDG12Nih+UY57Vy9nas9xnBABrt74C4O0KDn3qlJpUm3KgDNAFBRFCFDZNdBpc/yAoCBWdZ6UfNBmbjPrW4sCpEFiAzigCnel7mQgg4pkFqkXXg1cEbjrnNDQbjl24FAELbQOOT7VDJJIQQBxReXkNupVAC1Zsd3LdNkZAoAtG78k8nJ9qWOW4uBwpApbaw8xwzVfup7ewtjlwCKAOd1RfJUtIwNRaU8l1IEjAAzjpWbqepxXs5RW7/AJ1veHLNlAcE8c0AaEtq1uoLMx/Gp7UOy8AY+lF/IV4JPFJazERcE5PtQA2d8MQQKajhRkEVHcKXYljVYSbGwKAJ5XlmbYuea9V+GuqxaDoj288cjOz7srXmVmSzAkdOa101aSFdkZOBQBy1jrETRBduTipXj+0NuTj2rj8tYuFXcWrf0m6aRQZGCgUAT3KtFwVNQROd/QgVoXMsUibVYlqztmxuSaALPnJxnGanjUuuU6VSVFkOBnNW0jkjThjg0ASxgQnMjipJJI512HBzxVAxNLJ8zHGfWrqCOFc8EigDLv8ATYYwXI65IrIjs4rmcJDExY9O9dHeyidMbelVrGI28wkTqKAN7QvDt7Hbho4yMj0pNS0+7iBM4OB14rU0fX5OI2fA6VtXLWt9CVeYZI5oA81YB32KhY5xSNp5Xkr1ro9Q0uCzcyRueaofakKkMD6dKAM5Y1XjBq3ahgQQpxVe4fLZjA59atWLznGVXFAE7q8hw3SqmsOLCxd0TkDNaqxop3yPg9SPSuY8V6ks4NtbguW46ZoAufDWW41TXowVyNw7dK+ytMIsdGjQFVJUdvavnj4F+FZYit5PFtBAPPFe26ndsdsMZXgAdaALkyR3asWBzjrmvI/iJDb6e7yysCB716nA7W1tukK8ivPvHGmQ6tDIZXUDnjNAHjyeIrW5mMMSd8VrWmhy3H75TgGsS/0mLTbsi0hMj5xwua7Twnp/iC9Cj7KUi45INAFU2pt12zAYHepLNbRn+VMmu7n8G3U1v++X5sc1zV74XvbAlo4ztHtQBXuI4NnCAVmPbIclSKfc2N/nJR/yp8NlfshHlD8cigDOk08yE/MKammrGOoz7VZuYLqDcWU59uarQXN7ni3zg9xQALAxcL5ZxnrWhHZmOPcB0FMgF9cHDRxRr65xVhrCQL/x8FieytmgCDy2LZdsLTnuYIUxuG6q76detJhRLtPdsirraHHHAZLiQbgM4zmgDEvLoMxIYkVPpE0s8gjigZ2PQ9aydRvFgn8sIu0HGfauw8E61ptmAZSm7rQBjeIbW8jjzONi56EYqhojiNvlRmOeua6Lx94js7mPbBhiTxVTwDpNzrFwBHHhSfpQAXcc91HgrtHbiucv7Q2oLSvzX0JafD91iy5JJ65rkfHPgJ47dnVScc0AeMwJLeMVhBwPamTQzWbgyRuT9a6HTSuk3TRyx9D3FO12YX8Z8pVXI69MUARaIZrhRhSvHerWp28i/ebg+lR+EDaW90EvbluCM8iu616bRFsP3B3vtHbvQBwlhpwYblDM31qxPY3bsFKMi+4rsvCSrOh8u2VgBnkVi+Nmuo59qkRr/snpQBzGoQizjy867vTNUbLVsPjqAaZqEa+VumlZmPrzWGz4Y+WQPxoA66fUo2QY61SfUWxgAkGsMXXlrluc0+CZ7iQbBgUAXJIpLlycEZOa0dPt44BiQBie9Nij2Q43fN9ak0+3nnmAIOKANu1tWkTKKcewrifHSNCrAhhx616zYW629ifMwDtPevMvEYh1HV1haYbScYzmgDkPCPhm+1W+ZoY2ZS27IGeK9Tl059FscS4VwOh617B8KvDulaXoUc5j3uU5+XPauT+JLwT3ZWOIbRx0oA81tGe+lO4cDpxT76T7Iu0Yz9Km80W+FjAU9KiuY0nG+RskDpmgDPWcyk5PWpoI1LZ681AtmXlJUkLmrZZIBtByxoAeS6n5BVmAJszM2GqKEbvmYkA1LJFHMQwJ4oA5670u4uhuityPesprCa0f/SJCMdsV6BBcIlgoUjOK5XVLczTszsT+NAFazu41IVRk9M1dKGUhtoxj1rCnheN/3QPFSw3RhI89yD9aAN1NkQzt5qKa6kYkKDT7S+iliAABNNwXfCgfhQBEkhAzIcVJBh265FJLpsjfMzADryaYrNCduVNAF19gXGOaryHC/L1NQlyx5zVqGRQvCEt9M0AVPMkQ8E5pBcXkb7gzYHvV94XYbioHfpWdMJXfYMc8cUAXxfXFymwqSfrUE0FwvLMcH2re0GziSPdLnI5qHVpBLJsjwO1AGRbbVI8wgmtGJyR+6Q0W+mjAd2X15qa4uIrSI4K9KAKd5FM4wM5biup+HngA399Hc3aZQHnNcno9w+o6mqEnaCK9z0W6XS9MUKQDjPX2oA6e9uLTQ9OS2tAqMBt4rCsriSWbfI5Oec1mSXb6jPliDzmup8P2aEAyYxQBja3fTpFtiLGs/SdHu9Yb96GCE8122rwWSAYCk59qZp8qRR5XCJQBn2HhbTNOlDyQLJL7+tdFHfmJBHbwLGmOwFYWq+KtL0sFpZA79+RXPXHxLsJH2xAAdOlAHojXm2LccM30rOEz3E2JIxtJ54Fczp/iZNSYBGXB9DXS2kluqDdvZzzxQBZk02ykTLKuT7VXGhW0xIBVQfarZYSqFjjfP0pBDLCu4uAPc0AV18I6aeXjVzSHwnp8ikLCo9OKGvJ/MwrjFW4dR8sAMwJ9qAOL8SeB2kU/ZlK/SsXR/DLaPOJLqNpAD0NepNqJblVJ+tIAbo/PGuPcUAeQ+M9XvrlFt9OtjCoON2Kx9M0u4Fs0mpXO5jzgjFe233hyG5jJWNAfauJ1rwy1oWcB2AycUAeN65o013eEQE+Xn9Kkt/Cpt4wVLM2M9e9b+saq9nMYhAFHTJWrGl61bpCTOQZD0FAHHXelywyAyRNgepr1P4TalHazxpuVeR2rmL+5j1AkBSF+lR6RMmnXiFWbrnrQB9QzahG1srI4JI9KwdUla9iaMpuBrK8K+ILWSzRZmGcd63JtWhEZ8hUJ7UAeGeO/DpE7SKgQk1x40xhAwaTj0r0r4gWWp6o7GAFVyT8uRXm82nX9kSkiSuxNAHNXVhJFOTbhi2eOtdh4L8M6jq0yC7LLF7+lLp+g6tekMkIRPVlNdJZ+foceJbhd47BqAO7kGl+EdIO4q0m319q8Q8TeIm1jUGEQIXOK3db1CTUwRK7lfrXJz6cUYupAweKAMzXI/Ls9zyhTzXEQX+bsx79+M8dK1fFV+0Ksm4sB/jisbQ9NmmuGkIGWP9aAOmtoTOikA4PY1uWGnSKoIXAqbRtKdVQsBkV0ojEUXOBQBlW1ntOWPStyxXZjYoyKy5pguduM02K8lVhgnrQBu648q6dIzSFRtP8AKvE7CRpvFiATF8MRt5r1fVLjzNPIkY4INefaWtvb6ysoUcMTQB9e+AYwnhWIsAmU6mvOvGUYmvmBmUDNUtP8dNbaZHbRh2yMALzWZeQ6tqCtcbQsXX5higDF1PT4owX84May0KluASBxTdUlaKYpI+W6YBplmwc5PSgC4Y22EqODWa+7zwduTmtOV3CYjBx71TVcNuZhQBMvmOg4xilUyoMBT+dMEzA8U8CR+eaAMvz5kbac7M8c1ajgSdNwb5qYUhC8ElvrTBceU3GAKAIbyCSPIC8VhX9oGO5jmuvVop0y7DP1rB1pEjJ2AkUAZlsXiGEJ4rT024cyguSKqWZQrgD5jROs65K4AFAHWG5haPD4as27KZJSEVjWl1sf96x461vwXttJFgYJxQBSiBZhlcCr0UohO4AEjtUMz5z5YHtUdvbPK2WbFAF97zzQcqADUAeGNsk8/SrBgjijHILY9arPbtIC3agC/BeFoyqdMVUdXeXcuTzVNZxbuQe1XF1QKhCxnPbigDVsbJ7kYaQqBWR4stEtIGCyZOKniv5irMGCiue1WWa9n2FiwPvQBe8ETLBcGWU8da7PUvFZlZYLc9RjiuEitWtrYYcKTUvh+3kkv1Yq0mD25oA9v8E2M9xAs0zHBGa6DUtQltF8q2bk1l+FxftZJHDCyDHcVJeaXcxT7rmQeuKALGmNPcSb7piQeetWNdklFm4tc9O1TaVGrDaMkCt+2itBH5cy5JoA+afE8863bi43Hk9a5a5a4nkC2pIzX0D4+8JQ30bSW8XPJGK8iHh2+s73CQt1PbNAHafC+xaPa95KcjnBr0vUfENnpkYYbTtHXNea6Zb3tla+ZP8AKoGemK4vxXr7TytB5pGSc80Ael678YxaK0drGC3QEGvPtS+KGv3kxZZHVCeme1czaxxuuWIc/nUyxRF8FcCgDpLX4kX8agSyNk8HNdR4d8erLKDcy557mvMrm3iKHG2ueu7lrRj5bHg9qAPrjSvE8F6qrBtOfSuss7geWDJxmvmv4RXtxd3aK4Yjjoa+mLe1RLJTICOP6UAKt8Ec7ORWhBHFfR4ljXmsU3ECsVVSSKPtc4IEQIH0oA4n4m+DlmjeS3UKevArw9tMksbwrPKcgnAr6k1WKS7sWErjJFeE+JtEc6uNmW57UAZMUriMJCpJPFPj0nUpz5gR/wAjXovhfQLe1tlnvigAGeazfGPxN03RIGt9PtVdxwCFBoA5WG9v9MfEm4gcY54rotE8Z7JkS4IXPqa8nvviBqeq3bfukjVunyVYg0m/1hBI9ykefTigD6h0LU9O1GFfnjJPuKr+IrXTreJrgQozLz0r550lb/QblQLtpAMdGzXrOkNe63phXJyRjmgDjPFHi6/ikeKxJiTkDBrk7ea7v7sNdXLuSenWtnxd4bv7W8ZpMlc9gadoMMEGDIvzj1oAW9VLezBLYOPSuM1HUgofE5IzXZ+KLC81CAi1UlRyNteX6ppt7ZMwuQUHfcO1AFGSFb66JYluQf1zXQ6Za/ZyoVB+dZmjQhpARKhPeunitEYAs4/A0AbNjeKiAEDIqSe4E5wDisYKyHEascd6liWdn4zgUAa0WnlxknrT1012kBHSm28k0MfJ7VJb6hKbgKMc0AUfEkXkWJ3GvP8ASjG16cnoa9P8TxxyacWmYZI9a8rsDCmpkRK33qAO3s7oW0qFR0IrvLbWY7jTTHNdFARgiuEiijMCkjkiqdzvQ4DNtNAGrq9vZNMzRSeY30rOtIpPOG1eAfpWnosEcoy2PxrRuraGJCysARQBnypKVweKoyQKrZZiTViWZdxUvx9aiUBnyvI9+aAFt4fNPyjpVpmaP5eKbI/lx/KDuqtskkO7kfjQBUPlwvluQfai4EM0R2Dn6VXuJPNfJI61JDgLxQBXgR1k2gnGatXFoJI+QM96haYpIQBzV1JHkhJANAHJ6kWsnyuOtaWgyC+Xa+MnjNZuvxS7tzA4zmmeHbkxSDqDQBs6vowUjyxkk1Z0rw7cRwGV1bb15q9p9xJd3iKqE/MK7+/WODRipKhto7e1AHjOs6g1lMUUdDim2WsSEAvnFbVxo0V3dSSSMrZOcVm6loxjUmGM8CgCaPUFmfAbv61t2zxmHmQZPvXn81tcQNuZyoHWrdjfpGwEkhJB9TQB1ktvG0nADZpLlRbwksoqnbaiGCiLr29637XTpr633zjauKAOJub+VpCsZIU1asI3Lhyc0uuW9vaTsAQSKk0VlmZVXuePegDa0yx+13KrPnZmvUdIsdO0yw3wW6vKBkfL3rzhZjasm3luK9A8N308lploSwoAkXxFrCysttCEQdMEirFpq1/eXSi9yecdauW9wjSkSKE9sCrPkxG4XylHNAHYaRHElqGVF3EUkqlpNxwAPeo9Pgm8gdQMd64rxh8QvDfh67ks9T1ZVvEOHgijZ3XgHkAEDqOuM54zQB36AOuJCMenWs++sbeR/wB3Cpb6V4XqXx9srcEaRpNxcsCRvuZBGMc84XJ9OM17B8NNY1LXfC8Op63DbQT3JMkUUKkbEP3QSSSTj6d6ALtx4cfULRowAowcV4h48+G99a3TyxKzL14r6GS8kjmGzJGeldBBBb6hEBdQDBHU4oA+KY7eXTRtnjYfUGpRKk/3SQa+qPE3w30zVAxjRAfpXlniH4S3FoWayUn3FAHlvlkDkk5qoNFa/ulVQMGu0/4QPV1k2uxVc85FdN4c8GxWcqyXUoJBz6UAa/wz8NDS4UlYgHGa9Ml1HzUEe9sDisKwNnFGI4skj0NaSgBfkjI9DQAsjCNdyk5pLO9LPiRyBmopYZiCxYAemKpSRLGMs4/lQB0N7cxG1IWQlsGvONW81LhpI4i3XBNbM+pLbZwC2PeuQ8W+NJbO2dYbRmOOCAKAOR8aeLtQgjMA3IOmBmvNzdXFzIzyRh8nOT2q/qWtT6xet9pTy1J79qluHtbW2+aVORmgColtH5ZknlEZxxjFZB1y6g1AQ2t3My56DtVm3bT72Ri0wYemT+VQXbxWMn+g2rMc5DcdeueaAPTvDU6XNrG91y/HLV674F1i0tiiMRszXhfg547xFOp3KIv93pj2rqb/AFCLT4iNNy3Gcg5oA938Qwabq1sfLCljz0rybxL4fa23vBkdTxXJab8R721nMchbOa6ZvFdxf2haSM7ccnFAFXw/e3SyCBlLZ4qPx74QmvLNrgl/u56VBo/iO1t9VBmlQAMM5+terXnijRL7RSnmxMxX1HpQB8iIZNM1JoW/hbHPGK9H0ryTaB22s2Acdaw/HWjJdalLNaA7Sc8fnWFputSaU+yRGOPegD0OJxI5VYyB7A1bWEqc4P5Vl+H/ABTb3WNyBSfXFdOZY7gqwYYxQBnzhxHlVHSs6KUrN8ygGummW1WDlgTj1rmblQZiYgQoPWgCn4od2sTlyAM153o1yiaky4BIbuD3rtPEsii0YbvWuA0aSN9TbC4YPyfWgD1C2bzIVJwB2pLiEScCizhL2qksAMVMq7RgMM0AVkke1IAYgE4611Hh+xj1IgSy9feuUvLWSTLCQY69KgtLu7sZ1KyEAHrQB3XiLwktvCXhfOOa4mOc2sxR85z3rvdM1gXljtncMStcZrMUYvsqRyaAHG43jOBjrUb3RJ+XoKcSFhG0ZyKz3LbjhDQAttCpGWNEyqrYU8UwfKuAxJo8tsbjQAxhjk9asW1x/Cc1WDFnwBV1I0VN20FqAM3xHtFsWxzjNcNpV841Ipgbc/yrsNen/ckMuOCBXIWEAN2WQkbjk+gxQB6Dp+opbxq3AY+ldBb3v9ox7ZJG2/WuLs4UbaGckg+lbfmCzh+TrigC9dww2zEozE1GhFwpjIbmq1lcPdPmSPjr1rRMqwDKoOKAMLVNHVEZ2LdCa4W9ljglYjAAOOR3r0HW7yWeEqvArznUtNkecs0vXoCOlAHUeEy97OFULgY5/rXZ67fnSrAxGQBiK5Pwi8enx5XBIGBz7VqXGm3PiC6DSKRF0JzQBychk1C5LZZsnpzXeeC/Dck21j8oHqa2dL8Mafp9sGJUso54rD1fxHLZXYttOJyeABQBt6vp8FlcqHYE7h05rsPD0ka2oEZPavPrTTdVvFS6vN2xuee1d34V8tlEZIyDigDRubNpnDRbs1taFYyxyq9xnipoU2sBGBU9/rFjo1o9xqNwiIgyS3YUAdM9xGtoSzLFGgJZ2OAAB1J9K+R/jz4y0LxXrMMGiWazS2bGM6mODMOfkUfxJk5BPvjgnN34o/FLUPG848PeGoZF0+ZhGVQfvLg5HHstehfBv4S2vh5YtX8QLHd6wQGji+9HbZ/m3v0HT1JAPA/h54Wn8SeOLHRpImQCXNyrrgoin5gRkEc/L6jNfcSWUNraxwWoG2NQqj6cVm23hjS08Sza9FbImpyxCGWReN6joW9+2fT1AGNtIZc/Iv60AUIoZVkyQAM1qwCQpguQvsaqTRXLNznGaswR+VHmRiKAFkuWh4VmJ+tVLm8uJFI5xTprmMN8oLH6UiGSQcqQKAMK7jeUkFeTWe+jF1JMhGeetdJcJsOODmoJLdWXAIyewNAGLp1jFazZklJwfWuge5g8oBX5x61SGmxE5Yj86Dp8a8gjFAA9wueHY/jVKeM3JIBK1cazQD5JOfYVWnspljJLHAoArQ2EMb/Oyv7Zqn4q0hbnTpDBZBjjqEqr9tazvclC4B967jTPFcAs/Le2BBGDmgD5F8TeG9UGoOYreVFBzwp6ViNpt1vEUySFj6ivrfWby0ui5S3QZ+leXeJNJklujJCgUDPQCgDgfDvg642ealumDz0qDxBpNzHmMQhDzyBivQdKvLqyYJJKQv0rVnis7wBptrEjnigDwyx0q7huA0sku3IOAf8ACvVvD0kBsPKlgZjwMla0pdNslX9zCrH2rNubqazJ8tQg7CgClq+lIWaS3tlz6la597y8hJidXAPZQa3m1q+kk2sWEfrioNSv7e3iLsw39aAOLvLa5kuPMjVlyed3Fb+mT3VrbbSQ7HsDVG4vXvgdsmB2wK2fB1xaW12pvSJFB5zQBjzX19JclZIysZ9c03U9DguIDIGPmY7etdh451Gwmth/ZkCl8/w1yOhy3TSD7RGVUnuaAOVhL6de4YsACB9a9D0XVfOtgsZyR+NJqegW13bmVQNwya4canJo2pLBGCcnj2xQB6Sk0+4mQHbST38UancB+VVrHUGvNPV3YLketYV1MouCZHyAaAKvie7SaJhGCDj0rgtMnaHUwT1LEHFdJ4n1KMQlYgMniuY0jab5Wk5xzzQB7N4Yhk1GBVJKj8q0NW0qS3jyrEn2NYvh3VPJt0EVbR1nzPlm70AYqGUcNmo5LfeCWIx9a17h45Fyiisq63bSOQDQBq+HCv2gRl+Dx1ro9b0GEWwmXk4rz+0kktphImeDXb2eui5s/LmPOKAOacbWaP0qrJb/ADffar+oqFmZlxgmqLXIzjbQBV+0BgEAG4dakZH2ZPSqm0q3y05pZsY5xQA5JSjZK9Ku2UE1/cKE4B4NVoVJX5gKu2d4tqhKnDCgDK8ZaSLO23PIMn3rz/QebxgXJG7OfXrW/wCNNSuL7cm5mGcY9cnFZWi2Dq25cljjJ/pQB21tPBHEoQAvjnNOZfOP7wkL+VQaVp7KQ9wQqjmtO5WGWPbD97GBigAtJI7cfKSamnvC33cflWLIk8TYK8VagdFjzITu+lAEV3bzTgtuwOvpXKa5cpbS7GIJ9vrXcyR7rRnWQ9DXm97bvea2qDLLkduKAO08L2iywLIwOAM1vPqht3ENsB+FWdK01bLRFeQAHbXGXF0ItS3RudoJ6fWgDvXaf+znkkYglfWuL8PW8l34nja4dBGGIJY9q059ZFxYrEJmzjHSs7S08tzK2c5JyaAPatT1PSbHSYohIHfH8JzXO6drMccxe3hlxXPaZFDfTKHywB716doWhQS2uAoQeuKAMLVfiBFpFi01yRGAOARy30HrXiXiPxNrnxE1lLO3R/JJykCngD+856Y6f/rrS+I3h7XLjxlLaXciGzU7oplUiNUJ/wDQv88Cuk8PxWvh7SWisohvb78h+85/z26UAT+EdG07wTF57Ok2pOuHmOPlHHC+g757/pXTr8SGt0IV1z714t4n1y5mvGVFZufeufvbu8UcnavqDmgD6CPxSuN4LSqFPpW5pnxaEe0M4avmK1vo0QefIXbGeR0q+k7Fd8X1GD29c0AfV8XxQgljBIHP0py/Em0Zxu/pXygPEVxDL5IZ85A/OtGPUpmTzHkYY60AfWVl8QNOfkqpP0qzceOraRNsSqM18taZrTLjLmuhtfEIyFLHNAHt8/iBJyW3gZ96z38TW0L4MxLfWuL0gm/iyJDjFMvNGcyFosn17UAdu/iIzrlZAF+tRDxDbw9ZXZvrmuMEJt48SyEcdKpSSHd+7jDY70AenWPiiJnACMfrW0viSFkCyFAp69K8ZjmvMcEovbmr9pBPOfmnfmgD1KTV9HA3N5Zb8K5rxD4ks2BjtiqjHbiueksRGn7xs/jWVdLaKTkjNAFiXWUt90jyu3cDNZ6eKpLuby4Ynx0yRmsrU7qJARHGGFRaXqHlNkW6rzQB2EM6qm+4ReR3FT28Ud2MxkDB7GuR1G9e6ULEzA+gFbfhK3ug6+YTs75oAsatJPYRExjPFY+iQ3Gs36iUHaTiu/1K2tJYAsjAufam+H9IFvOGgBAP8WMUAXpfDun2GlGSeM7gp6464rwTxrex3Gpm3tRjnFe4+PrtoNMZWuD0I618+20S3Ot7izN8x7e9AHXeHPDbPYrLIRjGa5rxfc/YXZbYAMM4A9RXp8MiWmjgE4+Xj8q8i8QyJcagdxyCT70AW/CWqGRlN2M55wex9Oa6a9IuCDbAAY7Vx9rbAKnlZrrtHVxEA5P1oAu2XmrCVlJxjFcP40hSNzJHGS2DyB+ldlfylBgOc+1ZV3YtdW7FiTQByHhu7lJUTuyr3XJHf/Cuk1C5geHEUbE4wTjPNc68EdvdlS3IOK1xEzRgRE8igDltRs2mkLNvC9QPc1XhhjicBMBj3J7V1lxpspjJfPIrDm0p/N3qmSOhoA6zw42YFBK1qYkeUYXiuU0qeSBwrKVAxXZ2lzG0Q5G71oAe8hhjGcc0xG8/nAxSTsGPzGk3gDEefyoAdJasV+UrUccjQNgsvFTxs4TBBqjdIWfJ6CgCxNM8o4IxUIjUDnrS208MQw4/SrLGGXkYx9KAMhCztgghe1Wx5YTHU+1V1UlQuefWpVCwDcxzQAgKbscikvVSO3J3Cmp/pMmF45qt4hmis7YxM+XPTmgDlbpjNeFFwcn8q6fR7URRqZMDpWDocKzXJcg56810dwSAFQHFAGj5MEgyz8fXFQiYQPiPBFUVdkUZySaswlQMtigC5G0dx/rAAetQXNqoz5ZFQmQl8RjgVcj2AAyH8KAM28uJILUqTkEYrN8NRRy6ispXnPf61f14+ZAREpx9KyvDWYbjkgHPTPvQB3OsTO1usQcBR1FYD2EWC0YBf355q9cP5rDcxGan09Y0u081ht+tAFOy8L3c4MzKRGOelZuq3EVpL5IIJ9M167ea1p8OheTEB5mwjp7V8/8AiO1up9RaSFzyxwMkfnQB2fha7uHvYxH93IzXuEeotaaGSrqsm309q8D8GzTWsgaYLgfrXftqFzqhWGJSEPBODQBg6tJNf6q73Dll3cYNac8ERsCAhzjrWlLZWulweZcsrPjnODzXL6t4gWRWitwoU8UAcP4gtT9pYrgDPpWBeWXmKMtjb3xxXUXVtJczF5GODTGtIwMBSSRQBxMVnI8hVgVx1OKsxC6thsiAZSa7FdNXy9wQcj0qhNp8nmHGBQBnaZpheQT3EgLHnmr125bEce3GMZxWlp2lMzDzXIX611NjodoSqhA7e4oA4i0dIRgKXY+la2l6Rf6ncoViZY/pXodh4TtmIcxID7AVpTWLWcW22Ugj0oAn8N2EWk2q/aCS2K0Z9TglB2444rm4YdQnl2tuKnrk1fmsHtoScLnr1oAgvpYXYkgmo7dUYYWJiKrJbTyyknG2tazKxMFJ5oAz7ncrYEbYzWjY3scMPzId1axtLeeEMxIbvxTLa0g83YE359RQBnybr08EqlY+qWcNsCN28/WvQZNI/wBGzHGFP0rCGhu9zmcDbmgDgI4meUhYzt9+a14bK2SPdcbRxzzXSa1YQW9tiADeRjiudsPDs+oznzp3VM+tAEEU2npchYsbgcZ6118NxFHYEhlBxxjg1l3nhOw0yHzRM7yfTPNV9F0691C7EeCIenPpQBreH0a41ItJuaMH613Opala2doI4VG/FUhpVvpFjuJO8DsK4HXtcm88xxKDyRk0AQ+L5/tyEFXyc1z3h/SIbWY3EoXg5rWj0/U71PNYAR9evasHWL02RMKv8/TGe9AEvi3XHkjNvbDaBx0rgoLOee8DM4wT/Wrl/dSkl2xzzxzVOwaS5uBsLLzigDvtOsrS3slMjKz1We62yEIp206yiWO3USkscVIwixkDigCo53PuKnk+taW5W09woHSsS7k+cKjHA4q1G0iWL5J6UAef6iksmssqsMbjkY9/8/56dzo9iIbVZJ2BOM1yrRn+02kKrwcn862r3U2MSxpjp2oA0buVHGFIqrHCsjbTjn2rNtZXMmWJ5rXgic4ZQaAFudKAhDoBkisxZJrWUBgceua6ayZmysmQAKy/EUQWNmUDOKAHwzrcJ15qdJGiHCkj6VyWlXpiucOTjNddFcJPFtHXHWgCRJXk5wVFSDyx/rHXNRom0YLNUckcZPJbP0oAJ44H6MM+1NgmESlQDilXCjCopqPyJDycD8aAIJ1bojBSKh2kqQXyasxcDMlK3locigC3YQokJaTHArgvGLPc3gjhbI6HnjH+cVt6vrRjXylwKyrIJLJ5koBNAGh4athbQLlscY5+lbxZCpJINYf2uNQFXjFWIrobcLk0AWXkV3woAxT/ACs9aohmeQYGOa0AxC4INAE8cSpHlWAOKrlGL7mfOKsRpuTlsfjQoVeByfTrQBWvGLwbFIOeKyNPtfLutzA4zk1sTmQkhVAqs0E3U4FAF+eSPy1CkbqS3h3nczYPaq8DbB8wBNOkLSHhiB7UATXZZEwHyMetYEjI0+WccVueSZEKljn61gatYm3JcseOaAN/QLP7dcqgb5Qa9MW3TSbDIZVbGc4rzf4fTmS72DA6c16N4k0t7myyJgMr6+1AHI6oo1ORhJcjFZC6LZwtlpgT1p8+mm0di0xOPeq9vA1zcBQxxnHJoA0GsLURZTDHHWs8WReXK/KoPpXT2EMFsFSVlOauajY2z2xMLKGPTkUAclcSW8UYjVgZDxUMemSyESMflNTW/h+cXjzSEsvYda27aJ5ZVgUY7UAM0nQWuAMg4FdPY6KLdOo/KtGz05rKzVmIyRUUFx++yzfLn1oAt2tlOPuk7a0EhcDDY/Ks+bUWVcRHiktrx34cnmgC5Oqxg7WAP0rLns5pjkMWFai20s3zKhIHPSs7UL24swUCpmgCo9vLECFjOaLS2bzAzgjBqAX08jZkK4+tXbe5RvvbvwoAtOMLhT0p9neSW8g2oc564qKW5VUyANtZl34iWzB2wF2H+zQB2kF5PcKPMlAHpVyFIZRtYBmPevM7PxPqN5PtitwinpuU11theTRR77l0zj+E0Aad5o8DNucgDPTNTWlnZwoQuCaxxfi5nwHYj68VrSXiW9ucKpP60AYuvwupJiU4zx3qnozagJNxBRPXAFUtW1WdZywIwT3qKCXUNRTy4nCKeuKANjxJ4gW3tjE90u/HSvN4Lp7rUQ5cMM/1roL3w6kTl7uZ5JCem7PNZdzp08Z3WyKiDueKAO/sbee60zbCw5U9vavJfGmiXNreM8hPc12OieILrThskkjI6da57xvrJ1Ekhl5HY0AcW0e6MA8kVa0iH96Ni81Hp6qzYbJPpWymYR8qgfQUAaoiYxgBDke9VZ7aYAl2wKreZMWz5jAfWrJuGaPaWBPvQBRbIcBRn39amvLxUtdhGCakiVNxLEZrP1EJJJgGgCxpWhC+BlPcZqO50VIJsYJxXSeGmMdsFCnkelWbq23MWI460AcmlpGjA45FadvlUAXFWZYI8kKOfpVdo5kbhcD6UASBXJOWx+FQ3lr58LA8mpZJ1SMbqqT3y+WQGAPrmgDi9RtmtbzPGM/lXQaRcR+WPb3rA1eaN7hsuGPsataazB1KqdtAHZRzgICIzj61BcNJIfkXaKZE++AAEg4qq8cobPmH86ALL7448lhmqqTSHPJqULhMyMxpu8A4C0ANO+Z8KvSodRkFtCS/ykUstw0K4iBzVOXN0p+0Hjv2oA4rUr2W4vCkQY4Pp/n2rTtfOwMA/wCNab21pG/yqCTTjGrMNpAxQBnvbTcsM+oqzbSvCfmycVcUYXBIqIwbmySMUASRXrmQfIMA+ta8d0JEwUUGsiSJFjG0nPfFULgsp4Lce5oA62GMynAYAfWrsNr5ZyST+Fcro+pCJxu3Hn1rrrfV4niwE5I60AT28cBkxLjmo9bjiWEmFR0rntXv5Vk3RnAzUC6uzwESEk0ANilPmkM3U1eC/MDuOKx7a5ia4yQcnp71tbWkAIwAKAJCCB8pOay9UhkkjYElq1EZIx85zioLgpPwvegDB0q+udPuf3ZKgH8q7CLxLcXMAQyMx4Fcze2TjlBnPfFdh8P9KtNwe+YAA96AMC8ubh5cuWANL57QRFlPPX6V6Rrnh+zvB/oIBPXiuI1/w3exjainH40AYNpqNzPdsGJwDkc9a7PQpBd3McUj4B681z9hoM1tDvkU5PPSrFqZ4X3QqQV6UAe0NpljaaSHwjMQe9cXZ25k1HzIgFAJxXOxarqt04gklKoDjmuv0i0eCzMjNub2oAh17UpYUEckm1QfWs6zv45RhZNxNct44u2WZiWYAViaD4gSCXlg2CQeR27UAe0aTHDJzO4AAzzU15q2k6cwJKsRXlWr+Olgt9qfKTkcetcDf+J57t3ZpH9h6/4UAe+ah8SrG1hZYSq4GOtedat8RYru4LLIMc968ruLuWdiWdsdMZ7VFIGBAYAED0xQB6zb+NI5Y1AI575ro9K8SWpQZkG414NbvIkgEeSTxj1rTQPG5dZZc8/KG457UAe5HXklchSCKmhuI5mBbAz714lYeIJoX2SZXH94/wA627XxJuORL0xnBzigD2OCSGPkuAPpVia9tBCQrh37CvKY/EZkQKsmT9a1NGupJZQzuMZ7mgDuba4lVt+fLXrnNOm1GaUERuW/GsuctJAArE/Q1FZILdtzq/r1oAztfa7Vw8srbAc4xRa+LZLSDybSLfIehz3rQ1y4SS0O2IkgHrXG6TdJDqIMkZ6+lAHZaAup6leG4vpGWI87TWh4v1C3htPLjkAIHPuamhuJri0At4iox6VyGv2chkYzuc+5oAwZL1ByWJJ4qlcSNNkquR9aZc+WkpReTnGa0tN05pMMche9ADtEtMvudPrWndhFYAEdKc8kdom1Rkng1AyiVCxzQBC5BUANUiQ/JuLGo4Ycy4J4Bqe5AVMKRQAieWobOM1jsxmvgEHersjbYyCecUzSo/8ASAxGcGgDs9Ij8m0UsQOKq6lelM/vBWbf38qrsizjpWYyySHfMxz6etAGraX6u5z1FRalqxT5VIqkZQsfyjH4Vi3dyglO7JPagC9cXjNGWLGubv7yZyQG+UHnmrl5dS+T+7X5TWPsZySzAGgCC3jSOfzZSZGHr/n/AD+Nb1rqEmwLHGEXGM1zs8jRsAkbOOeRVqxZpcbgy5425oA7nTJfMQGR6s3E0fQHmsWxZYYR97gY601rsvJgEelAGyrmQBRip1tnYZrKgdsZLqK1LZmaPhhQBSuGRFIHUVlXE27IGc9KljmaTmWkmWM/dxmgCiIWJyAMdaiuWaMcEjHvVkYzyagvhGFyDk/WgCG2md2wSasNIykAHis6GQKTuBpJbskkKOPrQBtRSLgZbn3PSpGVHGSAawYJWzk568VowksoznBoAZOu1sqAMe/SpLa6kXgM3FI1ujnJbnr360CdIDgrxQBZmkEi/vGOaht1iY8kkHNIT54JGcfSoo2WKYLnnrQBNdMsRHlICw6exrW0pp5ogZGAH1rOnj3xbh6VJpLoBtd+c0AacrQq+GYkj2pYPL3cVBOEjbcnzGiOZmIypAoA0ZZkC4CioHnnSM+WxX0wajJPXaaaXLHBU0Adl4G1v7PLi7clffmu2vdR069kVVIyevFePQDaflOD9avW63SyB0kIAoA9dbRrOSx8wsu3B71w15Lp9pdNGpGcnpWTca3cxQ7JJiVHGM4rFTUrdrjmNmkJ65zQB1JhiuJA8RI59MVqyfbFsyttk8cc1i2NvdXiK0cgjQc81vwXEtnGEZw5+nWgDy3xTaXk8zfaNwOa5OLT5LQHYufevYvENq95GX2fpXHy6VclWCqeCaAPNdQ83zz52epxTGiVmUQMZDjnjFaev2M0NwzSEALng5FZdpIIpgW+6eDQBGwaN8HIYVYiSJ42eeVg2eMHJ/HvWoIhIhyVPGSCPeqT2jI3mW5AI7HtQBUiikZwYgQOzdKtw283mDfM2Ovykk/lUcfm3OY5SVC9eME5q5ZXEUEyw+W+Rkc0AMurEyDehOR1z0rMjiZ22gfN6E4rory9jjACDO7AwKy5rdYczRvtI5wR/n1oAbbPPBcIZGYKxwec16B4efz1UB2/nXNeGtIuNXnUygGPggY6Y7ivXfDugWtmY02gE9aANDSLdYbcE7nOO4qpqbyvKANqL9a6zUJrWxsNqFd+MV5tcx3d9eli58vJ6elAGy6wR2xMkzMSDx1rAga0h1BXdSwBz0rcSO2ggAKlnAweay7+7tbUGT7MSRz1oA6ibxba2mnBLW3JfBA+UivOtUn1fWbz5UCRk+uMCop/FV1PP5VrAEXOOQOBWrZC5mj3TToCf4QKAKlvoqWy+Zdvlx1+tWBfKimOL7v0p12hBxuJxWe5wcKp5oAuJcIWy4BoecMcRg0y1tQw3NnjmrMbxqcEDjvQA2ONwu4ioSrO4Bz1q3NgrlWGKqiYq3FADL9BFACSMml0P94SRjrWP4huWkTYDgg81Bo2ri0XaWGc8c0AdVfOkTfNnd6VmPM0rcA05Jpr07ux56UjxyI3zAUAVrpyifMSBWSXUsSACR61s3IOzkA1jTgDPagDO1S7ljjwmRngAVBaRkoDcMxJ5Ptx0p9y2DkkY68io7O8WVymePegC0VhGSOce2KktXiDfKgz7CpxGsgAC8CphHDDGSUwcUAJPKWjwGIqK0ibfuZzjPrmop3804TPFXNPj2jDUATtcIuAoJwatwagI0wT1rOucqSVBqonnMCQOKANK7bjEecUlttRCZGH51BveM+1QXZ3JuLc/WgCzPMkj7UB/KmyQqq8gk/yrOtbxUcqCCRjPNXzdEr1A79KAFghRwRIvbiq91ZBW3IBjrV61kjZgXnGPpVuSS2ddqgMaAOej+V+Rz2z2rSgDOB8oH+FTNZoSGIAA5pJJVA2xkZoAH2xJnAJx9ayr2YsCdvAPpVmSRoyWkPB6VALiOWUA/dz6UATabNuQDb7VfFqpcOQc/SmwLFEu5MVZilMpwXwBQAGAvEwUjgd6yVRku8ZroFEYQgHJIrEuEaG53upxmgDXJKwKQMk1LbybkPQYqCO5Sa3CqvOKiizuIKkZoAknnZXwM/hUiTfJ0bNTQxwkfMvNNkwHwhxQBHFvZ924jvVxbiQLhWOPrURXK5NJDII2yeg/WgCaNdzlpSSOpzT55YBxFEu7HXHNVZ53uG2xjAzVe7le1iIBy2OKANzTdSubd8yyKsQ6AntW0fEEcqgRqrt7c15rbWuoapcETSERduO3p7109nDHpcYGAzUAdI2pSOm2UKBT7SPzWyu78qwDfI7BmUevFbWl6oQg2Rjj3oAh1zwgNQhaSNQHIJHbmvMNR8J32m3RZ4GeMHspPP4V7Ut/cuc5wKvnUYmgKSxq5NAHzrJbzTnaN1uwP8AFx2qrc21zECWmBCjs2P0r3mXwjp+tzl3Cpk1Q1/4aWcdozxkEgccZoA8IjkkV8ozbifzrZsdC1LU3VoosH1A5+tao8LmDUj5n3FbIGOK7vT9U/si3C28AdsUAeY6r4X1OwXfPEzZ9ua2/Cmiw3Dr9tkck9QTx/8Aqr0u2v49aj23iqp7j0qhdadZW0+LcDceeDQAlnBHayiGyjAA4zjFdLDG8UO5jl6pWFi6xiQnAxUeo3MicCQ0AF1G0x3XM4VB71lX+vWNihjt8yP7CuX8Q6pPuMZkODxisuxuLeEb3wW9yaANyfxJdzORFAOfY06EXt381zsVD71lG/ZmzGoH4VBd6hKyFS5AxQBd1SOG0O6NxuzzginaTdyO4ZmOB71z7EOu4y7iParGl3Txy7AhwTQB1dzeZ6KMmoUkypbAyKiQecuSdtKsiRnBbJoAet624qRgVKZ4yvGcmoGVZegHNPWBI1yKABVZ2yGO361bAiRPmJzVeOVV4IGKW6eIxHjtQBz+vSguwj5zWZp1oBIZJWbGc4Jq8LWW/vWjgQ8Hr9a0Lvw7c2aCSdzjrigC/ZSKIwIw3FPmuMgja2fcVJpF3DDCAyA8daW7uY5yRFGBmgDMmuhGh3Yrn7ySSd8oCFNa97bxx5eX69awrzUXWQR20JIPf9PSgCvdLKseAoYnjDen41HpVq6y/OBk1rQRh49838XapYYY0kyqdD60AalhagKCxqK/t42fhxx60jXLbAowv41UNs8hL+YSeuKAHpEi/dHSo2kZZMDocUAsrbRnH1p0tq7ru34wKAJxKPLw2CaWHlSVU4zVGPbCf3jAntV5JyFHpQBhy31xPNkRkRnvnGP88VZWPzITuYAn3qa2t8cthvwpLqA9clQBQBkm1EUzSITznp25z/SrAueNpU5IxwD/ADpWdQ2AST9KnhQbw7Lxj060ATWySsmVTAx1IqzaQSNIN0iDtTWuMx7VYj8KqQq4lyMk/wBaAN6YCNMFg39Ky7qWKHJXOetWJJGSHMigccc1jtMzykFAef0NAEF1LcXLAICFzkn09v8A9dSQMsLAtjP51dRX28IFFVJVj80GQkDvQBuWFwLhAAox06VceCKNSS6qfrisizvEgXbEo5HBp1wpnO536jpmgDcspI1yOG/WqOvAMvGORWfFcLAwUSEc4q5dXEL2/JDNQBU0u4ZTjAx09c1pyZbDHA/SsnTcNMSPu549q1LmRVAGeKADewXgilt5gH+dTn6U632tGCAPxps0b5JUCgC1NIGT5eKhjX+NiMfWmRIzEB2NTSRIFwrcmgCSGVS/yiodTniVMspY1ZtlijQs+Olc5rmqQRylQR36c/yoAuwazPGpW0iGfcVQu5dRuX3TuEU5z2qvb3boNyjFMmvnm4cnmgDRtJjCwBZn/E10dhfNtGGC+xrlrZ12DywM1bslYyhpZDigDuLS7diMnIrWXc0JK4zXNWdzGihUwT6102knfHljxQA+wnlilG5iBn1rfN6ZYdp5GO9c5eukbEg4xVvSbhJCAWJAOOlAGNr0LPL8qoPeobDSo5hmQ/N7GtvW3ixhYx1qPQ0hDAytjmgCrcW8VlDmMNu71nWYee5DN6966/UltZIiIwCR39a5K5Z7eX5BxzQBvy3PkW4GTisDUb95VZYEGPcUNcPKmGJxWdd3AhiZV6nnOOlAGJqcWdzTlcmsJWi8z5cY6cVNq0skzkM5qrYphsnGetAE11KAmFDVREckgJyefXir1w+OgHWq7bip2E/rwfSgCFSIwQxHtU1teKr7VRt3qVpsUJzlwD+NJOEQAocN6e1AHX6YomgBkYc+9Q3EKrJ8oJPbvVPQJWZQGPGK15iFYFcZoAgHmKoxgAUiOzcEjrTbiYlQCTzUVumDlmOSc5oAlljbI+YcmrH2dWtjucdKrSS7Dz839KhuriQxEKny+lAFO2uWttQIiPcc10l5K9za7pSxAFclYMzXpLKOOea6qS6BgCBAKAKlvJEo2BTmlbyrdS7Mc9aC8UKF5GHTNc1rGqvMxW1Tdzg89P8AOaADW9S+0OYokfJ4HBwPqfSobG0uFUM5Qk9yP0plnE6KHnOT61chug7hVGRQBOiv/FtI9hUqSBewoVJGHyripo7ME5kbmgCvIpfnI5psbFHxhs1pLbKoypGKa0sMIOVBagDNuZ2DYWMk/SokNw55yB+VaSsJmJ2DBqG5Z1bqQPrQBXWEHBbJP8qm3KvGKrzTvsxGBk8dabFFM65JwaANAhYxhcHFYms37rEyj6VpCQMh57dawtWi3I/PI+agCjprDzyzN83p69/6V1Nq3mQ549OlcbCQsqFjgAgmumtJt0a+Vkqec46UAaCQuW4Ax9KlCFQSxAIqGCdo/vEfnSS3UUh4ZiaAFnZpF2oQx9qom3lU54GK0Yl2KGAAzzTuZDliAPrQBSaR0QZweKqPN82Qh3D261ozeUBtPP4VGkKN9wHNAFH95KTllUDNCMQAofOKnnttvJJ7kimJAxB2gCgCGSBJGBlDZHI5Iwagv7jyFAU5PYVfSI5xIxJ7c1BeWav98Egfh/nrQBJoVy0mC3B6fjW8UjJy57Vh2FuIyAn+RXQQWrMnzZoAjKlMmM/L2oRpCwyen61FcymNyqqeKLcN945AoAtNtAyzUxipOVJIHvTGZCevI7U5OB91aAK987CI4YiueZUM25gGboD/AE/Wr+qyOZMZ49jUVnJDGpLKGb3FACFhtCgYApjABSSuTUs7tK37uMYz6dKZhgdr4A6mgB1mO4OAffpUwFzNKI4s4OeasIirEDGgyfWr2ixv5weQqAPegDQ0rT/JjDTycj6112jTkYWMbh0rEldHGAFOKuabM0YAjwM0AaGsElhkEc1a0ZxjEaHNVjG0nzStn61dsTHB0OKAE1aHccyHA/Kq9sFRTtyxq7dtHKMliaoksMiNQKANWBh5eWU9KyNVCGToKu25l2jcT71W1BowfnAzQBUVoxFwuTisq+VnVj5ZGK27UKwyqn8qp6yzpCxCjGKAPONXVjMwIxz3qin7teTWjqSPPOSvU1nzW0iDLEGgAiBlkOXxjp71bVhGhAGcccc1Wtx8uABnB5qGeQqxyTgdhz/KgB88jFhzwabGhY5OeTxSoQ68gEj1FBZ16qMDvQBp6Wkvm/KeO3FbU7NGnzdcVm6DHNM/yjgVp6jEyDDMC2KAKokEgOe1RxMzNyTioS0qkAKAvSpo3IX58f40AWDJGvXrUd9cnyCI15x6UQQiZs81U1WQQjaDyKAIdOgXzTNI4GeSKdq2sJbjapye2OapwTDGSTzSzWC3GG2BsDjIoAoyy3d6FaJsKcZBHP8AnHap7DTZVxkNjOSW9xitXT7cxHlPzq/PIAAAoXjsKAKLWaNGA7DipLSxgi+YEZ9+aaY03Es7flSSTn7sSjHSgCe4eQDEeMZoiK4zIx9+aSA7F3SAcjjvTCGZiSBjNAE0kyYwrdKqybGXgkt2qG5wzYUHNT2cJBBKjNABbrIB904ptyodsFTu/lViaZlbauM9OO1aGl2JdhLKGGOeRQBkQ6bMwDBWx71ZVDGNrkA/StXV7xoovLgVeOK4+4muHclnxz60AS3auTtjBwOtQPassReQjcPWthniWPhTkd6xrqbzXK5IHb0oAxLcpHekMo27iBntzXT2TqIwI1yp6n3rDeCKOQys3TnrkVoafdKVwnI7/WgC/JCjtkkg05YVUcAYpc/KCRUMhcng8d6ALL7EjyXA4qiTKXOzJX61Y84KmAAzdOeajEjscYAGedtAE0EY4MgOfrUjXCodqEflTI4485d3pWMe8Bf1oAkbDplgd1U5YXJOGwKnaTnAI/OkdFK5BNAFZHWFiHOSangjN22egqDyMkk5I9+9Pt/NVgF4H4igC8wS0xjBar1pfMwwykDpzWZJx8x5NNN4VXBUAfSgDTn2yMTxVSbfGMBhz7VVF3IxATG3txU4dmTLYzQA+CIv8xYCpJgijaXBPtVYSSFiDgCrFssPmASnJPbNAGVd2xZi2Tiq0ahDnvXSamsS23yDtXKLIPNbO78u1AF1rpgpAAAA/OqhZ5ZBjO7tTXha5bCMy85yDj8Kuwqlufn+8P8AOaAHS/aY4R1C0WEgEgLSHd6VHc3W84BOPTNQ2cuJAQvU55BHf3oA7TToVkXcz8V0GnpGGAjUsfrXH2uoqAqnA7cV2Hh+RDHuXO73oA1ZlPl/NCRgcc1mEyCTluKvzzFmIkY49qz5gnJG+gDUtfLZBuYVKsa7sqK5/wA8xt8u7H0q/bag6gZH50AaV3cRpCFAwwrJBWR/nOakubpZBliuTUCqmdwOTQBpwK6r+7HFZOuySeW0ZI59qvpcSCPC9MVzmuyM0hJY8UAYtxZ7VZy4ya5278xpCMkita5mZjjc2KolwM4ViT60AVkj+Q7Sc/8A1qijhKtukyQDxkDgegrQDqB8wUcZqKS6jkJRQDzg0AVnkTpEpGaYOHG/P41oQWpcZSM898daJrdojmUrj0HFAGlpt0kEOYyM4xUZaS6l3sxwKy45H8whRhR0rStpNoAyvPXmgCZplDbMdODSyKI4iTyTSMArbsDmop7qKMgH5/pQBJaXLoSCpC1Sv9k0+SeaWe9aVP3SYGM1lyGQMSxOaALLwNJtWIdO9aemwzwqN3I7cVW09mVd0ma043OdwPAoAknnKLyuKoCcyNn3qzPIspAJHFQTW8QHyPz1/GgAJ8wjnrU6eRGOcZNU4lVG5YkfWpJnjHIyD6UALK5dvlU47Uqq4QluBUUc0i9UGKeZiwO/IHf2oAjLL5mAATU5mSOLJIyO3SqM0qKSIxk9KrXNrczIXVimPpwPpQBvaSFnuN+w81uarfTQW+yBABj0rjLC6ktG+YnH41sDVUkiwxJPvQBmzX0rMfPfB5qhuMnzZq1enzpAQB1qzZxxRxYcZNAFi4dUgGVFYbqruSF5J4q3qEgY8kcdRmqMTKrcBj3oAj1C1kNuwVfT8ef/AK1VdGcrMYycc5x/n8K2pGMsJAU4rGLxWlycq29jkn0zQB0pkiiQGQjpQk1rIOMVl5W445GKRo/JJx83TFAF24aGP/VAZPWn2hJOSDiqdtcDcN4yTWmHBThSPwoAbc7SOBxUAaJEyTzRK+M556/lUBcN91DuHSgBQ5ZsgYHUGiSZydqH260PIVXHGe+KZGuAXJHrzQBZQShASaikkcH5c/zqSBzISCDxUMhKyDJ475oAd55AAYHmpotkq/zqOQIYwSRmooHKHIUn8KALEsqQ5AHI61WW+fdwvHpU88yMoyvNRwqkpGMUAXILqNxhgAasxxJnzAM4/CqElky/MrjnmmrIUU+YTkehoAnv7wsNgQAfWsmSFvvAcVoCOOUZBOT7017Z2PUAUAVFkMagk8kUgRp2zuO09PaiWAxn94wIp9vgDGD6CgBsqpGuCQce1JE6jlVPHaphAHfLA4qZvKjTbGvzEUARpGzMGHGDmug0bVJICEYnFc0vmF/nYBenoDWvZRo7KFIJoA7u1voJFBkAJNSS3ECgnjmuZjSWOMYIxQJwThnH50Aa099ECQAOKgFyHPGaoEq3I5FNDFTwDQBqgxH7wGf51PDdwxDhRxWBJNIx2jio5FZVzvGaANy71hh8sajFY93M8wLyAcc9aqPIQMtnis+4uNzbSWFAEd1OvmYQc5pu0lfmYjNOjWJRuKsSOeveq11dFuFUgUATpDbsf3koYmpYo9OtBuWJSaw555EAKqzZ9O1W4HllIAGRxwf/AK1AGhJqsrHbbR4XpTEgmunzLkZ/SpkURoCQM1ahDPGTkAD2oAz7q3jgj2+Yc/Sq9pEFk3s/Q/nU1/IivhsHmorNjI4Cjjn8KAJbqd5CEjyecH6VNbWaqN0oGevPar8cLRpkKpJ9ulVrkSMDudRQA2VRjEZqI2wb7x5qsz7HOCSc5NXLRXn+6DzxzQA4LsQAAcVCbh9wUnFaL2rRJukYAVmXJgLEYLN7UAS4QgEuCaY2GbG08VBGpByAwB9ato4RcZXP05oARNgPIAzT5IVYAgjioHd5GwFI/CnFWUfMetADjcrCuGOMVXkujcHZGCc/WnvbLMMtkY96WIxWp+RTuH86AIY9PuVbeQcHvmr4bbHh3H09aha9nkB4wv5VRmKl8s5I+tAF6QwlSSATVIje+ETihUEn+rznrzU9vC8bZZhQAiw7cEgCrSg49KZK8WznORzmqi3arkfNQAXDKzZCjJpsSgLkKM57VHI7O3AAHbJzSKpHVxgdeKAHmRi20sQOvFTPZQyIJCQzDoTUBKheCW+lIrEjByB9aAGsjqT5Z4HNMZnDYJ5qdZAinPWsy8u2MwWLBbODx+lAGlDH/ECCc561OS7nb5hHHQHpVaBHZPlYAfypYl2tlmJxQBJMDGvLEnvSWbM7gEYXOamVlkIXaeP0omRVUqrgHFAEk0cCnO85qozbmIGfSowoD/NIMdfSrCsEX5cZx+dAE0M0cS4KnP0PNRyFp2+VMD+dMEzZ5AIFSyzbY8DAoADEEAyAccGnBXZcKAtU4GkeQkscCpbq4YLtBAOKAG3ELhTkk/jVeJmRxgkZNT28vI3kn1pbtAVyo/8A10Aadmu+MF2zx+dNvoVIypxXPJqE1rIRLkr2K96vreSzx5QZB6f5NABGrrLkMf8ACtBpgsf7wnNZ9vMI3/eDk1eLxyrwM0AU3uo1cgxbvw6VZilh27ggyecVDI6KcJHz0pRYsy794HAoAlaXfwFCj2NIrRI4yxzVGTzEfaWJ96swKjLlgc+tAFhRHK/OMentW/pUMCD5EGfpWFawbnBB4z+ldHaTR20YwMkUATXSsy9cCq0NvEGywBPvTbi7848nGKpy+Yw5JxQBsFlVcRogA9KqTuDnc+36VRt2QvgsST71ZmSKNNzZx9aAHxbcZBJH0prAFs4qKO8RQQqHAphvUZwMdaAIrx224Cis0xlvmfrW20QmXII5qvNahBlsmgDDmaQ/KhOB9ajWCRj8zH860nBY4jSnKFjH7wc0AZy2cm4lunvTzPFaRk5wR6VosPtI2kEKPSo5LewhQmQ5b69aAM61uGvJgVLFc1uFUhh+ZjyPSsGG/VbkrZxEqOrYyB+NX7id5I8zMAO4xQBFeCOQEp8x7VVtvMicHBA61PAy7/l9fr/nrUl0paPIYA0AWl1JETazZ44qlLeZLFkHX0NUlXbJyCQOlSyIzrncMDtigBkt05/1ajkjj0HrV/S7plfBYg59Kz4lQvtfPJ7VsW1j8u6PjNAFi9mSSPBkYn0rLjaJGJA6mrpspd5YyLz69qgubKQcmQfl0oAgmlZujcfWmRyBGLMCcU5SkZ5G8n0p6xmZsiMoPc0AKbguAIxiiJ8n94/P1FK8ZJ2IME05dMIBkZqAFeYY2rxiqe1pJBljyaWSNwxVBkg9aWOMxks2Qe9AF2S3224O85x61zd3culyUTnHYjrW3cXBMWFz71ztwJmuS21sg8EDtQB0VhKyxZZAOBn/AApXuFkPb3rOsbppIFVnXgc1dit4+pYZzQBIqiTIOMCqlwMycL+lTtMsJ+Xn6U2SdnIJT9B/jQBBcK+CI2IPQcdPwpIIjgeYxJHUkYqRywJbGQfbFKpyuSCKAEZlDBf1xQ7hSBznv7VDNdRx/eI5/H+Xamg5AIIweR70AStICpGDmsmZN96VTjJ6ir3nR/8APRPzFQw2nlTBw2QM8fXNAGrApEWR1PSolDCQ5ztp8MpVQFxkDpilO5snB/AUAJNJgYTIPan2ttJO3Ulu2e1NCMSSAc/lVmC6MBweMd6AG3dm0C7pAKz47uNpCgPzDjGD2q9d3RuDtLDBqpFaRxKWVRkn+v6UATFlUZAYn6ZppMspIVRiiNgzcAnHr3qyX2rknAoAit7dg2GYg9MA0+axLgkkYxjnv9arPqEaTBFYM2eMAmpXuJZ0IY7RQBEbeGEYVwG64UYp+TgjJwaVLdFO4jdkfn/nNLJOqjCxDp60AR7VzkgZqTzgkW0KBVYSFnzsIIOB7+9EhJbkEYHrQA0xNM4IZgBjgce/1/CrKymFMdz1qCOQoeOlSnbIMk5P8qAImkYtnJHpzUi3DqMZP505NsfXJBpJGG7lDjtxQA5Zt+SVFWIHBGCR06U2MxiPkDcOKzbuWUuEhPXvkcUAb1u2GBzxmty0eB0wzc1xcE0kaAMwJHUip4rp93DHPXrQB1V35anKYrPuWkZfkzgVTS4YgAsfr61aFyoQ9KAKO5o5PmJBzVgs8i8MzD0NVXkR5stgita1MaxjatAEKLiPknI6is663LJnJx2rUmKqSxA59aybyXzmIUDjpQBpWF6wQKME4xV0pLOhyAAfesaxjMOGY+1XLjUgsezcAaALixJCCSwz35qrcJG4JJFZMl4244Ymq/2iSX7r5HPQ5/WgCze3E5BjtwAR6+mazhC0zj7RI2e4BwPp71abzVAIznvUltFEWzO3OeaAJ7aOOJBtA6YzjpUFwwZsyHj61ZmaER4iI9qz3X5ssflzx7UATRc/6qkeRgcSd6jhkKSfIOp/KpjE07gsf/1UAOWLeuVJxRGNpO7v+tWQFiiwrc4qhK4Gc8k9qAJ9se7K4zVwTMFGGIHsazImGPlBGKk87bw5JHagCSWeTecO3+NTW9zgDzCD9aou7OTsFJHv53dO1AF+WeJ84UAn2xSooI5kPPbNUTbkncCMnmgZSQbm4HHpQBoISvQk/WrL3hEeCBz7VnvdR7cKRu+tQmRj1J+lAEs1w4YlQAPyqAXBkOHx6ZpQqPnzXwB9arzhVJ8slupoAt/usd84qCflcgcA/pTLeQkDzcrnsTVrbEwxzQBmwwpCDtzzjJP+fep5ZvLjyilsdsU24jPKqxX0I7DPb9aa2yCHJyQOcZJ/OgCl9vZpMsg2+3XFaMF8kqA+nGCP/r1lyF7xhsQAqOf/ANdWbEMkbK0ZGD19aANUSoy4UE4qrdyhFJboB279sCpZMRJhTzWRPJNcB2UfugTnmgAnuw4ARARj+IA81AvmyAqu4jPQdBUNXLOZIwd8hUZzjHX9KAI/sk39z/x4VqQokcYXB4qWFUZd2QRjP1psgTlQoIPB5zQA0HBBB5FPEjsdowKaQzD92AB0PPWmTSRRffkG7jgDP+RQBKwKnLMcH0NIzKeu786iglSXJAJA4qRsEgKtAD4mRWyc+2R2qeWXzFxGAPqOtQAKn3sFuwqGfUBGwQqw9SBQBKAI2BY8+1DM8h78VEGEgDZyDzmnSyFF/cqWPHegAVVSTLKM45OBzUwmCj5arwJM2Wlxz0A7Us7LErEk4H8/SgCb7Q+c8flTTc72I2nP0/qajDAAMwwAOc8YqvJfRk4jQse3vQBbWNmGeMU1lKnBxmnpI0gGBtyAcEdKSRCOScjvQBWhlySJJIieANhqVm2qSQTgdB/hUTxW7PtKpu9BwelWIYdqgKMLnpk+tADbe4ByPLde/wAwqz5zOAFUYHQkdKhuJ44QN+Pyz+lVDqOWARGOevFAF9ldlzlcH9ahktnkxsba69D7elKZGAyWAA5PtU1pKkjD5weucf8A1qAI1i2AeawOOvufWnlgTtiUk5/OrclsjjIJNOsoXjfhDj6frQAWsMrDdIMAc1FfyMQVhwCB39fert4ZdvDFR3HrVERrz5jY9aAI9PB3r5rKW74P8q6GCRQnCjGKwYxEkgIBPNakchZAANooAW9mjZcDGazimFLKBk81YlVFbLN+dQSSq4IjPtQBVeRy3zOAO3PUVEqmRuD9M0SIyvls9/xpYiF+YnntQAOvljGOe5P9KRFYnK1E92083lqmQvVvSriIFj5IzjNADkTzF+ZuR1qGeNUJ5OT70jyc4X8fes+W4kF4Ez8uQMUAXlcrx2p0jKycEZ7UHaYQe/8AWqcUUiylmlJXJ+Xrn/69AFqEkj5eh5OeP/r1dUHZgEZ9fSqUaseQcDPrVhWK9Mc0AMdTkl3OB05pIWjzgAnOQT9KjlTzD+8GAfXvTozHDwqgj24oAlZhnsB0prqhUnJz/Kmu3msAowBQ0O0Zc0ANSXYuABwKC7uTj9BUE0KykBiSAeg71aiUqpyBQA+KTbgMTnoRmorwM6NsOPc0SqdxI6UiSbRzn2oAq2MLxs285JIPXP41emkbaAMU0s+35VGMetQuAwIbJyDn3FADUlWRm2tuK9f/ANfer0JHl5ZRgc9PWqcaDG1QqjGR2qQSMBgEGgAk+aU4x/hTipVMAjk9/wClQswTBweD2GalVg6kuBgUAET4GJD+Q61FcyBMlEZsnGB6/wCFIUjD7lRQfXFOZ9q7SQATgdufSgAgkcRgsqhu4qZGjZdwKnPcGq0sayqA4OM59Kr7Y1J8iISepyaAH6pMnzRgNkjv06//AFqyqfJI0jZckmmUAFWoYhGDJOj4UjAx1/OooZPKkDBQSK00lSUDCttYd1496AFt7gSq2wkAdQcUrxq5BYHI6EHFQSTxQEhFBbuFGB+dPhuFkQscLjrnp+dAEV3c7cpGfm7n0pLa2SVQ7iTOec9/ekX7KsjEsDycDHAqwl2XjPkxMcfh+tAE20hSqLjjj5elVHS7Viwddw/hHb6VF9tmSRt2OvI9KvPIsY3SHj35zQAR7tg8wgt3IqE2s1xuDyrtByOKRLpp5cRoAo6k9h+FWGJUFl5bBOMjmgBvkxWin5lBPqetJFcRPIArBjjpiqQlN3Oiyfdz0H0q3IY4ELhFU9OBjNAFgyE8DgVWN3CGwW/HGaggkkuXZWcKhHIAqysUMA3FFwDnJ5oABLmTaI5OvXGBUgGOAB60NcxNHgOo9icVmXEsgmbEpI7bWoAsSvcQsHZgyZ5AGMfWp471Jj5YVgT3NVZLhJLUq7HzP50lnGFBmfO0dOD+dAFicvFulBUqMZUjt7GljvjKuPLfPfaM015oJl8sufmPYGpYYliTauevOaAM+dGaTKpLz/eHOaEtp1cMEGQc9RTZ3f7QxJZWB49QKktmZ2+ecqBzy3WgCbUEYqG3DYONvTJqTRmVGLFTkEc9vpVa6uFkXYuWA/iPeolEiw71bC5xgN3oA69NVt4FBkA/Sq8/iiIHEER+uBXMRW7yxl0wQDjFQUAdKNZS5JMuE+tOa6tpOFYMRzwawYI43RmkkC47VCjbeRuDdiDigDrLaSJMtvUZ9aZe6tEFKo65HBx6/TrXLM7P95mb6nNMoA6RhJKm4nipbFdsoDDOT+VZttfp5SpISG78frVpZGZwYmP4GgDUvLBpEDghR16VlMqK20v831/OtDbcyxYkc4IqkIoIZSTyx60AMI2tlBuqQwTSDJHFQXOowrxEASPT/GnW17NKoLAIpIxzQA9oduQSc1WkSNHMrbcgdf8APftV6R02Z3ZaqJRXdXJzt6D3z/OgCBb5WkC7SF9SatU0RxNJ0TcDk8DIouJUhALEnPp60AIyuZQQ+Ex0wDk/0qQMyqduMnkfWmQP5sYZR17fjiq91cvDKFULjAPNAEqPcM/71UCj0/z/ADqXIHLfdHJ+lVLa5klfaUBz3GRipblJJVKqECn16/y4oAmS6hZisRBb8f50TM8qEByD69ajtrQQjc5w2ME5pLiWFcoZGUnHI6j8aAEgV0by2wUABDdPwq0kmM5yR/KooWGxWXLDA5YH86hmuJDJ+7hJHckEfzoAtvJuGBnB61F5e6QPlsqCMdhnv/n+lKzBVJIJ46DvVZRdTEsgEajgButAFwyMRjj0+tU57VpWLGT6DFKbJmGZ5GY9eD0qaKNYl2pn3oAqpbTggGYhfYmtGzEcSjzSzn161FTZU8yNlzjPcUASXN7brIcDkdgM4/z6UO7twm0fhmqNvbeVKDKUJ/hGe9XRkEYzQAgLYw+3PfC4qt9mleUNOQVHQD61aU7WyexokYyIVORnPTj8aAGhlYkKQSDg96huFnZgYnAXHp3oSKO2DPlscDJ+v/6qswyKVOVJ+qmgDBorc/4RPX/+gPff9+TVSbS7iyn8vU4JrXI6ONp/WgCnFG0jHau7HJ7VpLPEGKBgNvGOnTtzxTpZUt4gAp2g4GOvfrWbNA0QyzJn0B5+tAFq5thIRJHg56gHqPUGobidWj8uEYj9+9WbKMLESH3buTjsf8aoTxiOVlUggUAPitZXJ+XaB/e4qwTOkRRmjQAYDE8ke1MluhJEOXR/9npmorWBpm7hB1NADLdlSVWYZAq+0UVyokAIyOo74pskNtCgMmSe3v8AlVPzCjHyWcJnOCaALUl0sXyQqDt4znIp4ilcBvtJ/wCAjiovszyxK37sMecgY4qNJ5LcbNoH1FADJWkmlCFt5BIGBVqO1jSPM+0nqTk4qslyyFiqoM8ZC9KhZmY5Ykn3oAuRy2qSAqrAjo3Jpbnbc48nczDr2FVISgceapZfQHFWzeRoMRRnHf8AhoAit7V5D8+UUeo60+78pMxJGMjnd6UhkuHYyoGAPy8DNRO5G4SRjeTnJ47UAQVbSadlUQqFUcfKuahjkaPO3HPByOtSyXbjAiARPQCgB62s4YOGUN168ikSW5dC6tlR1OBxTo7xzw+3ocH1NQpcyIcrtAz90DAoAa0rzYEkgwPUf4VGm3PzAn6HFB5OemabQA44zx09KdDGZJFQEDPertvbxPCrMAzHrg9PaqboEl2l1K/3hzQBqQwrDHhSCe/vWVPu81yw2knJHpV9JIoT807OcdySB9KimuTITsiDovdhkf8A1qAKaqTnAJxyabRT2fcFGFAAxwMZoAZTyoAB3A59O1K8bR43AcjIwQajoAKuRX80ZyCpPqRVOigDYn1R5IMLNhscgjP+TWXJI0hy7En3qOlzxigBKfvbbt3Nt9M8Uyrtnaifl2KqeBigCBoZFTcyELnvTFdk+6zL9Ditua1jMO0lyMdjnHvWdJHBC43eYTnpjigCIoqIrrMoYjOB2/KoWYscsSSe5qW6lE0m5QQAMc1BQBrW08aQph0HAyCf6VTvZhJIApyq9/U1VooAvWlyI1Eflknn7vU5q48iom5/lHv/APWrJjdo23IQD9K0YCHtg05VhySWA47UAMe6RxhZDHg9SucimRxsAzQTqzMM4wMmq1yqLMwjxt+tSyQGGMSCUbscY/pQBJKtwq+Y8oGAOM/5FPsp2kLq5yw5HHb8KqLIGBE7SkdsHP8AOnRS+VL+6XIPGD1IoA1yiqNxYGoJJrjzBsjG3pkn+lP3u0IwoDY4B7E1VimZJGS4cZ4x0oAuMzMuOCRyM1npDcsx3My55J3VYkuYkXO7dnsvNQtfLn5UJ+pxQAnnG3YqX871zxg1PbzmYH92VGOtZkjl3LHGTzxWvAweNSg4x0A6dqAIL6DzF3Jyy/qKWwV0jy+RzwCOnvS3CTuxCMqr+INU3mmVDE5+uev0oAdfSiSX5WJUflmpBe4iA25fHU9PrTLdEijE8uTk4UD1/wAirMK28537RkdR+dAFeK6dX3y5KMO3H5VchuFmBKKwxwTjr+tJIsUoMY24HQAjIxxVNrSZD+7bIPocUAfT/wAS/HWu6V8MtE1GyuhHdzgeY4QZOcda5ZYY/F/wkvtf15FudViOEmIHFeU+IfHOqa74fs9Hu/L+yWuNmBzT9N8catZ+FZ/D1sENnLy3GTQBzVsJXBVCSn3Tk8AGrLWEW3Ku2emDVSGV7Z+Vxnsw61NPdrIm1AQD1JoApsNrEZBx3FSwQNNu2EDHrUiLaqoLMzHHTFQOwEhaLKDtzyKAJVtJWdlwBjuen4U+GC4Rsr8vrk8flTlS6eP75GDkAnBNVMtG5GSGU44oAuzW00gVmkDkDoePwFVzazAZKcfUUjSOqqRMxJGSAx4p0Lzsfkck9ME/40ANW5lQBVfgdBgUx5XfO52IJ6Z4pX4lbzlYnPODipENqDysrD3oArU5ACwDHC+uM05yruPLXYPTNJImxsblb3U5oAfIkaqNkm49xjFQ0U5cbhuzjPOKAJYriSIAKw256HpSTztMRuxx0xU3lWuzd5j/AEyM1VOM8dPSgBtOZSMZBGeRTlYKrAKMnueajoAKKkAZQH28epXikkfe2dqr7KMUAMopzIygFgQG5FNoAKcOTjpmm05SVYFeCO9AFh4Ggy0iB1x2J4NFrliFM5QDov19KZK8/wDy0ZwD2PANQUAWbuExNn5irdz61WpxJIAJOB0FNoAKKlMrGIR5+Qdsf1qKgAooooAKKKKACt21CyopUHb0ArERGdsKCTWxaH7PABIQMdT9aALUjiFDkheMVmXam52tFhgCQf0pbqWKd9qiRyDn5eamLLDCCEbAHQdqAMyWJ48bxjNRVNcSmaQtzt7AnpUeDjPagBtFFPiAaRQxwCeTQBNZKrTYZA3HftSXQi8zMJyD1HYfSprtFhCmE7G7gHmhIraTAV2BPY8UAVBt29Tu9MU6GF5T8g/HtRMgjlZQcgGpI7t40CgIQPUUAQOpRirDBHUVatZDCpLRkqf4wP61XlLs2585Iz9amtVgdWEpAbsSccUAJJcySNwxRe3tVgWcaRsZGJxzkdqp5CzfucnB+XIq2l0UGy5Rsn/ZHNAFZDACd6uRjg57/SoyNz4jDH045qx9pj/590/T/Cp1vV25aNwM445/yaAK8cITDXPyqeg7mpjeJEu2AHAHXJH+f0pZGW7QqisGUZBIH5VRGUcZGSD0NAFr7fJuG5VI/EVP5McpWZxjIBIzxVLz2DBgkYwc4Cir4jMyK0u4ZHKZwPr/AFoALl7ZoNu5fQY5xx1xWYFZgSASB1xWlJZwkDaCPUg1WjuRAhjVQxyfmzwffFAFaMsrgoSGzxirhhunwTKAfTJH8hT7CJkDO64J4GfSlnu5TKyxxE7eDxmgDMrR0t2d/JOMdRWr4t8IX/h2TzJEMtixxFcqPlf6Vz0EphlDr2/WgDduLZM9A59x0/OsS7QRzYC7RjI5zWzA0s8fzjYMZ5rHvIvJm27t2RnNAFenAkHIODTaKALaQzTxg78qT/ETUM0RifaxUn2OaiooAKlTAQuJCHB4AHX8aiooAczFjliST3NKrsowGYKewPWmUUAFFFFAFhVh25aVgcH5QvQ1Xopw5OOmaAG1Mgh2sXLFuwHH61K8ESwk+cpcehB/CqlABVkTILfYI139N2O3+NRnZ5S4z5mefSoqAHxpvbG5V92OKdNH5b7SVP8AumoqKAHEkgAk4HQU2irDzqYRGIlB/ve/FADYxEUcuzBh90DvUNFS+afJMeF25znHNACAs+0FsgdAT0/OkkRkcqwwR1q5FZKYgzl9xGcD+XNUlJVgV4I70APgZUcF0DD0om8vfmLO33olleTG85xThbykgbCM9yKAIKK0re0EbBpCGYdB6UmpH92q4PXr/T9aAM6iipXMW35A+73IwKAIqkRS24AMWxxio6lhkkjD+WcDHPH+fWgBqOyHKEg9OKGdn+8zN9TmkJJOScmnM5KhTjA9hQBKlxsjCxoqv/eHeo2mkbOXY596YQRye9OjZVbLpvHpnFAEdFSSMrNlE2D0zmo6AJIlDyBWYKPU9qnmghVCY5QSOxYc1UooAsw2jyLnhQRkZ71WqZbiVU2h8Dp0qGgAqSKRo2yhwfpSBGK5AOPWkBI4HegAd2dssSTTkZQrbk3Ejg5xio6KAHKSrArwR3qeaUTKGclXUYwBwff2qAEjgd6BjPPT1oAFxn5uB7DNTzzs5AV324wc4H8qdvtkB2IWYdC3Q06B/Mkd5FV8D7oXmgAt7begdJWUng4BH4VHPEiAsJg7HsKkuLtz8qqU+vWqVAE9qE85S7bQDn8amvZz5gEUh24/hNLZ26SR7pATzx/n86S8lCKYEXCjGT+tAFTBxntU9rtWXfJnaoznGcHtTUeV08pclfTFDiWBSjZVW7etAF5r+NV2rkjuQKQTyknFu34nH9Kz4ZDHIrgA47VuLGzDIU4+lAHrnxYvrSb4S+H4op4pJVAygbJH4V4yohWJG8tAxGQT29s/1rNeWSQBXkdlHQE5p/mzPEV5MYAzgdKALkeobFwwYH/Z5FUrmTzZi4ztI4zUYBJwBk0MrKcMCD70ANooooAKKKlihkkBKLuA680ARUU5gVYhuCO1NoAKKKKACinKBzkgU2gAooooAKKKKAClNSmcmIIVQgdDjmoaAHLjcN2cZ5xUk7RMR5KlR3zUNFAFuW1ZYg6kMMZOO3/1qqU7cdu3JxnpUjvGUAWMqfXdmgCGrVvamZN24KOnAzVWigC1cq8GF80sCOmccfSqtFFABUyTyIVw7YHQE8VDRQBqJeRFQWbafTFTsFdMHlTWTChkkCqM1pyyLbxrkHbnaAOe3/1qAM+WCRXIEbEdiBVerct7M5GCFA7VArDfucbh3GcZoAarFTlSQR3FKWLNlyW+pokKlsou0emc0ygC8ltFMuYpGyOuaU2yQKZHJcL0HSqccjRtlCQafNcSS/ebj0HSgBJ5mmYFgAR6CpWtHCblKtxng/yqrU8MskK7l+6T0I4zQAsU7wZUKv4jBqKV/MkLEAZ7CllkaVyzYyfSo6AHhWYEgEgdcUynq7KMBmCnsD1plAD1CnO5scccZzSKdrA4Bx2NTW0BmJw2AOtNni8qQqSDj0oAbJIXxnAA6AdBUdTRSRqpDxByT1zio2ILEgYHpnpQA2rEFwYkZQqkH1qvRQA5juYnAGewptFSRqjA7pApHTjOaAI6cOOQcEU7zH243ttxjGaapAYEjI9M9aAHyyvJjec4pqbQctzjHHrT3eNhhIgh9ck0kUfmZ+dFx/eOKALDXpAAjRVAHeq80rTPubGfamHg464qdlgMf7tnMmeFPegCeNkjsziXDEZ4659MVSLFnBkZiPrzUy2khUMdq8gfMcdafcwJBCOS0jHg0ASRz2qAfuyfw5Falrdgx5GCO3BrBtwhlVZFLK3HXHNaygKMKMD0AoAw6swSukLbTj5h29jRRQBACQcjginSSNKwLnJx6UUUAR0UUUAFFFFADtx2bflx9Bn86bRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFXPLT+z9+0bs9fxoooAp0UUUAW76JItmwYz1qpRRQBrWiKsQIABIBNSSqGjYMMiiigDFooooAKKKKACiiigCxZIrzYYZGM1qbR93A29Me1FFAGHRRRQBYslDXUasAQc5B+lP1CNEcbFC59KKKAKysyHKkg+1NoooAKKKKACiiigAooooAKKKKACiiigArYit4kkUquD9TRRQBFfyvFs8s4z14+lRO7SWUhc5IYY4+lFFACaaoLuSMkDj9av0UUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal view of pelvic MR shows flow void (arrow) in the uterine fundus suggesting a rapid arteriovenous connection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Right and left uterine angiograms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right (A) and left (B) uterine angiograms before uterine artery embolization shows increased vascularity and an arteriovenous malformation (arrow in A) in the uterus with dilated uterine arteries (arrow in B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Right and left uterine angiograms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right (A) and left (B) uterine angiograms after uterine artery embolization reveal occlusions of both uterine arteries and their intrauterine branches (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelvic ultrasound after uterine artery embolization no longer demonstrates the abnormal intrauterine vascular structures within the uterus (arrows), which were present before uterine artery embolization. The patient's uterine bleeding was stopped immediately after the embolization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38314=[""].join("\n");
var outline_f37_26_38314=null;
var title_f37_26_38315="Treatment of hyponatremia in SAH";
var content_f37_26_38315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protocol for management of hyponatremia in patients with subarachnoid hemorrage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        For Na level &lt;133 mEq/L or a decrease of 6 mEq/L in 24 to 48 hours:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. NaCl tabs 3 g PO/NGT every 6 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Initiate 3 percent NaCl infusion at 20 ml/h IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        3. Check serum Na every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        a. If Na &lt;130 mEq/L:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increase rate by 20 ml/h (max rate = 80 ml/h)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        If on hold at present, initiate 3 percent NaCl infusion at 20 ml/h IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        b. If Na = 130 to 135 mEq/L:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increase rate by 10 ml/h (max rate = 80 ml/h)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        If on hold at present, initiate 3 percent NaCl infusion at 10 ml/h IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        c. If Na = 136 to 140 mEq/L:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        No change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        d. If Na &ge;140 mEq/L:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hold infusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Woo CH, Roa VA, Sheridan W, Flint A. Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia. Neurocrit Care 2009; 11:228, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38315=[""].join("\n");
var outline_f37_26_38315=null;
var title_f37_26_38316="Features of hemorrhage II";
var content_f37_26_38316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathologic features of major causes of immune or idiopathic alveolar hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Glomerular pathology",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Pulmonary pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Histopathology",
"       </td>",
"       <td class=\"subtitle2\">",
"        IF/EM",
"       </td>",
"       <td class=\"subtitle2\">",
"        Histopathology",
"       </td>",
"       <td class=\"subtitle2\">",
"        IF/EM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        ABMA disease",
"       </td>",
"       <td rowspan=\"3\">",
"        Variable - segmental necrosis, crescents common",
"       </td>",
"       <td rowspan=\"3\">",
"        Linear IgG by IF",
"       </td>",
"       <td>",
"        Alveolar hemorrhage",
"       </td>",
"       <td rowspan=\"3\">",
"        Linear IgG by IF along alveolar capillary basement membrane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No evidence of vasculitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        SLE",
"       </td>",
"       <td rowspan=\"3\">",
"        Variable - segmental necrosis, crescents in minority",
"       </td>",
"       <td rowspan=\"3\">",
"        Granular IgG by IF, electron dense deposits by EM",
"       </td>",
"       <td>",
"        Alveolar hemorrhage",
"       </td>",
"       <td rowspan=\"3\">",
"        Granular IgG by IF along alveolar capillary walls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis of small arteries and veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capillaritis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        WG",
"       </td>",
"       <td rowspan=\"2\">",
"        Segmental necrosis, crescents",
"       </td>",
"       <td rowspan=\"2\">",
"        Negative (granular IF in minority)",
"       </td>",
"       <td>",
"        Cavitary nodular parenchymal disease",
"       </td>",
"       <td rowspan=\"2\">",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrotizing vasculitis with granulomatous inflammation of the parenchyma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nonspecific systemic necrotizing vasculitis (microscopic polyarteritis, polyangiitis, overlap syndrome)",
"       </td>",
"       <td>",
"        Segmental necrosis, crescents",
"       </td>",
"       <td>",
"        Negative (granular IF in minority)",
"       </td>",
"       <td>",
"        Small vessel arteritis and capillaritis",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Idiopathic pulmonary hemosiderosis",
"       </td>",
"       <td rowspan=\"3\">",
"        Normal",
"       </td>",
"       <td rowspan=\"3\">",
"        Negative",
"       </td>",
"       <td>",
"        Alveolar hemorrhage",
"       </td>",
"       <td rowspan=\"3\">",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemosiderin-laden macrophages",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IF: immunofluorescence; EM: electron microscopy; ABMA: antibasement membrane antibody; SLE: systemic lupus erythematosus; WG: granulomatosis with polyangiitis (Wegener's); ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibody; p-ANCA: perinuclear ANCA; GN: glomerulonephritis.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Leatherman JL. In: Immunologically Mediated Pulmonary Diseases, Lynch JP, DeRemee RA (Eds), JB Lippincott, Philadelphia, 1991, p.490.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38316=[""].join("\n");
var outline_f37_26_38316=null;
var title_f37_26_38317="Risk of cardiac catheterization and coronary angiography";
var content_f37_26_38317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60388%7ECARD%2F51490%7ECARD%2F54367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60388%7ECARD%2F51490%7ECARD%2F54367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of cardiac catheterization and coronary angiography (based on 59,792 patients)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality",
"       </td>",
"       <td>",
"        0.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular accident",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia",
"       </td>",
"       <td>",
"        0.38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular complications",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contrast reaction",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemodynamic complications",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Perforation of heart chamber",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        0.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other complications",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total of major complications",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Noto, TJ Jr, Johnson, LW, Krone, R, et al. Cardiac catheterization 1990: A report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&amp;I). Cathet Cardiovasc Diagn 1991; 24:75. Copyright &copy; Wiley-Liss, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multivariate predictors of major complications of coronary angiography (based on 58,332 procedures)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moribund",
"       </td>",
"       <td>",
"        10.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock",
"       </td>",
"       <td>",
"        6.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute MI &lt;24 h",
"       </td>",
"       <td>",
"        4.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency",
"       </td>",
"       <td>",
"        3.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy",
"       </td>",
"       <td>",
"        3.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic valve disease",
"       </td>",
"       <td>",
"        2.72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve disease",
"       </td>",
"       <td>",
"        2.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        2.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        New York Heart Association Functional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class I",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class II",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class III",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class IV",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        1.45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"       <td>",
"        1.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Outpatient/inpatient",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Moribund indicates a patient who responds poorly due to a life threatening condition.",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Scanlon, PJ, Faxon, DP, Audet, AM, et al, J Am Coll Cardiol 1999; 33:1756.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative contraindications to coronary angiography",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acute renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal failure secondary to diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained fever, which may be due to infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated active infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe uncontrolled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe symptomatic electrolyte imbalance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe lack of cooperation by patient due to",
"psychological or severe systemic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe concomitant illness that drastically shortens",
"life expectancy or increases risk of therapeutic interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refusal of patient to consider definitive therapy such",
"as PTCA, CABG, or valve replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digitalis intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Documented anaphylactoid",
"reaction to angiographic contrast media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe peripheral vascular disease limiting vascular",
"access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompensated heart failure or acute pulmonary",
"edema&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic valve endocarditis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTCA: percutaneoas transluminal coronary angioplasty; CABG: coronaryartety bypass graft.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Scanlon, PJ, Faxon, DP, Audet, AM, et al, J Am Coll Cardiol 1999; 33:1756.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38317=[""].join("\n");
var outline_f37_26_38317=null;
var title_f37_26_38318="Magnetic resonance image of cleft soft palate";
var content_f37_26_38318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of cleft soft palate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2 weighted MR imaging of fetus at 20 weeks gestational age with micrognathia and cleft soft palate (without cleft lip). Note how the tongue is high in the oropharynx and there is absence of the soft palate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38318=[""].join("\n");
var outline_f37_26_38318=null;
var title_f37_26_38319="OS imatinib AP CML";
var content_f37_26_38319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Overall survival estimates for patients with chronic myeloid leukemia in accelerated phase treated with imatinib",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 397px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Of the 119 patients in the 600-mg dose group, 24 have died, and overall survival was censored for the remaining 95; 1 of these 95 patients discontinued therapy with imatinib to undergo BMT. Of the 62 patients in the 400-mg dose group, 27 have died, and overall survival was censored for the remaining 35; 1 of these 35 patients discontinued treatment with imatinib to undergo BMT. The difference between dose groups was statistically significant (P = .014, log-rank test).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Talpaz, M, Silver, RT, Druker, BJ, et al. Blood 2002; 99:1928. Copyright &copy; 2002 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_26_38319=[""].join("\n");
var outline_f37_26_38319=null;
